

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Effectiveness and cost-effectiveness of a guided internet- and mobile-based depression intervention for individuals with chronic back pain: protocol of a multi-centre randomised controlled trial



Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-015226
Article Type:	Protocol
Date Submitted by the Author:	24-Nov-2016
Complete List of Authors:	Lin, Jiayi; Albert-Ludwigs-Universitat Freiburg, Department of Rehabilitation Psychology and Psychotherapy, Institute of Psychology Sander, Lasse; Albert-Ludwigs-Universitat Freiburg, Department of Rehabilitation Psychology and Psychotherapy, Institute of Psychology Paganini, Sarah; Albert-Ludwigs-Universitat Freiburg, Department of Rehabilitation Psychology and Psychotherapy, Institute of Psychology Schlicker, Sandra; Universitatsklinikum Erlangen, Department of Clinical Psychology and Psychotherapy, Institute of Psychology Ebert, David; Friedrich-Alexander University Erlangen Nuremberg, Clinical Psychology and Psychotherapy Berking, Matthias; Universitatsklinikum Erlangen, Department of Clinical Psychology and Psychotherapy, Institute of Psychology Bengel, Jürgen; Albert-Ludwigs-Universitat Freiburg, Department of Rehabilitation Psychology and Psychotherapy, Institute of Psychology Nobis, Stephanie; Hochschule Vechta, Department of Gerontology Lehr, Dirk; University of Lüneburg, Department of Psychology Mittag, Oskar; Universitatsklinikum Freiburg, Center for Medical Biometry and Medical Informatics, Section of Health Care Research and Rehabilitation Riper, Heleen; VU University Amsterdam, Dept. of Clinical Psychology Baumeister, Harald; Universitat Ulm, Department of Clinical Psychology and Psychotherapy, Institute of Psychology
Primary Subject Heading:	Mental health
Secondary Subject Heading:	Evidence based practice, Health economics, Health services research, Public health, Rehabilitation medicine
Keywords:	depression, chronic back pain, e-mental-health, health care services research, randomized controlled trial, study protocol

SCHOLARONE™
Manuscripts

1
2
3 **Effectiveness and cost-effectiveness of a guided internet- and mobile-based depression**
4 **intervention for in individuals with chronic back pain: protocol of a multi-centre ran-**
5 **domised controlled trial**
6
7
8
9
10

11 Jiaxi Lin¹ (jiaxi.lin@psychologie.uni-freiburg.de)

12 Lasse Sander^{1,2} (lasse.sander@psychologie.uni-freiburg.de)

13 Sarah Paganini¹ (sarah.paganini@psychologie.uni-freiburg.de)

14 Sandra Schlicker³ (sandra.schlicker@fau.de)

15 David Ebert³ (david.ebert@fau.de)

16 Matthias Berking³ (matthias.berking@fau.de)

17 Jürgen Bengel¹ (bengel@psychologie.uni-freiburg.de)

18 Stephanie Nobis⁴ (stephanie.nobis@uni-vechta.de)

19 Dirk Lehr⁵ (dirk.lehr@inkubator.leuphana.de)

20 Oskar Mittag⁶ (oskar.mittag@uniklinik-freiburg.de)

21 Heleen Riper⁷ (h.riper@vu.nl)

22 Harald Baumeister⁸ (harald.baumeister@uni-ulm.de)

23
24
25
26
27
28
29
30
31
32
33
34
35 1) Department of Rehabilitation Psychology and Psychotherapy, Institute of Psychology,
36 University of Freiburg, Germany

37
38 2) Medical Psychology and Medical Sociology, Medical Faculty, University of Freiburg,
39 Germany

40
41 3) Department of Clinical Psychology and Psychotherapy, Institute of Psychology, University
42 of Erlangen-Nürnberg, Germany

43
44 4) Department of Gerontology, University of Vechta, Germany

45
46 5) Department of Psychology, Leuphana University Lüneburg, Germany

47
48 6) Center for Medical Biometry and Medical Informatics, Section of Health Care Research
49 and Rehabilitation, Medical Center, University of Freiburg, Germany

50
51 7) Department of Clinical, Neuro and Developmental Psychology, VU University Amster-
52 dam, Netherlands

53
54 8) Department of Clinical Psychology and Psychotherapy, Institute of Psychology, University
55 of Ulm, Germany
56
57
58
59
60

1
2
3 Issue Date: 22 November 2016
4
5

6 Correspondence:

7
8 Address corresponding author:

9 Prof. Dr. Harald Baumeister

10 Department of Clinical Psychology and Psychotherapy,

11 Institute of Psychology and Education, University of Ulm,

12 Albert-Einstein-Allee 47, D-89069 Ulm, Germany

13 Phone: +49-(0)731-50-31180

14 Email: harald.baumeister@uni-ulm.de
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction: Depression often co-occurs with chronic back pain (CBP). Internet- and mobile-based interventions (IMIs) might be a promising approach for effectively treating depression in this patient group. In the present study, we will evaluate the effectiveness and cost-effectiveness of a guided depression IMI for individuals with CBP (eSano BackCare-D) integrated into orthopaedic health care.

Methods and analysis: In this multicentre randomised controlled trial (RCT) of parallel design, the groups eSano BackCare-D vs. treatment as usual will be compared. 210 participants with CBP and diagnosed depression will be recruited subsequent to orthopedic rehabilitation care. Assessments will be conducted prior to randomisation and 9 weeks (posttreatment) and 6 months after randomisation. The primary outcome is depression severity (HAM-D-17). Secondary outcomes are depression remission and response, health related quality of life, pain intensity, pain related disability, self-efficacy and work capacity. Demographic and medical variables as well as internet affinity, intervention adherence, intervention satisfaction and negative effects will also be assessed. Data will be analysed on an intention-to-treat basis and an additional per-protocol analysis. Moreover, a cost-effectiveness and cost-utility analysis will be conducted from a societal perspective after 6 months.

Discussion

The innovative approach of using an IMI to treat depression in people with CBP will substantially increase the likelihood of psychological interventions being accessible in routine health care.

Ethics and dissemination: All procedures are approved by the ethics committee of the Albert-Ludwigs-University of Freiburg and the data security committee of the German Pension Insurance (Deutsche Rentenversicherung). The results will be published in peer-reviewed journals and presented on international conferences.

Registration details: The trial is registered at the WHO International Clinical Trials Registry Platform via the German Clinical Studies Trial Register (DRKS): (DRKS00009272).

Keywords: Guided self-help; Internet-based; Chronic back pain; Depression; after care; Randomised controlled trial, effectiveness, cost-effectiveness

Strengths and limitations of this study

- First trial examining the effectiveness of a depression IMI for individuals with CBP and comorbid depression.
- First trial examining the cost-effectiveness of a depression IMI for individuals with CBP and comorbid depression.
- IMI will be implemented as integrated part of the routine orthopaedic health care, thus overcoming the participant selection bias due to self-referral as one of the core limitation of most prior IMI trials.
- The IMI will take place after routine orthopaedic health care, examining the possibility to improve patients' medical sector transitions by means of an e-mental-health offer.
- Use of standardised interviews for the diagnosis and use of clinical rating scales for the assessment of the severity level of depression (SKID and HAMD/QIDS).

Introduction

The two widespread conditions chronic back pain (CBP) and depression belong to the top ten causes of years lived with disability (YLDs) worldwide [1]. The global one-month adult prevalence for low back pain is estimated to be 23.2% and a substantial increase during the next decades can be expected [2]. Depression has been shown to be the leading cause of burden of diseases in middle- to high-income countries with a lifetime prevalence of about 14.6% [3]. A strong association between depression and CBP has been frequently reported with prevalence rates for depression ranging from 21% to 50% in back pain and chronic low back pain individuals [4]. Several systematic reviews highlight a significant prognostic association between comorbid depression and increased morbidity of different somatic conditions and health care costs as well as diminished quality of life [5–7]. Moreover, depression is one of the core predictors of persistent pain symptoms, increased pain-related disability, and poor treatment outcomes in pain patients [4, 8, 9].

There is strong evidence for the efficacy of psychological interventions for chronic pain [10] and especially for chronic low back pain [11] with regard to pain intensity or disability/interference. To the best of our knowledge however, there is no study that has examined the effects of psychological depression interventions for individuals with CBP and depression [12]. In order to improve health care for CBP individuals, internet- and mobile-based interventions (IMIs) are considered to be a promising approach [13, 14]. Among numerous meta-analyses highlighting the efficacy of IMIs with regard to the reduction of depressive symptoms [15–18], one meta-analysis quantified the superiority of online depression interventions

over waiting-list and treatment as usual (TAU) with standardised mean differences of $d=-.68$ (CI: $-.85;-.52$; $n=8$) and $d=-.39$ (CI: $-.66;-.12$; $n=8$) [15], albeit effect moderating factors of IMIs remain unclear [19]. As most trials used highly selective recruitment strategies, the evidence for the effectiveness of IMIs for depression (i.e., performance of an intervention when implemented within typical clinical practice, investigated by means of pragmatic trials) is far less conclusive [20] and many health systems have not included IMIs as an integrated treatment component. As an implemented part of a comprehensive care system, IMIs could reduce the deficiencies of most current health care systems in coordinating transitions of care, such as the transition from the inpatient to outpatient setting, where recommendations are regularly lost in transition [21–23].

The present WARD-BP study (web-based aftercare depression intervention following rehabilitation for individuals with depression and chronic back pain) aims to investigate the effectiveness and cost-effectiveness of the depression IMI “eSano BackCare-D” in a study population of CBP with a diagnosed depression in the aftermath of orthopaedic rehabilitation care. The primary research question is:

1) Is eSano BackCare-D effective in reducing depression in individuals with CBP and diagnosed depression compared to treatment as usual (TAU)?

Secondary research questions are:

2) Is eSano BackCare-D effective with regard to depression remission and response, health related quality of life, pain intensity, pain related disability, self-efficacy and work capacity in individuals with CBP and diagnosed depression compared to TAU?

3) Is eSano BackCare-D cost-effective in individuals with CBP and diagnosed depression compared to TAU from a societal perspective?

4) Which factors moderate and mediate the effects of eSano BackCare-D?

Methods and analysis

Study design

WARD-BP is a multi-centre pragmatic randomised controlled clinical trial (RCT) of parallel design. All participants receive TAU. We conduct assessments in both groups before randomisation (T0), nine weeks (T1= post treatment in case of regular IMI use) and six months (T2) after randomisation. Trial participants receive 15€ per completed post- and follow-up telephone assessment, see figure 1 for study flow. We conduct and report the RCT in accordance with the CONSORT 2010 Statement [24], the supplement of the CONSORT statement for pragmatic effectiveness trials [24, 25] and current guidelines for executing and reporting In-

1
2
3 ternet intervention research [26]. All procedures are approved by the ethics committee of the
4 Albert-Ludwigs-University of Freiburg and the data security committee of the German Pen-
5 sion Insurance (Deutsche Rentenversicherung). The trial is registered at the WHO Interna-
6 tional Clinical Trials Registry Platform via the German Clinical Studies Trial Register
7 (DRKS): (DRKS00009272).
8
9
10

11
12
13 - Figure 1 about here -
14
15
16
17
18
19

20 ***Randomisation***

21 Randomisation and allocation of participants to the two groups (intervention or TAU) was
22 prepared in advance by an independent researcher (SaS) by means of a web-based program
23 (<https://www.sealedenvelope.com/>) using permuted block randomisation with variable block
24 sizes of 4,6,8 (randomly arranged), ratio of 1:1. Participants are stratified by center. Centers
25 are all eight orthopedic clinics where recruitment is conducted personally and a ninth (meta-
26)clinic, which includes all participants recruited by letter (see recruitment). An independent
27 researcher SaS is responsible for the allocation as well as the administration of the trial and
28 participants to trial arms and is blinded to the treatment content.
29
30
31
32
33

34 ***Recruitment***

35 Recruitment has started in October 2015. Using the Patient Health Questionnaire (PHQ-9;
36 27), we conduct two consecutive depression screenings within 2-3 weeks. In case of only one
37 positive screening (PHQ \geq 5), a third PHQ will be administered two months later via tele-
38 phone interview. We recruit potential participants in orthopaedic rehabilitation units in Ger-
39 many with two different recruitment strategies.
40
41
42
43

44 In the first recruitment setting (personal recruitment), patients with two positive screenings
45 receive information on the intervention by clinic staff during their orthopedic care. Patients
46 providing their informed consent (model consent form available on request) are contacted by
47 the study team in order to clarify further eligibility criteria by means of an online- and tele-
48 phone assessment including a telephone administered clinical interview. Recruitment efforts
49 (i.e. selection of back pain patients, screening procedure, informed consent, documentation
50 according to CONSORT, providing access to medical records) are completed by the clinic
51 staff who are compensated with a case payment of 320€ per randomised participant. The se-
52 cond recruitment strategy (recruitment by letter) involves a letter with information flyers and
53
54
55
56
57
58
59
60

study process for back pain patients after discharge from orthopaedic rehabilitation units across Germany with a link to fill out an online PHQ-screening. Individuals screened positive, providing informed consent are contacted for the second PHQ-screening and a clinical interview via telephone equivalent to the first recruitment strategy.

Inclusion/exclusion criteria

We include patients if they fulfil the following inclusion criteria: 1) age 18 years or older, 2) CBP assessed by physician for at least six months assessed during telephone interview, 3) mild to moderate depression or dysthymia according to SCID assessment, assessed during telephone interview 4) sufficient knowledge of German language, 5) Internet and PC access. Patients are excluded in case of 6) receiving ongoing psychotherapy or beginning psychotherapy within the next three months, 7) being currently suicidal or reporting suicidal attempts in the past five years or 8) a current diagnosis of severe depression (ICD-10 F32.2/F32.3/F33.2/F33.3 diagnosis), see table 1. The exclusion of individuals with severe depression is due to ethical concerns and based on ICD-10 criteria for severe depression according to the German treatment guidelines for depression [28]. A trained psychotherapist (HB, LS, EM or SaS) contacts the participant to initiate further actions when severe depression is classified. We invite participants with a depression severity of PHQ \geq 5, who do not fulfil the criteria to participate, in a parallel conducted trial for CBP and subclinical depressive symptoms: eSano BackCare-DP [29].

Procedure on suicidal ideation

Participants who are currently suffering from suicidal ideation are identified by suicide screenings within the telephone interviews (SCID, HAM-D, QIDS) and questionnaires (PHQ-9). Following a suicide protocol adapted from prior trials [30–32] we send an email with detailed information on available health services and the advice to seek professional help if participants report low suicidal ideation (HAM-D, QIDS or PHQ-9 item score = 1). In case of moderate to high suicidal ideation during the assessments or any suicidal thoughts or intentions reported to an eCoach or the study administration, a trained psychotherapist from the study team (HB, LS, EM or SaS) contacts the participant and initiate further actions, including the possibility to amend or terminate the intervention as well as unblinding respective study participants.

- Table 1 about here -

Intervention development

eSano BackCare-D is based on cognitive behaviour therapy (CBT), systematic behavioural activation [33–35] and problem solving [36]. The depression-specific components are based upon a prior IMI “GET.ON Mood Enhancer”, that has been evaluated in numerous RCTs in different samples [32, 37, 38] and shown to be effective in lowering depressive symptoms in individuals with diabetes mellitus type 1 and 2 with an intention to treat (ITT) effect size of $d=0.89$ at two-months post treatment [37] and $d=0.83$ at 6 months follow up [39]. We added CBP-relevant information, videos and audio clips, based on existing literature on psychological back pain treatment [40, 41], our clinical experience, and an existing IMI for chronic pain individuals based on acceptance and commitment therapy [42]. Think-aloud interviews with five persons with CBP helped us to further improve the feasibility and acceptability. Access to the platform proceeds through a unique username password combination and is available on a 24/7 basis. All transferred data are secured via www.minddistrict.com based on ISO27001 and guidelines NEN7510.

Intervention content

eSano BackCare-D provides six minimally guided sessions with an estimated proceeding duration of 45-60 minutes each, developed to be processed weekly. Three optional sessions with back pain specific topics (sleep, partnership and sexuality, returning to work) are available at the end of sessions 3 through 5. Two booster sessions following the intervention are offered to improve sustainability of intervention effects. Session-specific contents and homework assignments are shown in table 2.

Session 1 provides psychoeducational information on depression, the interaction between CBP and depression as well as pain acceptance. Participants define their depression- and CBP-related goals and get to know the mood diary as the homework assignment for the next week. In session 2, the concept of behavioural activation and the connection between pleasant activities and mood is introduced. Based on the principles of action planning and coping planning [43, 44], participants create an individual list and schedule for completion of pleasant activities in the next few days. The main focus in sessions 3 and 4 is on the six-step plan to handle solvable problems and to better manage emerging issues, comparable to other studies [37, 45–47]. In addition, techniques to reduce rumination on unsolvable problems and the concept of mindfulness are introduced. Session 5 includes information and exercises on physical activity [33], a mindfulness exercise and techniques to strengthen self-esteem. The sixth

1
2
3 session serves to assess intervention-related changes in mood and provides a list of additional
4 treatment options. Participants are encouraged to create a plan for the future. At the end, they
5 write a letter to themselves about specific goals for the next four weeks and choose the date of
6 the next booster session (after two, four or six weeks) that are developed to review what the
7 participants have learned in previous sessions and to provide motivation to maintain and ex-
8 pand learned skills in the future.
9

10
11 The sleep session builds on an evidence based IMI for insomnia, i.e: GET.ON Recovery [48,
12 49]. As insomnia is a predictor and symptom of depression [50], participants learn about the
13 principles of sleep hygiene, sleep restriction and stimulus control [51]. The partnership and
14 sexuality session provides communication skills and exercises for improving physical close-
15 ness and sexuality. In the returning to work session, participants receive information on self-
16 management and interpersonal competences as well as exercises in problem-solving and phys-
17 ical relaxation.
18
19
20
21
22
23
24
25
26
27

28 - Table 2 about here -
29
30
31
32
33

34 ***Text message coach***

35 The text message coach in eSano BackCare-D automatically sends one supportive text mes-
36 sages per day for the duration of six weeks as text message prompts have been shown to in-
37 crease efficacy and adherence of IMIs [52–54]. The contents include a) reminders to complete
38 the weekly assignments, b) repetition of the content, and c) motivation enhancement compo-
39 nents.
40
41
42
43

44 ***Guidance***

45 Based on previous studies showing that guidance and reminders and strict deadlines seem to
46 be important with regard to the respective primary outcomes and adherence in IMIs [15, 55–
47 57] the feedback manual of eSano BackCare-D provides instructions to remind, set deadlines
48 and formulate standardised feedback for each session. Trained and supervised eCoaches (psy-
49 chologists) serve as contact person and provide feedback within two work days after each
50 completed session. Feedbacks are adapted to the participants' assignments and include posi-
51 tive reinforcement for completion of assignments and encouragement to proceed with the time
52 spent on guidance will be approximately 60-100 minutes per participant.
53
54
55
56
57
58
59
60

Control condition

Participants have unrestricted access to TAU. All types of medical/psychological help received during the last three months are tracked at T0 and T2 with the Trimbos/iMTA questionnaire for costs associated with psychiatric illness [58].

Proposed sample size/power calculations

The sample size calculation is based on the primary endpoint, the HAM-D score at post treatment. According to the results of trials on online interventions for depression [15], a treatment effect (pooled effect size) of $d=0.39$ would be of clinical interest and is considered feasible for the type of treatment. On the basis of a two-sample t-test at two-sided significance level of 0.05, the study is planned to detect this effect with 80% power. This requires a sample of 105 individuals in each arm.

Assessments

Depression screening. Depressive symptoms are assessed by the Patient Health Questionnaire (PHQ-9) which is a well validated depression screening instrument that has also been evaluated to be delivered as online-version [59], with a Cronbach's alpha of .89 and 88% sensitivity and 88% specificity for major depression [60].

Depression diagnosis. The 17-item HAM-D is the most widely used clinician-rated measure of depression severity and as such viewed as the gold standard for the assessment of depression severity. Additionally, we use the Quick Inventory of Depressive Symptomatology (QIDS [61]) which assesses the severity of depressive symptoms, covering all criterion symptom domains of the DSM-IV to diagnose a major depressive episode [61]. Moreover we use Section A (Affective Syndromes) of the Structured Clinical Interview (SCID; 62) as a comprehensive, structured interview designed to be used by trained interviewers for the assessment of mental disorders according to the definitions and criteria of DSM. It enables a reliable, valid and efficient assessment of depressive disorders [63]. As an add-on to the SCID for DSM-IV, we use a German translation of the SCID-V-RV to allow for DSM-V [64] diagnoses as well.

Interviewers are trained and weekly supervised by a psychologist (LS, EM) and are blinded to randomisation condition. After an initial training session, a supervisor and the interviewers assess the same participant together, with comparison of results as follows: The Inter-Rater Reliability (IRR) for the SCID, measured by *Cohen's kappa* and the *Intra-Class Correlation* for the HAM-D and QIDS. An almost perfect *Cohen's kappa* $\geq .81$ [65] and an excellent ICC coefficient $\geq .75$ [66] is considered as sufficient. Each interviewer is compared to trainers'

rating (LS, EM) until the sufficient IRR values are met. Afterwards, the interviewers are compared to each other on a random basis to assess the IRR.

Primary outcome

Depression severity. Depression severity is the core patient-relevant outcome in trials among depressed individuals [67, 68] and is assessed by means of the clinician-rated Hamilton Rating Scale for Depression (HAM-D-17; 69) (see table 1) at post-treatment (T1).

Secondary outcomes

Depression response and remission. HAM-D scores are used to determine depression response in accordance to the recommendations of Riedel and colleagues [70]. Depression remission are assessed with all measures to diagnose a major depressive episode (HAM-D /SCID/QIDS).

Health related quality of life (QoL). The AQoL-6D includes 20 items and six dimensions and is suitable for quality of life assessments and economic evaluations of health programs with good psychometric properties [71] and a Cronbach's alpha of .89 [72]. We additionally obtain the most widely used quality of life assessment EuroQol (EQ-5D-5L) as a basis for cost-utility analyses with five health domains of importance to quality of life [73].

Pain intensity. We use an 11-point numerical rating (0-10) of the worst, least and average pain during the last week as well as the current pain level and calculate the mean of the four scales. Additionally, we use a categorical rating of pain intensity (none, mild, moderate, severe).

Pain related disability. We obtain the Oswestry Disability Index (ODI) [74] as a reliable ($\alpha = .86$; [75]) and valid 10 item self-report questionnaire, sensitive to change in difficulties in completing activities of daily living [74].

Pain self-efficacy. The Pain Self-Efficacy Questionnaire (PSEQ) is a validated and reliable (internal consistency: $\alpha = 0.93$) 10 item instrument that assesses self-efficacy expectations related to pain [76].

Work capacity. The subjective prognostic employment scale (SPE) is a validated 3-item self-report questionnaire (sum score 0-3) with high internal consistency (rep (Guttman scaling) = .99; [77]).

Intervention adherence. The attrition rate (calculated using the percentage of individuals who no longer use the intervention, as assessed by their log in data) gives an estimate of the individuals' intervention adherence.

Patient satisfaction.

1
2
3 The Client Satisfaction Questionnaire (CSQ-8, German: ZUF-8), optimised for the assessment
4 of client satisfaction in IMIs (CSIQ-8) [78] is a validated 8 item instrument with high internal
5 consistency ($\alpha = 0.92$) [79]. The adapted version for the assessment of client satisfaction in
6 IMIs has shown to have high internal consistency in a range of studies ($\alpha = 0.92-0.94$) [48, 80,
7 81] and to be associated with treatment adherence and outcome.
8
9

10
11
12 **Negative effects of psychotherapy.** We include different ways of monitoring serious adverse
13 events (SAE) adapted from the National Institute for Health Research recommendations [82]
14 and Horigian et al. [83] who give general principles and examples to help illustrate their defi-
15 nition of SAEs: participants' responses in interviews, reported SAEs to the eCoach and SAEs
16 assessed by means of the Inventory for the Assessment of Negative Effects of Psychotherapy
17 (INEP) during the online assessments [84]. The INEP consists of 15 items assessing a range
18 of common changes participants experienced in line with the intervention. Cronbach's alpha
19 is $\alpha = 0.86$ [84]. At the beginning of every session, participants are asked about adverse events
20 and are also encouraged to report the events to their eCoach who monitors the SAEs and initi-
21 ates further actions if needed.
22
23
24
25
26
27
28
29

30 **Costs.**

31 We use the German version of the Cost Questionnaire "Trimbos Institute and Institute of
32 Medical Technology Questionnaire for Costs Associated with Psychiatric Illness" (TiC-P;
33 58), adapted for the German health care system by Nobis and colleagues [30] and for CBP
34 individuals by the present authors. The TiC-P allows assessment of all direct healthcare ser-
35 vices received during the last three months. Moreover, direct non-medical costs (e.g. parking
36 costs) and indirect costs are assessed, including the number of 'work loss' days (absenteeism),
37 the number of 'work cut-back' days (presentism) and costs associated with domestic tasks.
38
39

40 **Covariates.** Demographic variables, prior depression treatments, and internet affinity level
41 are assessed by patient self-report, see table 1. We use the German version of the Internet Af-
42 finity Scale (IAS) by Haase and colleagues [85] to assess familiarity with the Internet. De-
43 pression type (Major Depression yes/no), baseline severity and depression chronicity are as-
44 sessed by the SCID, back pain type, severity and chronicity are extracted from medical rec-
45 ords.
46
47
48
49
50
51
52
53

54 **Statistical Analysis**

55 **Clinical analyses.** The primary endpoint will be analysed with the HAM-D score at T1 as
56 dependent variable and baseline value as covariates, adjusting for sex and age. Continuous
57
58
59
60

1
2
3 secondary outcomes will be analysed accordingly. Standardised mean differences and 95%
4 confidence intervals will be calculated to measure the between-group effect size at post-
5 treatment and follow-up. Additionally, clinical significance analyses, such as number needed
6 to treat (NNT) will be conducted. All analyses will be performed on an intention-to-treat
7 (ITT) principle with multiple imputations to replace missing data [86]. Completer analyses
8 (per-protocol) will be conducted to investigate the influence of study attrition on study results.
9 Rates of patient-reported adverse events will be compared.
10
11
12
13
14
15

16 **Economic evaluation.** We will conduct a cost-effectiveness analysis (CEA), a cost-utility
17 analysis (CUA) and the incremental cost-effectiveness ratio (ICER) and the incremental cost-
18 utility ratio (ICUR) after six months. A cost-effectiveness analysis with depression response,
19 defined by Riedel and colleagues [70], as clinical outcome and a cost-utility analysis with
20 quality-adjusted life-years (QALYs) will be conducted from a societal perspective including
21 all direct and indirect costs. Bootstrapping methods will be applied to estimate nonparametric
22 confidence intervals for mean differences in costs and outcomes between the groups. Further,
23 we will calculate a cost-acceptability curve to test the likelihood that the intervention is cost-
24 effective relative to TAU, given varying threshold for the willingness to pay for one depres-
25 sion response or gained QALY, respectively.
26
27
28
29
30
31
32
33
34
35

36 *Quality assurance and safety*

37 The Clinical Trials Unit Freiburg performs monitoring visits to the participating clinic centres
38 before, during and after completion of the study to ensure that the study is conducted, record-
39 ed and reported according to the study protocol, relevant standard operating procedures
40 (SOPs), and requirements of the sponsor and/or the Ethic Committees in accordance with
41 ICH-GCP. Rigorous operating procedures for data management and safety have been imple-
42 mented.
43
44
45

46 Furthermore, an independent Data Safety and Monitoring Board (DSMB) consisting of two
47 experienced scientists and psychotherapists (MHä, MHa) and one statistician (LK) with long-
48 standing experience in clinical trials has been established. The function of the DSMB is to
49 monitor the course of the study and, if necessary, to give recommendations to the steering
50 committee for discontinuation, modification or continuation of the study.
51
52
53
54
55
56
57
58
59
60

Discussion and conclusions

The present effectiveness and cost-effectiveness trial focusses on individuals with CBP and comorbid depression as two of the most frequent, most disabling health conditions with high associated economic burden [7, 87].

The WARD-BP trial is innovative in several ways: a) Studies examining the effectiveness of psychological depression interventions are regularly methodologically limited as they lack diagnostic clarification of depression status [15, 67, 88]. By carrying out the SCID and HAM-D prior to randomization and at follow-up assessments, the present trial will be the first trial on a psychological depression intervention for people with chronic pain with verified DSM diagnosis of depression. b) With a target sample of 210 participants, the study will be optimally powered, overcoming limitations of small scale trials on psychological depression interventions in the medically ill [12, 67, 88]. c) The eSano BackCare-D intervention is tailored to the special needs of the target group of chronic back pain patients. This has been discussed as having an uptake and adherence facilitating effect [89], likely to improve the effectiveness of online interventions. d) The implementation of the intervention into the health-care system overcomes one of the main criticisms regarding IMI trial being only representative for a selective online population [90, 91]. e) The current trial design will allow examination of the reach of this IMI and will provide valuable information about which CBP individuals are willing to utilise such interventions. With the use of two different recruitment strategies, we will be able to compare two different ways of implementing IMIs into clinical routine. This will allow for conclusions on feasible ways of improving the adherence and uptake of IMIs in respective target populations [92–94]. f) Finally, as one of still few clinical trials on psychological depression interventions the present trial comprises a cost-effectiveness analysis.

If the results of WARD-BP indicate that eSano BackCare-D is effective and cost-effective, its clinical impact on depression health care services could be substantial. When implemented as part of the standard health care, IMIs have the potential to reduce the “lost in transition phenomenon” caused by fragmented health care systems [21, 95, 96]. Engaging individuals in treatment at the interface of different health care sectors, as in the present (cost-)effectiveness trial, will contribute important information on potential approaches to improve the delivery of mental health care and at the same time provide insights on possible ways of implementing depression IMIs into chronic back pain care in order to exploit their full potential. The first results of WARD-BP are expected in 2018, which will be published in peer-reviewed journals and disseminated broadly to healthcare professionals, the public, and other relevant groups.

Authors' contributions

HB, DE, MB, OM and HR initiated this study. All authors contributed to the design of this study. HB, LS, SP, DE, SaS, DL, SN, JB, HR, MB and JL developed the intervention content or intervention content eSano BackCare-D is based on as well as the assessment. HB, LS, SP, SaS, DE, and JL are responsible for recruitment. SaS is responsible for randomisation and allocation as well as the administration of participants. JL wrote the draft of the manuscript. HB provided expertise on depression, CBP and psychological pain interventions. All authors contributed to the further writing of the manuscript and approved the final version of the manuscript.

Conflict of interest

A committee of independent scientists has been formed (Data Safety and Monitoring Board (DSMB)) to supervise study-related decisions and prevent any influence of a potential conflict of interest.

Funding

This study is funded by the Federal Ministry of Education and Research of Germany (project: Effectiveness of a guided web-based intervention for depression in back pain rehabilitation aftercare, Grant number: 01GY1330A). This funding source has no influence on the design of this study and will not influence its execution, analyses, interpretation of the data, or decision to submit results.

Acknowledgements

We thank Dr. Kristin Kieselbach and Prof. Dr. Anja Göritz for their support with providing their expertise in the content of the intervention. We thank colleagues who were part of the development of prior interventions [30, 42] that partly build the basis of eSano© BackCare-D. Moreover we like to thank our study assistants and interns and students for their support in the development of the intervention and in conducting the study. We thank Ellen Meierotto for supervising the SCID-interviewers. Many thanks go to the Data Safety and Monitoring Board, consisting of Prof. Dr. Martin Hautzinger, Prof. Dr. Martin Härter and Dr Levente Kriston as well as the Clinical Trials Unit Freiburg for their support in carrying out the study project. Special thanks go to the eight orthopedic clinics Schoen Klinik, Bad Staffelstein; Rehaklinik Sonnhalde, Donaueschingen; RehaKlinikum Bad Säckingen; Städt. Rehakliniken Bad Wald-

1
2
3 see; Schwarzwaldklinik Orthopädie - Abteilung Medizinische Rehabilitation, Bad Krozingen;
4 Rheintalklinik Bad Krozingen; REGIO-Reha Tagesklinik, Freiburg and Universitäts- und
5 Rehabilitationskliniken, Ulm as well as the further orthopedic rehabilitation units of the se-
6 cond recruitment strategy. We are very grateful to Mary Wyman for proofreading this manu-
7 script.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

REFERENCES

- 1 Vos T, Barber RM, Bell B, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. *The Lancet* 2015;**386**:743–800.
<http://www.sciencedirect.com/science/article/pii/S0140673615606924> (accessed 17.8.16).
- 2 Hoy D, Bain C, Williams G, et al. A systematic review of the global prevalence of low back pain. *Arthritis Rheum* 2012;**64**:2028–2037.
<http://onlinelibrary.wiley.com/doi/10.1002/art.34347/full> (accessed 17.8.16).
- 3 Bromet E, Andrade LH, Hwang I, et al. Cross-national epidemiology of DSM-IV major depressive episode. *BMC medicine* 2011;**9**:90.
<http://bmcmedicine.biomedcentral.com/articles/10.1186/1741-7015-9-90> (accessed 17.8.16).
- 4 Bair MJ, Robinson RL, Katon W, et al. Depression and pain comorbidity: a literature review. *Arch Intern Med* 2003;**163**:2433–2445.
<http://archinte.jamanetwork.com/article.aspx?articleid=216320> (accessed 17.8.16).
- 5 Baumeister H, Hutter N, Bengel J, et al. Quality of life in medically ill persons with comorbid mental disorders: a systematic review and meta-analysis. *Psychother Psychosom* 2011;**80**:275–286. <http://www.karger.com/Article/FullText/323404> (accessed 17.08.16).
- 6 Baumeister H, Balke K, Härter M. Psychiatric and somatic comorbidities are negatively associated with quality of life in physically ill patients. *J Clin Epidemiol* 2005;**58**:1090–1100. <http://www.sciencedirect.com/science/article/pii/S0895435605001605> (accessed 17.8.16).
- 7 Baumeister H, Knecht A, Hutter N. Direct and indirect costs in persons with chronic back pain and comorbid mental disorders--a systematic review. *J Psychosom Res* 2012;**73**:79–85. <http://www.sciencedirect.com/science/article/pii/S0022399912001468> (accessed 17.08.16).
- 8 Miles CL, Pincus T, Carnes D, et al. Can we identify how programmes aimed at promoting self-management in musculoskeletal pain work and who benefits? A systematic review of sub-group analysis within RCTs. *Eur J Pain* 2011;**15**:775.e1-11.
<http://www.sciencedirect.com/science/article/pii/S1090380111000334> (accessed 17.8.16).
- 9 Nicholas MK, Coulston CM, Asghari A, et al. Depressive symptoms in patients with chronic pain. *Med J Aust* 2009;**190**:S66. <http://europepmc.org/abstract/MED/19351296> (accessed 17.8.16).
- 10 Williams AC, Eccleston C, Morley S. Psychological therapies for the management of chronic pain (excluding headache) in adults. *Cochrane Database Syst Rev* 2012;**11**:CD007407.
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007407.pub3/full> (accessed 17.08.16).
- 11 Hoffman BM, Papas RK, Chatkoff DK, et al. Meta-analysis of psychological interventions for chronic low back pain. *Health Psychol* 2007;**26**:1–9.
<http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0024119/> (accessed 17.08.16).
- 12 Baumeister H, Härter M. Psychische Komorbidität bei muskuloskelettalen Erkrankungen. *Bundesgesundheitsbl.* 2011;**54**:52–58. <http://link.springer.com/article/10.1007/s00103-010-1185-x/fulltext.html?view=classic> (accessed 17.08.17).

- 13 Buhrman M, Gordh T, Andersson G. Internet interventions for chronic pain including headache: A systematic review. *Internet Interv* 2016;**4**:17–34.
<http://www.sciencedirect.com/science/article/pii/S2214782915000421>.
- 14 Eccleston C, Fisher E, Craig L, et al. Psychological therapies (Internet-delivered) for the management of chronic pain in adults. *Cochrane Database Syst Rev* 2014:CD010152.
doi:10.1002/14651858.CD010152.pub2.
- 15 Richards D, Richardson T. Computer-based psychological treatments for depression: a systematic review and meta-analysis. *Clin Psychol Rev* 2012;**32**:329–342.
<http://www.sciencedirect.com/science/article/pii/S027273581200027X> (accessed 17.08.16).
- 16 Andrews G, Cuijpers P, Craske MG, et al. Computer therapy for the anxiety and depressive disorders is effective, acceptable and practical health care: a meta-analysis. *PLoS one* 2010;**5**:e13196.
<http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0013196> (accessed 17.08.16).
- 17 Ebert DD, Zarski A, Christensen H, et al. Internet and computer-based cognitive behavioral therapy for anxiety and depression in youth: a meta-analysis of randomized controlled outcome trials. *PLoS one* 2015;**10**:e0119895.
<http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0119895> (accessed 17.08.16).
- 18 Sander L, Rausch L, Baumeister H. Effectiveness of Internet-Based Interventions for the Prevention of Mental Disorders: A Systematic Review and Meta-Analysis. *JMIR Ment Health* 2016;**3**:e38. <http://mental.jmir.org/2016/3/e38/> (accessed August 24, 2016).
- 19 Andersson G. Internet-Delivered Psychological Treatments. *Annual Review of Clinical Psychology* 2016;**12**:157–179. <http://www.annualreviews.org/doi/full/10.1146/annurev-clinpsy-021815-093006> (accessed September 15, 2016).
- 20 Andersson G, Carlbring P, Cuijpers P. Internet interventions: Moving from efficacy to effectiveness. *EJAP* 2010;**5**.
<http://sensoria.swinburne.edu.au/index.php/sensoria/article/view/169/194> (accessed 17.08.16).
- 21 Kim CS, Flanders SA. In the Clinic. Transitions of care. *Ann Intern Med* 2013;**158**:ITC3-1.
<http://annals.org/article.aspx?articleid=1657883> (accessed 17.08.16).
- 22 Ebert D, Tarnowski T, Gollwitzer M, et al. A Transdiagnostic Internet-Based Maintenance Treatment Enhances the Stability of Outcome after Inpatient Cognitive Behavioral Therapy: A Randomized Controlled Trial. *Psychother Psychosom* 2013;**82**:246–256.
<http://www.karger.com/Article/FullText/345967> (accessed 17.08.16).
- 23 Snow V, Beck D, Budnitz T, et al. Transitions of Care Consensus Policy Statement American College of Physicians-Society of General Internal Medicine-Society of Hospital Medicine-American Geriatrics Society-American College of Emergency Physicians-Society of Academic Emergency Medicine. *J Gen Intern Med* 2009;**24**:971–976.
doi:10.1007/s11606-009-0969-x.
- 24 Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials. *PLoS Med* 2010;**7**:e1000251.
doi:10.1371/journal.pmed.1000251 [published Online First:
<http://www.bmj.com/content/340/bmj.c332>].
- 25 Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. *BMJ* 2008;**337**:a2390.
<http://www.bmj.com/content/337/bmj.a2390.long> (accessed 17.08.16).

- 1
2
3 26 Proudfoot J, Klein B, Barak A, et al. Establishing guidelines for executing and reporting
4 internet intervention research. *Cogn Behav Ther* 2011;**40**:82–97.
5 <http://www.tandfonline.com/doi/abs/10.1080/16506073.2011.573807> (accessed
6 17.08.16).
- 7
8 27 Löwe B, Kroenke K, Herzog W, et al. Measuring depression outcome with a brief self-
9 report instrument: sensitivity to change of the Patient Health Questionnaire (PHQ-9). *J*
10 *Affect Disord* 2004;**81**:61–66.
11 <http://www.sciencedirect.com/science/article/pii/S0165032703001988> (accessed
12 17.08.16).
- 13
14 28 DGPPN BÄ, KBV A, AkdÄ B, et al. S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare
15 Depression–Langfassung. DGPPN, ÄZQ, AWMF, Berlin, Düsseldorf 2009.
- 16
17 29 Sander L, Paganini S, Lin J, et al. Effectiveness and cost-effectiveness of an Internet-based
18 intervention for the prevention of major depression in patients with back pain and sub-
19 threshold depression - a randomized controlled trial submitted.
- 20
21 30 Nobis S, Lehr D, Ebert DD, et al. Efficacy and cost-effectiveness of a web-based interven-
22 tion with mobile phone support to treat depressive symptoms in adults with diabetes
23 mellitus type 1 and type 2: design of a randomised controlled trial. *BMC Psychiatry*
24 2013;**13**:306. [http://bmcp psychiatry.biomedcentral.com/articles/10.1186/1471-244X-13-](http://bmcp psychiatry.biomedcentral.com/articles/10.1186/1471-244X-13-306)
25 306 (accessed 17.08.16).
- 26
27 31 Buntrock C, Ebert DD, Lehr D, et al. Evaluating the efficacy and cost-effectiveness of web-
28 based indicated prevention of major depression: design of a randomised controlled trial.
29 *BMC Psychiatry* 2014;**14**:25.
30 <http://bmcp psychiatry.biomedcentral.com/articles/10.1186/1471-244X-14-25> (accessed
31 17.08.16).
- 32
33 32 Ebert D, Lehr D, Baumeister H, et al. GET.ON Mood Enhancer: efficacy of Internet-based
34 guided self-help compared to psychoeducation for depression: an investigator-blinded
35 randomised controlled trial. *Trials* 2014;**15**:39.
36 <http://trialsjournal.biomedcentral.com/articles/10.1186/1745-6215-15-39> (accessed
37 17.08.16).
- 38
39 33 Prochaska JO, Velicer WF. The transtheoretical model of health behavior change. *Am J*
40 *Health Promot* 1997;**12**:38–48. <http://ahp.sagepub.com/content/12/1/38.long> (accessed
41 17.08.16).
- 42
43 34 Hopko DR, Lejuez CW, Ruggiero KJ, et al. Contemporary behavioral activation treatments
44 for depression: Procedures, principles, and progress. *Clin Psychol Rev* 2003;**23**:699–717.
45 <http://www.sciencedirect.com/science/article/pii/S0272735803000709> (accessed
46 17.08.16).
- 47
48 35 Cuijpers P, van Straten A, Warmerdam L. Behavioral activation treatments of depression:
49 a meta-analysis. *Clin Psychol Rev* 2007;**27**:318–326.
50 <http://www.sciencedirect.com/science/article/pii/S027273580600136X> (accessed
51 17.08.16).
- 52
53 36 Cuijpers P, van Straten A, Warmerdam L. Problem solving therapies for depression: a me-
54 ta-analysis. *Eur Psychiatry* 2007;**22**:9–15.
55 <http://www.ncbi.nlm.nih.gov/pubmed/17194572> (accessed 17.08.16).
- 56
57 37 Nobis S, Lehr D, Ebert DD, et al. Efficacy of a web-based intervention with mobile phone
58 support in treating depressive symptoms in adults with type 1 and type 2 diabetes: a
59 randomized controlled trial. *Diabetes Care* 2015;**38**:776–783.
60 <http://care.diabetesjournals.org/content/38/5/776> (accessed 18.08.16).

- 1
2
3 38 Buntrock C, Ebert D, Lehr D, et al. Effectiveness of a web-based cognitive behavioural
4 intervention for subthreshold depression: pragmatic randomised controlled trial. *Psy-*
5 *chother Psychosom* 2015;**84**:348–358. <https://www.karger.com/Article/Pdf/438673> (ac-
6 cessed 17.08.16).
7
8 39 Ebert DD, Nobis S, Lehr D, et al. 6-months effectiveness of internet-based guided self-
9 help for diabetes and comorbid depression. Results of a randomized controlled trial. *Dia-*
10 *bet Med* (accepted).
11
12 40 Kröner-Herwig B. *Rückenschmerz*: Hogrefe Verlag 2000.
13
14 41 Martin A, Härter M, Henningsen P, et al. *Evidenzbasierte Leitlinie zur Psychotherapie*
15 *somatoformer Störungen und assoziierter Syndrome*: Hogrefe Verlag 2013.
16
17 42 Lin J, Lüking M, Ebert DD, et al. Effectiveness and cost-effectiveness of a guided and un-
18 guided internet-based Acceptance and Commitment Therapy for chronic pain: Study pro-
19 tocol for a three-armed randomised controlled trial. *Internet Interv* 2015;**2**:7–16.
20 <http://www.sciencedirect.com/science/article/pii/S2214782914000359> (accessed
21 17.08.16).
22
23 43 Krämer LV, Helmes AW, Seelig H, et al. Correlates of reduced exercise behaviour in de-
24 pression: The role of motivational and volitional deficits. *Psychol Health* 2014;**29**:1206–
25 1225.
26 <http://www.tandfonline.com/doi/abs/10.1080/08870446.2014.918978?journalCode=gps>
27 [h20](http://www.tandfonline.com/doi/abs/10.1080/08870446.2014.918978?journalCode=gps) (accessed 17.08.16).
28
29 44 Krämer LV, Helmes AW, Bengel J. Understanding activity limitations in depression: Inte-
30 grating the concepts of motivation and volition from health psychology into clinical psy-
31 chology. *Eur Psychol* 2014;**19**:278. <http://psycnet.apa.org/journals/epp/19/4/278/> (ac-
32 cessed 17.08.16).
33
34 45 van Straten A, Cuijpers P, Smits N. Effectiveness of a web-based self-help intervention for
35 symptoms of depression, anxiety, and stress: randomized controlled trial. *J Med Internet*
36 *Res* 2008;**10**:e7. <http://www.jmir.org/2008/1/e7/> (accessed 17.08.16).
37
38 46 Ebert D, Lehr D, Boß L, et al. Efficacy of an internet-based problem-solving training for
39 teachers: results of a randomized controlled trial. *Scand J Work Environ Health*
40 2014;**40**:582–596. http://www.sjweh.fi/download.php?abstract_id=3449&file_nro=1
41 (accessed 17.08.16).
42
43 47 Warmerdam L, van Straten A, Twisk J, et al. Internet-based treatment for adults with de-
44 pressive symptoms: randomized controlled trial. *J Med Internet Res* 2008;**10**:e44.
45 <http://www.jmir.org/2008/4/e44/> (accessed 17.08.16).
46
47 48 Ebert DD, Berking M, Thiart H, et al. Restoring depleted resources: Efficacy and mecha-
48 nisms of change of an internet-based unguided recovery training for better sleep and
49 psychological detachment from work. *Health Psychol* 2015;**34** *Suppl*:1240–1251.
50 <https://www.apa.org/pubs/journals/releases/hea-hea0000277.pdf> (accessed 17.08.16).
51
52 49 Thiart H, Lehr D, Ebert DD, et al. Log in and breathe out: internet-based recovery training
53 for sleepless employees with work-related strain - results of a randomized controlled tri-
54 al. *Scand J Work Environ Health* 2015;**41**:164–174.
55 http://www.sjweh.fi/show_abstract.php?abstract_id=3478&fullText=1#box-fullText (ac-
56 cessed 17.08.16).
57
58 50 Baglioni C, Battagliese G, Feige B, et al. Insomnia as a predictor of depression: a meta-
59 analytic evaluation of longitudinal epidemiological studies. *J Affect Disord* 2011;**135**:10–
60 19. <http://www.sciencedirect.com/science/article/pii/S0165032711000292> (accessed
17.08.16).

- 1
2
3 51 Morin CM, Bootzin RR, Buysse DJ, et al. Psychological and behavioral treatment of in-
4 somnia: update of the recent evidence (1998-2004). *Sleep* 2006;**29**:1398.
5 <http://www.journalsleep.org/ViewAbstract.aspx?pid=26676> (accessed 17.08.16).
6
7 52 Fry JP, Neff RA. Periodic prompts and reminders in health promotion and health behavior
8 interventions: systematic review. *J Med Internet Res* 2009;**11**:e16.
9 <http://www.jmir.org/2009/2/e16/> (accessed 17.08.16).
10
11 53 Ritterband L, Gonder-Frederick L, Cox D, et al. Internet interventions: In review, In use,
12 and Into the future. *Prof Psychol Res Pr* 2003;**34**:527.
13 <http://psycnet.apa.org/psycinfo/2003-08155-014> (accessed 17.08.16).
14
15 54 Webb T, Joseph J, Yardley L, et al. Using the internet to promote health behavior change:
16 a systematic review and meta-analysis of the impact of theoretical basis, use of behavior
17 change techniques, and mode of delivery on efficacy. *J Med Internet Res* 2010;**12**.
18 <http://www.jmir.org/2010/1/e4/> (accessed 17.08.16).
19
20 55 Baumeister H, Reichler L, Munzinger M, et al. The impact of guidance on Internet-based
21 mental health interventions — A systematic review. *Internet Interv* 2014;**1**:205–215.
22 <http://www.sciencedirect.com/science/article/pii/S2214782914000244> (accessed
23 17.08.16).
24
25 56 Almlöv J, Carlbring P, Berger T, et al. Therapist factors in internet-delivered cognitive be-
26 havioural therapy for major depressive disorder. *Cogn Behav Ther* 2009;**38**:247–254.
27 <http://www.tandfonline.com/doi/abs/10.1080/16506070903116935?journalCode=sbeh20>
28 0 (accessed 17.08.16).
29
30 57 Kleiboer A, Donker T, Seekles W, et al. A randomized controlled trial on the role of sup-
31 port in Internet-based problem solving therapy for depression and anxiety. *Behav Res*
32 *Ther* 2015;**72**:63–71.
33 <http://www.sciencedirect.com/science/article/pii/S000579671530005X> (accessed
34 17.08.16).
35
36 58 Hakkaart-Van Roijen L, van Straten A, Donker M, et al. Trimbos/iMTA questionnaire for
37 costs associated with psychiatric illness (TIC-P). Institute for Medical Technology Assess-
38 ment, Erasmus University Rotterdam. Trimbos 2002.
39
40 59 Erbe D, Eichert H, Rietz C, et al. Interformat reliability of the patient health questionnaire:
41 Validation of the computerized version of the PHQ-9. *Internet Interv* 2016;**5**:1–4.
42 <http://www.sciencedirect.com/science/article/pii/S2214782916300033> (accessed
43 17.08.16).
44
45 60 Kroenke K, Spitzer RL, Williams JBW. The PHQ-9. *J Gen Intern Med* 2001;**16**:606–613.
46 <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1495268/> (accessed 17.08.16).
47
48 61 Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symp-
49 tomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric
50 evaluation in patients with chronic major depression. *Biol Psychiatry* 2003;**54**:573–583.
51 <http://www.sciencedirect.com/science/article/pii/S0006322302018668> (accessed
52 17.08.16).
53
54 62 First MB, Spitzer RL, Gibbon M, et al. User's guide for the Structured clinical interview for
55 DSM-IV axis I disorders SCID-I: clinician version: American Psychiatric Pub 1997.
56
57 63 Wittchen HU, Zaudig M, Fydrich T. *Strukturiertes Klinisches Interview für DSM-IV*. Göttin-
58 gen: Hogrefe 1997.
59
60 64 American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders:*
61 *DSM-5: ManMag* 2003.

- 1
2
3 65 Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. *Fam Med* 2005;**37**:360–363. <http://www.stfm.org/fmhub/fm2005/May/Anthony360.pdf> (accessed 17.08.16).
- 4
5
6
7 66 Fleiss JL, ed. *The Design and Analysis of Clinical Experiments*. Hoboken, NJ, USA: John Wiley & Sons, Inc 1999.
- 8
9 67 Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for depression in patients with coronary artery disease. *Cochrane Database Syst Rev* 2011:CD008012. <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008012.pub3/full> (accessed 17.08.16).
- 10
11
12
13
14 68 Baumeister H, Hutter N. Collaborative care for depression in medically ill patients. *Curr Opin Psychiatry* 2012;**25**:405–414. <http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0951-7367&volume=25&issue=5&spage=405> (accessed 17.08.16).
- 15
16
17
18
19 69 Hamilton M. A rating scale for depression. *J Neurol Neurosurg Psychiatry* 1960;**23**:56–62. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC495331/> (accessed 17.08.16).
- 20
21
22
23 70 Riedel M, Möller H, Obermeier M, et al. Response and remission criteria in major depression—a validation of current practice. *J Psychiatr Res* 2010;**44**:1063–1068. <http://www.journalofpsychiatricresearch.com/article/S0022-3956%2810%2900075-0/fulltext> (accessed 17.08.16).
- 24
25
26
27 71 Richardson, Jeffrey R J, Peacock SJ, Hawthorne G, et al. Construction of the descriptive system for the assessment of quality of life AQoL-6D utility instrument. *Health Qual Life Outcomes* 2012;**10**:38. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3349491/> (accessed 11.5.16).
- 28
29
30
31 72 Allen M, Iezzoni LI, Huang A, et al. Improving patient-clinician communication about chronic conditions: description of an internet-based nurse E-coach intervention. *Nurs Res* 2008;**57**:107–112. <http://www.ncbi.nlm.nih.gov/pubmed/18347482> (accessed 17.08.16).
- 32
33
34
35 73 Rabin R, Charro Fd. EQ-SD: a measure of health status from the EuroQol Group. *Ann. Med.* 2001;**33**:337–343. <http://www.ncbi.nlm.nih.gov/pubmed/11491192> (accessed 17.08.16).
- 36
37
38
39 74 Mannion AF, Junge A, Grob D, et al. Development of a German version of the Oswestry Disability Index. Part 2: sensitivity to change after spinal surgery. *Eur Spine J* 2006;**15**:66–73. <http://link.springer.com/article/10.1007%2Fs00586-004-0816-z> (accessed 17.08.16).
- 40
41
42
43 75 Wittink H, Turk DC, Carr DB, et al. Comparison of the redundancy, reliability, and responsiveness to change among SF-36, Oswestry Disability Index, and Multidimensional Pain Inventory. *Clin J Pain* 2004;**20**:133–142. <http://www.ncbi.nlm.nih.gov/pubmed/15100588> (accessed 17.08.16).
- 44
45
46
47 76 Nicholas MK. The pain self-efficacy questionnaire: Taking pain into account. *Eur J Pain* 2007;**11**:153–163. <http://onlinelibrary.wiley.com/doi/10.1016/j.ejpain.2005.12.008/full> (accessed 17.08.16).
- 48
49
50
51 77 Mittag O, Raspe H. A brief scale for measuring subjective prognosis of gainful employment: findings of a study of 4279 statutory pension insureds concerning reliability (Guttman scaling) and validity of the scale. *Die Rehabilitation* 2003;**42**:169–174. <https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2003-40095> (accessed 17.08.16).
- 52
53
54
55 78 Boß L, Lehr D, Vis C, et al. Assessing Client Satisfaction in web-based interventions. *The CSWQ-8*. JMIR in prep.
- 56
57
58
59
60

- 1
2
3 79 Larsen DL, Attkisson CC, Hargreaves WA, et al. Assessment of client/patient satisfaction:
4 development of a general scale. *Eval Program Plann* 1979;**2**:197–207.
5 <http://www.sciencedirect.com/science/article/pii/0149718979900946> (accessed
6 17.08.16).
- 7
8 80 Ebert DD, Heber E, Berking M, et al. Self-guided internet-based and mobile-based stress
9 management for employees: results of a randomised controlled trial. *Occup. Environ.*
10 *Med.* 2016;**73**:315–323. [http://oem.bmj.com/content/early/2016/02/16/oemed-2015-](http://oem.bmj.com/content/early/2016/02/16/oemed-2015-103269.full.pdf)
11 [103269.full.pdf](http://oem.bmj.com/content/early/2016/02/16/oemed-2015-103269.full.pdf) (accessed 17.08.16).
- 12
13 81 Thiart H, Lehr D, Ebert DD, et al. Log in and breathe out: efficacy and cost-effectiveness
14 of an online sleep training for teachers affected by work-related strain--study protocol
15 for a randomized controlled trial. *Trials* 2013;**14**:169.
16 <http://trialsjournal.biomedcentral.com/articles/10.1186/1745-6215-14-169> (accessed
17 17.08.16).
- 18
19 82 Duggan C, Parry G, McMurrin M, et al. The recording of adverse events from psychologi-
20 cal treatments in clinical trials: Evidence from a review of NIHR-funded trials. *Trials*
21 2014;**15**:335. <http://trialsjournal.biomedcentral.com/articles/10.1186/1745-6215-15-335>
22 (accessed 17.08.16).
- 23
24 83 Horigian VE, Robbins MS, Dominguez R, et al. Principles for defining adverse events in
25 behavioral intervention research: lessons from a family-focused adolescent drug abuse
26 trial. *Clinical Trials* 2010;**7**:58–68.
27 <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3163837/> (accessed 17.08.16).
- 28
29 84 Ladwig I, Rief W, Nestoriuc Y. Welche Risiken und Nebenwirkungen hat Psychotherapie?-
30 Entwicklung des Inventars zur Erfassung Negativer Effekte von Psychotherapie (INEP).
31 *Verhaltenstherapie* 2014;**24**:252–263. <http://www.karger.com/Article/PDF/367928>
32 (accessed 17.08.16).
- 33
34 85 Haase R, Schultheiss T, Kempcke R, et al. Use and acceptance of electronic communica-
35 tion by patients with multiple sclerosis: a multicenter questionnaire study. *J Med Internet*
36 *Res* 2012;**14**:e135. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3510727/> (accessed
37 17.08.16).
- 38
39 86 Schafer JL, Graham JW. Missing data: our view of the state of the art. *Psychological*
40 *methods* 2002;**7**:147. <http://psycnet.apa.org/journals/met/7/2/147/> (accessed 17.07.16).
- 41
42 87 Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence,
43 impact on daily life, and treatment. *Eur J Pain* 2006;**10**:287–333.
44 <http://www.sciencedirect.com/science/article/pii/S1090380105000868> (accessed
45 17.08.16).
- 46
47 88 Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for
48 depression in patients with diabetes mellitus and depression. *Cochrane Database Syst*
49 *Rev* 2012;**12**:CD008381.
50 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008381.pub2/full> (accessed
51 17.08.16).
- 52
53 89 Cuijpers P, van Straten A, Warmerdam L, et al. Recruiting participants for interventions to
54 prevent the onset of depressive disorders: Possible ways to increase participation rates.
55 *BMC Health Serv Res* 2010;**10**:181–7.
56 <https://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-10-181> (ac-
57 cessed 17.08.16).
- 58
59 90 Gilbody S, Littlewood E, Hewitt C, et al. Computerised cognitive behaviour therapy (cCBT)
60 as treatment for depression in primary care (REEACT trial): large scale pragmatic random-

- 1
2
3 ised controlled trial. *BMJ* 2015;**351**:h5627. <http://www.bmj.com/content/351/bmj.h5627>
4 (accessed 17.08.16).
- 5 91 Baumeister H. Kein signifikanter Zusatznutzen als Add-on in der allgemeinärztlichen
6 Routineversorgung: (Review und Kommentar). *InFo Neurologie* 2016;**18**:14–15.
7 <http://link.springer.com/article/10.1007/s15005-016-1601-3/fulltext.html?view=classic>
8 (accessed 17.08.16).
- 9 92 Baumeister H, Seifferth H, Lin J, et al. Impact of an Acceptance Facilitating Intervention
10 on Patients' Acceptance of Internet-based Pain Interventions - A Randomised Controlled
11 Trial. *Clin J Pain* 2015:528–535. <http://www.ncbi.nlm.nih.gov/pubmed/24866854> (ac-
12 cessed 17.08.16).
- 13 93 Ebert DD, Berking M, Cuijpers P, et al. Increasing the acceptance of internet-based men-
14 tal health interventions in primary care patients with depressive symptoms. A random-
15 ized controlled trial. *J Affect Disord* 2015:9–17.
16 [http://linkinghub.elsevier.com/retrieve/pii/S0165-0327\(15\)00069-5](http://linkinghub.elsevier.com/retrieve/pii/S0165-0327(15)00069-5) (accessed 17.08.16).
- 17 94 Baumeister H, Nowoczin L, Lin J, et al. Impact of an acceptance facilitating intervention
18 on diabetes patients' acceptance of Internet-based interventions for depression: A ran-
19 domized controlled trial. *Diabetes Res Clin Pract* 2014.
20 <http://www.sciencedirect.com/science/article/pii/S0168822714002149> (accessed
21 17.08.16).
- 22 95 Coleman EA, Berenson RA. Lost in transition: challenges and opportunities for improving
23 the quality of transitional care. *Ann Intern Med* 2004;**141**:533–536.
24 <http://annals.org/article.aspx?articleid=717858> (accessed August 17, 2016).
- 25 96 Batterham PJ, Sunderland M, Clear AL, et al. Developing a roadmap for the translation
26 of e-mental health services for depression. *Aust N Z J Psychiatry* 2015;**49**:776–784.
27 <http://anp.sagepub.com/content/49/9/776.long> (accessed September 15, 2016).
- 28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: Key variables and measurements

Variables	Measurement	Depression screenings			T0	T1	T2
		1	2	3			
Inclusion/exclusion criteria							
Chronic back pain	MR + TI	x			x		
Mild to moderate depression or dysthymia	PHQ-9/HAM-D/QIDS/SCID				x	x	x
Severe depression (ICD-10 F32.2/F32.3/F33.2/F33.3 diagnosis)	SCID				x	x	x
Suicidality	HAM-D/QIDS/SCID				x	x	x
	PHQ-9	x	x	x	x	x	x
Further inclusion and exclusion criteria 1, 4, 5 and 6	SRQ +TI	x			x		
Primary outcome							
Depression severity	HAM-D				x	x	x
Secondary outcomes							
Depression remission and response	HAM-D /SCID/QIDS				x	x	x
Quality of life	AQoL-6D/ EQ-5D-5L				x	x	x
Pain intensity	Numerical Rating scale				x	x	x
Pain related disability	ODI				x	x	x
Pain self-efficacy	PSEQ				x	x	x
Work capacity	SPE				x	x	x
Measurements for the economic evaluation							
Costs	TiC-P				x		x
Quality of life	AQoL-6D/ EQ-5D-5L				x	x	x
Covariates							
Demographic variables	SRQ/MR	x			x		
Depression type and chronicity	SCID				x	x	x
Prior depression treatment	TI				x	x	
Back Pain type and chronicity	MR	x			x		
Internet affinity	IAS				x	x	
Patient adherence *	attrition rate				x	x	
Patient satisfaction *	CSQ-8					x	
Negative effects of the intervention	INEP/SRQ/TI/SReC						x

AQoL-6D = Assessment of Quality of Life; CSQ-8 = Client Satisfaction Questionnaire; EQ-5D-5L = European Quality of Life scale; HAM-D = Hamilton Rating Scale for Depression ; IAS=Internet Affinity Scale; INEP = Inventory for the Assessment of Negative Effects of Psychotherapy; MR = Medical record; ODI= Oswestry Disability Index, PHQ-9= Patient Health Questionnaire-9; PSEQ= Pain Self-Efficacy Questionnaire; SCID = Structured Clinical Interview; SPE = Subjective Prognostic Employment scale; SReC = self-report during treatment to the eCoach; SRQ = self-report assessment questionnaire, TI = telephone interview; TiC-P=Trimbos/iMTA questionnaire for costs associated with psychiatric illness. * intervention group only

Table 2 Overview of the sessions

Session	Depression-specific topics	Back pain-specific topics	Assignments
1	Psychoeducational information about depression	Connection between back pain and depression Pain acceptance	To write down medical history and set goals Homework assignment: mood diary
2	Behavioural activation Information on connection between behaviour and mood	Worrying about back pain-related complications	To create an activity plan Homework assignment: to complete the activation plan.
3	Problem solving I Introduction in problem solving. Information on solvable and unsolvable problems		To work with the 6 problem solving steps based on own problems Homework assignment: to implement the problem solving steps during the week
4	Problem solving II Information about techniques to reduce rumination. Introduction to mindfulness	Rumination about back pain	To review the problem solving steps and implement a technique to stop rumination Homework assignment: to practise and track mindfulness exercises
5	Behavioural activation, focus on physical activity and self-esteem. Connection between mood and movement	Physical activity and back pain. Connection between back pain and physical rest	To raise awareness of successes and strengths. To learn to value oneself Homework assignment: to implement physical activity in daily life
6	Plan for the future Collection of pleasant activities	Conversation with a General Practitioner	To improve patient-physician relationship Homework assignment: to implement positive activities and create a future plan
Additional (optional) sessions			
a	Healthy sleep Information on sleep hygiene, sleep restriction and stimulus control		To implement the 10 rules for healthy sleep into daily life
b	Partnership and sexuality Information on communication skills, physical closeness and sexuality		To implement communication skills and massage exercises in daily life
c	Returning to the workplace Information on self-management and interpersonal competencies	Fitness exercises at the workplace	To set priorities, to implement the 6 steps for problem-solving at the workplace, and to review communication skills
Booster sessions (within 3 months after the regular sessions)			
7	Summary: behavioural activation; review; pleasant activities; problem solving		To reflect on positive changes and update the activity plan; to practice the 6 steps for problem -solving
8	Summary of the key elements, behavioural activation		Choice of the intervention topics (1-6 above)




Figure 1. study flow

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Page NO in manuscript
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
	2b	All items from the World Health Organization Trial Registration Data Set	3
Protocol version	3	Date and version identifier	2
Funding	4	Sources and types of financial, material, and other support	15
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1
	5b	Name and contact information for the trial sponsor	15
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	15
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	15
Introduction			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	4
	6b	Explanation for choice of comparators	(5/10)
Objectives	7	Specific objectives or hypotheses	5

1				
2	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	5-6
3				
4				
5				
6				
7				
8	Methods: Participants, interventions, and outcomes			
9				
10	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	6
11				
12				
13				
14	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	7
15				
16				
17				
18	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	8-9
19				
20				
21				
22		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	7
23				
24				
25				
26		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	9,14
27				
28				
29				
30		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	7
31				
32				
33	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	10-12
34				
35				
36				
37				
38				
39				
40				
41	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	6
42				
43				
44				
45	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	10
46				
47				
48				
49	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	6-7
50				
51				
52				
53	Methods: Assignment of interventions (for controlled trials)			
54				
55	Allocation:			6
56				
57				
58				
59				
60				

1				
2	Sequence	16a	Method of generating the allocation sequence (eg, computer-	6
3	generation		generated random numbers), and list of any factors for	
4			stratification. To reduce predictability of a random sequence,	
5			details of any planned restriction (eg, blocking) should be	
6			provided in a separate document that is unavailable to those	
7			who enrol participants or assign interventions	
8				
9	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central	6
10	concealment		telephone; sequentially numbered, opaque, sealed envelopes),	
11	mechanism		describing any steps to conceal the sequence until interventions	
12			are assigned	
13				
14	Implementation	16c	Who will generate the allocation sequence, who will enrol	6
15			participants, and who will assign participants to interventions	
16				
17	Blinding	17a	Who will be blinded after assignment to interventions (eg, trial	6,10
18	(masking)		participants, care providers, outcome assessors, data analysts),	
19			and how	
20		17b	If blinded, circumstances under which unblinding is permissible,	7
21			and procedure for revealing a participant's allocated intervention	
22			during the trial	
23				
24				
25				
26				
27	Methods: Data collection, management, and analysis			
28	Data collection	18a	Plans for assessment and collection of outcome, baseline, and	5,10-
29	methods		other trial data, including any related processes to promote data	12
30			quality (eg, duplicate measurements, training of assessors) and	
31			a description of study instruments (eg, questionnaires,	
32			laboratory tests) along with their reliability and validity, if known.	
33			Reference to where data collection forms can be found, if not in	
34			the protocol	
35		18b	Plans to promote participant retention and complete follow-up,	5
36			including list of any outcome data to be collected for participants	
37			who discontinue or deviate from intervention protocols	
38				
39	Data	19	Plans for data entry, coding, security, and storage, including any	13
40	management		related processes to promote data quality (eg, double data entry;	
41			range checks for data values). Reference to where details of	
42			data management procedures can be found, if not in the	
43			protocol	
44				
45	Statistical	20a	Statistical methods for analysing primary and secondary	12-13
46	methods		outcomes. Reference to where other details of the statistical	
47			analysis plan can be found, if not in the protocol	
48		20b	Methods for any additional analyses (eg, subgroup and adjusted	13
49			analyses)	
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

1				
2		20c	Definition of analysis population relating to protocol non-	13
3			adherence (eg, as randomised analysis), and any statistical	
4			methods to handle missing data (eg, multiple imputation)	
5				
6				
7				
8				
9				
10				
11				
12				
13				
14				
15				
16				
17				
18				
19				
20				
21				
22				
23				
24				
25				
26				
27				
28				
29				
30				
31				
32				
33				
34				
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

1				
2	Ancillary and	30	Provisions, if any, for ancillary and post-trial care, and for	n.a.
3	post-trial care		compensation to those who suffer harm from trial participation	
4				
5	Dissemination	31a	Plans for investigators and sponsor to communicate trial results	14
6	policy		to participants, healthcare professionals, the public, and other	
7			relevant groups (eg, via publication, reporting in results	
8			databases, or other data sharing arrangements), including any	
9			publication restrictions	
10				
11		31b	Authorship eligibility guidelines and any intended use of	15 /
12			professional writers	n.a.
13				
14		31c	Plans, if any, for granting public access to the full protocol,	n.a.
15			participant-level dataset, and statistical code	
16				
17				
18	Appendices			
19				
20	Informed consent	32	Model consent form and other related documentation given to	6
21	materials		participants and authorised surrogates	
22				
23	Biological	33	Plans for collection, laboratory evaluation, and storage of	n.a.
24	specimens		biological specimens for genetic or molecular analysis in the	
25			current trial and for future use in ancillary studies, if applicable	
26				

27 *It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013
 28 Explanation & Elaboration for important clarification on the items. Amendments to the
 29 protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT
 30 Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by/3.0/)"
 31 license.
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60

BMJ Open

Effectiveness and cost-effectiveness of a guided internet- and mobile-based depression intervention for individuals with chronic back pain: protocol of a multi-centre randomised controlled trial



Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-015226.R1
Article Type:	Protocol
Date Submitted by the Author:	16-Jun-2017
Complete List of Authors:	Lin, Jiayi; Albert-Ludwigs-Universitat Freiburg, Department of Rehabilitation Psychology and Psychotherapy, Institute of Psychology Sander, Lasse; Albert-Ludwigs-Universitat Freiburg, Department of Rehabilitation Psychology and Psychotherapy, Institute of Psychology Paganini, Sarah; Albert-Ludwigs-Universitat Freiburg, Department of Rehabilitation Psychology and Psychotherapy, Institute of Psychology Schlicker, Sandra; Universitatsklinikum Erlangen, Department of Clinical Psychology and Psychotherapy, Institute of Psychology Ebert, David; Friedrich-Alexander University Erlangen Nuremberg, Clinical Psychology and Psychotherapy Berking, Matthias; Universitatsklinikum Erlangen, Department of Clinical Psychology and Psychotherapy, Institute of Psychology Bengel, Jürgen; Albert-Ludwigs-Universitat Freiburg, Department of Rehabilitation Psychology and Psychotherapy, Institute of Psychology Nobis, Stephanie; Hochschule Vechta, Department of Gerontology Lehr, Dirk; University of Lüneburg, Department of Psychology Mittag, Oskar; Universitatsklinikum Freiburg, Center for Medical Biometry and Medical Informatics, Section of Health Care Research and Rehabilitation Riper, Heleen; VU University Amsterdam, Dept. of Clinical Psychology Baumeister, Harald; Universitat Ulm, Department of Clinical Psychology and Psychotherapy, Institute of Psychology
Primary Subject Heading:	Mental health
Secondary Subject Heading:	Evidence based practice, Health economics, Health services research, Public health, Rehabilitation medicine
Keywords:	depression, chronic back pain, e-mental-health, health care services research, randomized controlled trial, study protocol

SCHOLARONE™
Manuscripts

1
2
3 **Effectiveness and cost-effectiveness of a guided internet- and mobile-based depression**
4 **intervention for individuals with chronic back pain: protocol of a multi-centre random-**
5 **ised controlled trial**
6
7
8
9
10

11 Jiaxi Lin¹ (jiaxi.lin@psychologie.uni-freiburg.de)

12 Lasse Sander¹ (lasse.sander@psychologie.uni-freiburg.de)

13 Sarah Paganini¹ (sarah.paganini@psychologie.uni-freiburg.de)

14 Sandra Schlicker² (sandra.schlicker@fau.de)

15 David Ebert² (david.ebert@fau.de)

16 Matthias Berking² (matthias.berking@fau.de)

17 Jürgen Bengel¹ (bengel@psychologie.uni-freiburg.de)

18 Stephanie Nobis³ (stephanie.nobis@uni-vechta.de)

19 Dirk Lehr⁴ (dirk.lehr@inkubator.leuphana.de)

20 Oskar Mittag⁵ (oskar.mittag@uniklinik-freiburg.de)

21 Heleen Riper⁶ (h.riper@vu.nl)

22 Harald Baumeister⁷ (harald.baumeister@uni-ulm.de)

23
24
25
26
27
28
29
30
31
32
33
34
35 1) Department of Rehabilitation Psychology and Psychotherapy, Institute of Psychology,
36 University of Freiburg, Germany

37
38 2) Department of Clinical Psychology and Psychotherapy, Institute of Psychology, University
39 of Erlangen-Nürnberg, Germany

40
41 3) Department of Gerontology, University of Vechta, Germany

42
43 4) Department of Psychology, Leuphana University Lüneburg, Germany

44
45 5) Center for Medical Biometry and Medical Informatics, Section of Health Care Research
46 and Rehabilitation, Medical Center, University of Freiburg, Germany

47
48 6) Department of Clinical, Neuro and Developmental Psychology, VU University Amster-
49 dam, Netherlands

50
51 7) Department of Clinical Psychology and Psychotherapy, Institute of Psychology, University
52 of Ulm, Germany

53
54
55
56 Issue Date: 22 November 2016

57
58 Revision Date: 28 May 2017

1
2
3
4
5 Correspondence:

6 Address corresponding author:

7 Prof. Dr. Harald Baumeister

8 Department of Clinical Psychology and Psychotherapy,

9 Institute of Psychology and Education, University of Ulm,

10 Albert-Einstein-Allee 47, D-89069 Ulm, Germany

11 Phone: +49-(0)731-50-31180

12 Email: harald.baumeister@uni-ulm.de

Abstract

Introduction: Depression often co-occurs with chronic back pain (CBP). Internet- and mobile-based interventions (IMIs) might be a promising approach for effectively treating depression in this patient group. In the present study, we will evaluate the effectiveness and cost-effectiveness of a guided depression IMI for individuals with CBP (eSano BackCare-D) integrated into orthopaedic health care.

Methods and analysis: In this multicentre randomised controlled trial (RCT) of parallel design, the groups eSano BackCare-D vs. treatment as usual will be compared. 210 participants with CBP and diagnosed depression will be recruited subsequent to orthopedic rehabilitation care. Assessments will be conducted prior to randomisation and 9 weeks (posttreatment) and 6 months after randomisation. The primary outcome is depression severity (HAM-D-17). Secondary outcomes are depression remission and response, health related quality of life, pain intensity, pain related disability, self-efficacy and work capacity. Demographic and medical variables as well as internet affinity, intervention adherence, intervention satisfaction and negative effects will also be assessed. Data will be analysed on an intention-to-treat basis and an additional per-protocol analysis. Moreover, a cost-effectiveness and cost-utility analysis will be conducted from a societal perspective after 6 months.

Discussion

The innovative approach of using an IMI to treat depression in people with CBP will substantially increase the likelihood of psychological interventions being accessible in routine health care.

Ethics and dissemination: All procedures are approved by the ethics committee of the Albert-Ludwigs-University of Freiburg and the data security committee of the German Pension Insurance (Deutsche Rentenversicherung). The results will be published in peer-reviewed journals and presented on international conferences.

Registration details: The trial is registered at the WHO International Clinical Trials Registry Platform via the German Clinical Studies Trial Register (DRKS): (DRKS00009272).

Keywords: Guided self-help; Internet-based; Chronic back pain; Depression; after care; Randomised controlled trial, effectiveness, cost-effectiveness

Strengths and limitations of this study

- This is a protocol for the first large scale, multi-centre RCT examining the effectiveness of a depression IMI for individuals with CBP and depression.
- This is the first trial examining the cost-effectiveness of a depression IMI for individuals with CBP and depression.
- The IMI will be implemented as integrated part of routine orthopaedic health care, thus overcoming the self-referral bias of most prior IMI trials.
- The IMI will take place after routine orthopaedic health care, examining the possibility to improve patients' medical sector transitions by means of an e-mental-health offer.
- We use standardised interviews for the diagnosis and clinical rating scales for the assessment of the severity level of depression (SKID and HAMD/QIDS).

Introduction

The two widespread conditions chronic back pain (CBP) and depression belong to the top ten causes of years lived with disability (YLDs) worldwide [1]. The global one-month adult prevalence for low back pain is estimated to be 23.2% and a substantial increase during the next decades can be expected [2]. Depression has been shown to be the leading cause of burden of diseases in middle- to high-income countries with a lifetime prevalence of about 14.6% [3]. A strong association between depression and CBP has been frequently reported with prevalence rates for depression ranging from 21% to 50% in back pain and chronic low back pain individuals [4]. Several systematic reviews highlight a significant prognostic association between comorbid depression and increased morbidity of different somatic conditions and health care costs as well as diminished quality of life [5–7]. Moreover, depression is one of the core predictors of persistent pain symptoms, increased pain-related disability, and poor treatment outcomes in pain patients [4, 8, 9].

There is strong evidence for the efficacy of psychological interventions for chronic pain [10] and especially for chronic low back pain [11] aiming at pain intensity or disability/interference as primary outcomes. To the best of our knowledge however, there is no study that has examined the effects of psychological depression interventions in the population of CBP focussing on depression as the primary outcome [12]. Indeed, the evidence on depression treatments for patients with chronic pain and clinical depression is very limited, mostly relying on a few collaborative/stepped care trials conducted in the last two decades [13–15].

In order to improve health care for CBP individuals, internet- and mobile-based interventions (IMIs) are considered to be a promising approach [16, 17]. Among numerous meta-analyses

1
2
3 highlighting the efficacy of IMIs with regard to the reduction of depressive symptoms [18–
4 21], one meta-analysis quantified the superiority of online depression interventions over wait-
5 ing-list and treatment as usual (TAU) with standardised mean differences of $d=-.68$ (CI: $-.85;-$
6 $.52$; $n=8$) and $d=-.39$ (CI: $-.66;-.12$; $n=8$) [20], albeit effect moderating factors of IMIs remain
7 unclear [22]. As most trials used highly selective recruitment strategies, the evidence for the
8 effectiveness of IMIs for depression (i.e., performance of an intervention when implemented
9 within typical clinical practice, investigated by means of pragmatic trials) is far less conclu-
10 sive [23] and many health systems have not included IMIs as an integrated treatment compo-
11 nent. As an implemented part of a comprehensive care system, IMIs could reduce the defi-
12 ciencies of most current health care systems in coordinating transitions of care, such as the
13 transition from the inpatient to outpatient setting, where recommendations are regularly lost in
14 transition [24–26].

15 The present WARD-BP study (web-based aftercare depression intervention following reha-
16 bilitation for individuals with depression and chronic back pain) aims to investigate the effec-
17 tiveness and cost-effectiveness of the depression IMI “eSano BackCare-D” in a study popula-
18 tion of CBP with a diagnosed depression in the aftermath of orthopaedic rehabilitation care.

19 The primary research question is:

20 1) Is eSano BackCare-D effective in reducing depression in individuals with CBP and diag-
21 nosed depression compared to treatment as usual (TAU)?

22 Secondary research questions are:

23 2) Is eSano BackCare-D effective with regard to depression remission and response, health
24 related quality of life, pain intensity, pain related disability, self-efficacy and work capacity in
25 individuals with CBP and diagnosed depression compared to TAU?

26 3) Is eSano BackCare-D cost-effective in individuals with CBP and diagnosed depression
27 compared to TAU from a societal perspective?

28 4) Which factors moderate and mediate the effects of eSano BackCare-D?

29 **Methods and analysis**

30 *Study design*

31 WARD-BP is a multi-centre pragmatic randomised controlled clinical trial (RCT) of parallel
32 design. All participants receive TAU. We conduct assessments in both groups before random-
33 isation (T0), nine weeks (T1= post treatment in case of regular IMI use) and six months (T2)
34 after randomisation. Trial participants receive 15€ per completed post- and follow-up tele-
35 phone assessment, see figure 1 for study flow.

- Figure 1 about here -

Randomisation

Randomisation and allocation of participants to the two groups (intervention or TAU) was prepared in advance by an independent researcher (SaS) by means of a web-based program (<https://www.sealedenvelope.com/>) using permuted block randomisation with variable block sizes of 4,6,8 (randomly arranged), ratio of 1:1. Participants are stratified by center. Centers are all eight orthopedic clinics where recruitment is conducted personally and a ninth (meta-)clinic, which includes all participants recruited by letter (see recruitment). The independent researcher (SaS) is responsible for the allocation of participants to trial arms as well as the administration of the trial and is blinded to the treatment process and assessments of the participants.

Recruitment

Recruitment has started in October 2015 and is planned to end in July 2017. While this study protocol has been submitted for publication after start of recruitment (due to usual writing-up, commenting and approving procedures by all co-authors), clinical trial registry took place a-priori to recruitment start.

Using the Patient Health Questionnaire (PHQ-9; [27]), we conduct two consecutive depression screenings within 2-3 weeks. In case of only one positive screening ($\text{PHQ} \geq 5$), a third PHQ will be administered two months later via telephone interview. We recruit potential participants in orthopaedic rehabilitation units in Germany with two different recruitment strategies.

In the first recruitment setting (personal recruitment), patients with two positive screenings receive information on the intervention by clinic staff during their orthopedic care. Patients providing their informed consent are contacted by the study team in order to clarify further eligibility criteria by means of an online- and telephone assessment including a telephone administered clinical interview. The participating clinics are compensated for their recruitment efforts (i.e. selection of back pain patients, screening procedure, informed consent, documentation according to CONSORT, providing access to medical records) with 320€ per randomised participant. The second recruitment strategy (recruitment by letter) involves a letter with information flyers and study process for back pain patients after discharge from

1
2
3 orthopaedic rehabilitation units across Germany with a link to fill out an online PHQ-
4 screening. Individuals screened positive, providing informed consent are contacted for the
5 second PHQ-screening and a clinical interview via telephone equivalent to the first recruit-
6 ment strategy.
7
8

9 10 11 ***Inclusion/exclusion criteria***

12 We include patients if they fulfil the following inclusion criteria:

- 13 1) age 18 years or older
- 14 2) CBP assessed by physician for at least six months assessed during telephone interview
- 15 3) mild to moderate depression or dysthymia according to SCID assessment, assessed during
16 telephone interview
- 17 4) sufficient knowledge of German language
- 18 5) Internet and PC access.

19 Patients are excluded in case of :

- 20 6) receiving ongoing psychotherapy or beginning psychotherapy within the next three months,
- 21 7) being currently suicidal or reporting suicidal attempts in the past five years assessed during
22 telephone interview or
- 23 8) a current diagnosis of severe depression (ICD-10 F32.2/F32.3/F33.2/F33.3 diagnosis) as-
24 sessed during telephone interview, see table 1.

25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
The exclusion of individuals with severe depression is due to ethical concerns and based on
ICD-10 criteria for severe depression according to the German treatment guidelines for de-
pression [28]. A trained psychotherapist (HB, LS, EM or SaS) contacts the participant to initi-
ate further actions when severe depression is classified. We invite participants with a depres-
sion severity of PHQ \geq 5, who do not fulfil the criteria to participate, in a parallel conducted
trial for CBP and subclinical depressive symptoms: eSano BackCare-DP [29].

45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 **Procedure on suicidal ideation**

Participants who are currently suffering from suicidal ideation are identified by suicide
screenings within the telephone interviews (SCID, HAM-D, QIDS) and questionnaires
(PHQ-9). Following a suicide protocol adapted from prior trials [30–32] we send an email
with detailed information on available health services and the advice to seek professional
help if participants report low suicidal ideation (HAM-D, QIDS or PHQ-9 item score = 1). In
case of moderate to high suicidal ideation during the assessments or any suicidal thoughts or
intentions reported to an eCoach or the study administration, a trained psychotherapist from
the study team (HB, LS, EM or SaS) contacts the participant and initiate further actions.

Table 1: Key variables and measurements

Variables	Measurement	Depression screenings			T0	T1	T2
		1	2	3			
Inclusion/exclusion criteria							
Chronic back pain	MR + TI	x			x		
Mild to moderate depression or dysthymia	PHQ-9/HAM-D/QIDS/SCID				x	x	x
Severe depression (ICD-10 F32.2/F32.3/F33.2/F33.3 diagnosis)	SCID				x	x	x
Suicidality	HAM-D/QIDS/SCID				x	x	x
	PHQ-9	x	x	x	x	x	x
Further inclusion and exclusion criteria 1, 4, 5 and 6	SRQ +TI	x			x		
Primary outcome							
Depression severity	HAM-D				x	x	x
Secondary outcomes							
Depression remission and response	HAM-D /SCID/QIDS				x	x	x
Quality of life	AQoL-6D/ EQ-5D-5L				x	x	x
Pain intensity	Numerical Rating scale				x	x	x
Pain related disability	ODI				x	x	x
Pain self-efficacy	PSEQ				x	x	x
Work capacity	SPE				x	x	x
Measurements for the economic evaluation							
Costs	TiC-P				x		x
Quality of life	AQoL-6D/ EQ-5D-5L				x	x	x
Covariates							
Demographic variables	SRQ/MR	x			x		
Depression type and chronicity	SCID				x	x	x
Prior depression treatment	TI				x	x	
Back Pain type and chronicity	MR	x			x		
Internet affinity	IAS				x	x	
Patient adherence *	attrition rate				x	x	
Patient satisfaction *	CSQ-8					x	
Negative effects of the intervention	INEP/SRQ/TI/SReC					x	

AQoL-6D = Assessment of Quality of Life; CSQ-8 = Client Satisfaction Questionnaire; EQ-5D-5L = European Quality of Life scale; HAM-D = Hamilton Rating Scale for Depression ; IAS=Internet Affinity Scale; INEP = Inventory for the Assessment of Negative Effects of Psychotherapy; MR = Medical record; ODI= Oswestry Disability Index, PHQ-9= Patient Health Questionnaire-9; PSEQ= Pain Self-Efficacy Questionnaire; SCID = Structured Clinical Interview; SPE = Subjective Prognostic Employment scale; SReC = self-report during treatment to the eCoach; SRQ = self-report assessment questionnaire, TI = telephone interview; TiC-P=Trimbos/iMTA questionnaire for costs associated with psychiatric illness. * intervention group only

Intervention development

eSano BackCare-D is based on cognitive behaviour therapy (CBT), systematic behavioural activation [33–35] and problem solving [36]. The depression-specific components are based upon a prior IMI “GET.ON Mood Enhancer”, that has been evaluated in numerous RCTs in different samples [30, 37, 38] and shown to be effective in lowering depressive symptoms in individuals with diabetes mellitus type 1 and 2 with an intention to treat (ITT) effect size of $d=0.89$ at two-months post treatment [38] and $d=0.83$ at 6 months follow up [39]. We added CBP-relevant information, videos and audio clips, based on existing literature on psychological back pain treatment [40, 41], our clinical experience, and an existing IMI for chronic pain individuals based on acceptance and commitment therapy [42, 43]. Think-aloud interviews with five persons with CBP helped us to pilot validate the intervention and further improve its feasibility and acceptability before recruitment start. Access to the platform proceeds through a unique username password combination and is available on a 24/7 basis from all devices with internet access, however, optimized for PCs, notebooks and (large-screen) tablets. It is not possible to assess which device will be used by individual participants. Additionally, a text message coach is provided in eSano BackCare-D that is described below. All transferred data are secured via www.minddistrict.com based on ISO27001 and guidelines NEN7510.

Intervention content

eSano BackCare-D provides six minimally guided sessions with an estimated proceeding duration of 45-60 minutes each, developed to be processed weekly. Three optional sessions with back pain specific topics (sleep, partnership and sexuality, returning to work) are available at the end of sessions 3 through 5. Two booster sessions following the intervention are offered to improve sustainability of intervention effects. Session-specific contents and homework assignments are shown in table 2.

Session 1 provides psychoeducational information on depression, the interaction between CBP and depression as well as pain acceptance. Participants define their depression- and CBP-related goals and get to know the mood diary as the homework assignment for the next week. In session 2, the concept of behavioural activation and the connection between pleasant activities and mood is introduced. Based on the principles of action planning and coping planning [44, 45], participants create an individual list and schedule for completion of pleasant activities in the next few days. The main focus in sessions 3 and 4 is on the six-step plan to handle solvable problems and to better manage emerging issues, comparable to other studies [38, 46–48]. In addition, techniques to reduce rumination on unsolvable problems and the concept of mindfulness are introduced. Session 5 includes information and exercises on phys-

ical activity [35], a mindfulness exercise and techniques to strengthen self-esteem. The sixth session serves to assess intervention-related changes in mood and provides a list of additional treatment options. Participants are encouraged to create a plan for the future. At the end, they write a letter to themselves about specific goals for the next four weeks and choose the date of the next booster session (after two, four or six weeks) that are developed to review what the participants have learned in previous sessions and to provide motivation to maintain and expand learned skills in the future.

The sleep session builds on an evidence based IMI for insomnia, i.e: GET.ON Recovery [49, 50]. As insomnia is a predictor and symptom of depression [51], participants learn about the principles of sleep hygiene, sleep restriction and stimulus control [52]. The partnership and sexuality session provides communication skills and exercises for improving physical closeness and sexuality. In the returning to work session, participants receive information on self-management and interpersonal competences as well as exercises in problem-solving and physical relaxation.

Table 2 Overview of the sessions

Ses- sion	Depression-specific topics	Back pain-specific topics	Assignments
1	Psychoeducational information about depression	Connection between back pain and depression Pain acceptance	To write down medical history and set goals Homework assignment: mood diary
2	Behavioural activation Information on connection between behaviour and mood	Worrying about back pain-related complications	To create an activity plan Homework assignment: to complete the activation plan.
3	Problem solving I Introduction in problem solving. Information on solvable and unsolvable problems		To work with the 6 problem solving steps based on own problems Homework assignment: to implement the problem solving steps during the week
4	Problem solving II Information about techniques to reduce rumination. Introduction to mindfulness	Rumination about back pain	To review the problem solving steps and implement a technique to stop rumination Homework assignment: to practise and track mindfulness exercises
5	Behavioural activation, focus on physical activity and self-esteem. Connection between mood and movement	Physical activity and back pain. Connection between back pain and physical rest	To raise awareness of successes and strengths. To learn to value oneself Homework assignment: to implement physical activity in daily life
6	Plan for the future Collection of pleasant activities	Conversation with a General Practitioner	To improve patient-physician relationship Homework assignment: to implement positive activities and create a future plan
Additional (optional) sessions			
a	Healthy sleep Information on sleep hygiene, sleep restriction and stimulus control		To implement the 10 rules for healthy sleep into daily life
b	Partnership and sexuality Information on communication skills, physical closeness and sexuality		To implement communication skills and massage exercises in daily life

c	Returning to the workplace Information on self-management and interpersonal competencies	Fitness exercises at the workplace	To set priorities, to implement the 6 steps for problem-solving at the workplace, and to review communication skills
Booster sessions (within 3 months after the regular sessions)			
7	Summary: behavioural activation; review; pleasant activities; problem solving		To reflect on positive changes and update the activity plan; to practice the 6 steps for problem -solving
8	Summary of the key elements, behavioural activation		Choice of the intervention topics (1-6 above)

Text message coach

The text message coach in eSano BackCare-D automatically sends one supportive text message per day for the duration of six weeks as text message prompts have been shown to increase efficacy and adherence of IMIs [53–55]. The contents include a) reminders to complete the weekly assignments, b) repetition of the content, and c) motivation enhancement components.

Guidance

Based on previous studies showing that guidance and reminders and strict deadlines seem to be important with regard to the respective primary outcomes and adherence in IMIs [20, 56–58] the feedback manual of eSano BackCare-D provides instructions to remind, set deadlines and formulate standardised feedback for each session. Trained and supervised eCoaches (psychologists) serve as contact person and provide feedback within two work days after each completed session. Feedbacks are adapted to the participants' assignments and include positive reinforcement for completion of assignments and encouragement to proceed with the time spent on guidance will be approximately 60-100 minutes per participant.

Control condition

Participants have unrestricted access to TAU. All types of medical/psychological help received during the last three months are tracked at T0 and T2 with the Trimbos/iMTA questionnaire for costs associated with psychiatric illness [59].

Proposed sample size/power calculations

The sample size calculation is based on the primary endpoint, the HAM-D score at post treatment. According to the results of trials on online interventions for depression [20], a treatment effect (pooled effect size) of $d=0.39$ would be of clinical interest and is considered feasible for the type of treatment. On the basis of a two-sample t-test at two-sided significance

1
2
3 level of 0.05, the study is planned to detect this effect with 80% power. This requires a sample
4 of 105 individuals in each arm.
5
6

7 *Assessments*

8 **Depression screening.** Depressive symptoms are assessed by the Patient Health Question-
9 naire (PHQ-9) which is a well validated depression screening instrument that has also been
10 evaluated to be delivered as online-version [60], with a Cronbach's alpha of .89 and 88% sen-
11 sitivity and 88% specificity for major depression [61].
12
13

14 **Depression diagnosis.** The 17-item HAM-D is the most widely used clinician-rated measure
15 of depression severity and as such viewed as the gold standard for the assessment of depres-
16 sion severity. Additionally, we use the Quick Inventory of Depressive Symptomatology
17 (QIDS [62]) which assesses the severity of depressive symptoms, covering all criterion symp-
18 tom domains of the DSM-IV to diagnose a major depressive episode [62]. Moreover we use
19 Section A (Affective Syndromes) of the Structured Clinical Interview (SCID; [63]) as a com-
20 prehensive, structured interview designed to be used by trained interviewers for the assess-
21 ment of mental disorders according to the definitions and criteria of DSM. It enables a relia-
22 ble, valid and efficient assessment of depressive disorders [64]. As an add-on to the SCID for
23 DSM-IV, we use a German translation of the SCID-V-RV to allow for DSM-V [65] diagnoses
24 as well.
25
26

27 Interviewers are trained and weekly supervised by a psychologist (LS, EM) and are blinded to
28 randomisation condition. At the beginning of each interview, participants and interviewers
29 will be reminded to keep blinding throughout the assessment. After an initial training session,
30 a supervisor and the interviewers assess the same participant together, with comparison of
31 results as follows: The Inter-Rater Reliability (IRR) for the SCID, measured by *Cohen's kap-*
32 *pa* and the *Intra-Class Correlation* for the HAM-D and QIDS. An almost perfect Cohen's
33 kappa $\geq .81$ [66] and an excellent ICC coefficient $\geq .75$ [67] is considered as sufficient. Each
34 interviewer is compared to trainers' rating (LS, EM) until the sufficient IRR values are met.
35 Afterwards, the interviewers are compared to each other on a random basis to assess the IRR.
36
37

38 *Primary outcome*

39 **Depression severity.** Depression severity is the core patient-relevant outcome in trials among
40 depressed individuals [68, 69] and is assessed by means of the clinician-rated Hamilton Rat-
41 ing Scale for Depression (HAM-D-17; [70]) (see table 1) at post-treatment (T1) as part of the
42 telephone interview. Inter-rater reliability of the SCID was reported to be high for inter-rater
43 reliability comparing telephone and face-to-face interviews [71].
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Secondary outcomes

Depression response and remission. HAM-D scores are used to determine depression response in accordance to the recommendations of Jacobson and Truax [72]. Depression remission is assessed by means of the SCID as part of the telephone interviews.

Health related quality of life (QoL). The AQoL-6D includes 20 items and six dimensions and is suitable for quality of life assessments and economic evaluations of health programs with good psychometric properties [73] and a Cronbach's alpha of .89 [74]. We additionally obtain the most widely used quality of life assessment EuroQol (EQ-5D-5L) as a basis for cost-utility analyses with five health domains of importance to quality of life [75].

Pain intensity. We use an 11-point numerical rating (0-10) of the worst, least and average pain during the last week and calculate the mean of the three scales. Additionally, we use a categorical rating of pain intensity (none, mild, moderate, severe).

Pain related disability. We obtain the Oswestry Disability Index (ODI) [76] as a reliable ($\alpha = .86$; [77]) and valid 10 item self-report questionnaire, sensitive to change in difficulties in completing activities of daily living [76].

Pain self-efficacy. The Pain Self-Efficacy Questionnaire (PSEQ) is a validated and reliable (internal consistency: $\alpha = 0.93$) 10 item instrument that assesses self-efficacy expectations related to pain [78].

Work capacity. The subjective prognostic employment scale (SPE) is a validated 3-item self-report questionnaire (sum score 0-3) with high internal consistency (rep (Guttman scaling) = .99; [79]).

Intervention adherence. The attrition rate (calculated using the percentage of individuals who no longer use the intervention, as assessed by their log in data) gives an estimate of the individuals' intervention adherence.

Patient satisfaction.

The Client Satisfaction Questionnaire (CSQ-8, German: ZUF-8), optimised for the assessment of client satisfaction in IMIs (CSIQ-8) [80] is a validated 8 item instrument with high internal consistency ($\alpha = 0.92$) [81]. The adapted version for the assessment of client satisfaction in IMIs has shown to have high internal consistency in a range of studies ($\alpha = 0.92-0.94$) [50, 82, 83] and to be associated with treatment adherence and outcome.

Negative effects of psychotherapy. We include different ways of monitoring serious adverse events (SAE) adapted from the National Institute for Health Research recommendations [84] and Horigian et al. [85] who give general principles and examples to help illustrate their defi-

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

inition of SAEs: participants' responses in interviews, reported SAEs to the eCoach and SAEs assessed by means of the Inventory for the Assessment of Negative Effects of Psychotherapy (INEP) during the online assessments [86]. The INEP consists of 15 items assessing a range of common changes participants experienced in line with the intervention. Cronbach's alpha is $\alpha = 0.86$ [86]. At the beginning of every session, participants are asked about adverse events and are also encouraged to report the events to their eCoach who monitors the SAEs and initiates further actions if needed.

Costs.

We use the German version of the Cost Questionnaire "Trimbos Institute and Institute of Medical Technology Questionnaire for Costs Associated with Psychiatric Illness" (TiC-P; 59), adapted for the German health care system by Nobis and colleagues [32] and for CBP individuals by the present authors. The TiC-P allows assessment of all direct healthcare services received during the last three months. Moreover, direct non-medical costs (e.g. travel costs) and indirect costs are assessed, including the number of 'work loss' days (absenteeism), the number of 'work cut-back' days (presentism) and costs associated with domestic tasks.

Covariates. Demographic variables, prior depression treatments, and internet affinity level are assessed by patient self-report, see table 1. We use the German version of the Internet Affinity Scale (IAS) by Haase and colleagues [87] to assess familiarity with the Internet. Depression type (Major Depression yes/no), baseline severity and depression chronicity are assessed by the SCID, back pain type, severity and chronicity are extracted from medical records.

Statistical Analysis

Clinical analyses. The primary endpoint will be analysed with the HAM-D score at T1 as dependent variable and baseline value as covariates, adjusting for sex and age. Continuous secondary outcomes will be analysed accordingly. Standardised mean differences and 95% confidence intervals will be calculated to measure the between-group effect size at post-treatment and follow-up. Additionally, clinical significance analyses, such as number needed to treat (NNT) will be conducted. All analyses will be performed on an intention-to-treat (ITT) principle with multiple imputations to replace missing data [88]. Completer analyses (per-protocol) will be conducted to investigate the influence of study attrition on study results. Rates of patient-reported adverse events will be compared.

Economic evaluation. We will conduct a cost-effectiveness analysis (CEA) and a cost-utility analysis (CUA). Outcome estimates will be the incremental cost-effectiveness ratio (ICER) and the incremental cost-utility ratio (ICUR) after six months. A cost-effectiveness analysis with depression response as clinical outcome will be conducted. The generic outcome for the cost-utility analysis will be quality-adjusted life-years (QALYs), that will be based on the AQL-6D [73] and in a sensitivity analysis based on the EQ-5D-5L [75]. Both analyses will be conducted from a societal perspective including all direct and indirect costs. Nonparametric bootstrapping will be used to take into account stochastic uncertainty of the ICER. Further, we will calculate a cost-acceptability curve to test the likelihood that the intervention is cost-effective relative to TAU, given varying threshold for the willingness to pay for one depression response or QALY gained, respectively.

Ethics and dissemination

All procedures are approved by the ethics committee of the Albert-Ludwigs-University of Freiburg and the data security committee of the German Pension Insurance (Deutsche Rentenversicherung). The trial has been registered prior to recruitment start at the WHO International Clinical Trials Registry Platform via the German Clinical Studies Trial Register (DRKS): (DRKS00009272).

We conduct and report the RCT in accordance with the CONSORT 2010 Statement [89], the supplement of the CONSORT statement for pragmatic effectiveness trials [89, 90] and current guidelines for executing and reporting Internet intervention research [91]. The results will be published in peer-reviewed journals and presented on international conferences.

Quality assurance and safety

The Clinical Trials Unit Freiburg performs monitoring visits to the participating clinic centres before, during and after completion of the study to ensure that the study is conducted, recorded and reported according to the study protocol, relevant standard operating procedures (SOPs), and requirements of the sponsor and/or the Ethic Committees in accordance with ICH-GCP. Rigorous operating procedures for data management and safety have been implemented.

Furthermore, an independent Data Safety and Monitoring Board (DSMB) consisting of two experienced scientists and psychotherapists (MHä, MHa) and one statistician (LK) with long-standing experience in clinical trials has been established. The function of the DSMB is to monitor the course of the study and, if necessary, to give recommendations to the steering committee for discontinuation, modification or continuation of the study.

Discussion and conclusions

The present effectiveness and cost-effectiveness trial focusses on individuals with CBP and comorbid depression as two of the most frequent, most disabling health conditions with high associated economic burden [5, 92].

The WARD-BP trial is innovative in several ways: a) Studies examining the effectiveness of psychological depression interventions are regularly methodologically limited as they lack diagnostic clarification of depression status [20, 69, 93]. By carrying out the SCID and HAM-D prior to randomization and at follow-up assessments, the present trial will be the first trial on a psychological depression intervention for people with chronic pain with verified DSM diagnosis of depression. b) With a target sample of 210 participants, the study will be optimally powered, overcoming limitations of small scale trials on psychological depression interventions in the medically ill [12, 69, 93]. c) The eSano BackCare-D intervention is tailored to the special needs of the target group of chronic back pain patients. This has been discussed as having an uptake and adherence facilitating effect [94], likely to improve the effectiveness of online interventions. d) The implementation of the intervention into the health-care system overcomes one of the main criticisms regarding IMI trial being only representative for a selective online population [95, 96]. e) The current trial design will allow examination of the reach of this IMI and will provide valuable information about which CBP individuals are willing to utilise such interventions. With the use of two different recruitment strategies, we will be able to compare two different ways of implementing IMIs into clinical routine. This will allow for conclusions on feasible ways of improving the adherence and uptake of IMIs in respective target populations [97–99]. f) Finally, as one of still few clinical trials on psychological depression interventions the present trial comprises a cost-effectiveness analysis.

If the results of WARD-BP indicate that eSano BackCare-D is effective and cost-effective, its clinical impact on depression health care services could be substantial. When implemented as part of the standard health care, IMIs have the potential to reduce the “lost in transition phenomenon” caused by fragmented health care systems [26, 100, 101]. Engaging individuals in treatment at the interface of different health care sectors, as in the present (cost-)effectiveness trial, will contribute important information on potential approaches to improve the delivery of mental health care and at the same time provide insights on possible ways of implementing depression IMIs into chronic back pain care in order to exploit their full potential. The first results of WARD-BP are expected in 2018.

Authors' contributions

HB, DE, MB, OM and HR initiated this study. All authors contributed to the design of this study. HB, LS, SP, DE, SaS, DL, SN, JB, HR, MB and JL developed the intervention content or intervention content eSano BackCare-D is based on as well as the assessment. HB, LS, SP, SaS, DE, and JL are responsible for recruitment. SaS is responsible for randomisation and allocation as well as the administration of participants. JL wrote the draft of the manuscript. HB provided expertise on depression, CBP and psychological pain interventions. All authors contributed to the further writing of the manuscript and approved the final version of the manuscript.

Conflict of interest

JL, LS, SP, SS, JB, SN, OM, HR and HB report no conflict of interest. DE, MB, and DL are stakeholders of the “Institute for Online Health Trainings”, a company aiming to transfer scientific knowledge related to the present research into routine health care. A committee of independent scientists has been formed (Data Safety and Monitoring Board (DSMB)) to supervise study-related decisions and prevent any influence of a potential conflict of interest.

Funding

This study is funded by the Federal Ministry of Education and Research of Germany (project: Effectiveness of a guided web-based intervention for depression in back pain rehabilitation aftercare, Grant number: 01GY1330A). This funding source has no influence on the design of this study and will not influence its execution, analyses, interpretation of the data, or decision to submit results.

Acknowledgements

We thank Dr. Kristin Kieselbach and Prof. Dr. Anja Göritz for their support with providing their expertise in the content of the intervention. We thank colleagues who were part of the development of prior interventions [32, 43] that partly build the basis of eSano© BackCare-D. Moreover we like to thank our study assistants and interns and students for their support in the development of the intervention and in conducting the study. We thank Ellen Meierotto for supervising the SCID-interviewers. Many thanks go to the Data Safety and Monitoring Board, consisting of Prof. Dr. Martin Hautzinger, Prof. Dr. Martin Härter and Dr Levente Kriston as well as the Clinical Trials Unit Freiburg for their support in carrying out the study project.

1
2
3 Special thanks go to the eight orthopedic clinics Schoen Klinik, Bad Staffelstein; Rehaklinik
4 Sonnhalde, Donaueschingen; RehaKlinikum Bad Säckingen; Städt. Rehakliniken Bad Wald-
5 see; Schwarzwaldklinik Orthopädie - Abteilung Medizinische Rehabilitation, Bad Krozingen;
6 Rheintalklinik Bad Krozingen; REGIO-Reha Tagesklinik, Freiburg and Universitäts- und
7 Rehabilitationskliniken, Ulm as well as the further orthopedic rehabilitation units of the se-
8 cond recruitment strategy. We are very grateful to Mary Wyman for proofreading and lan-
9 guage editing of this manuscript.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

- 1 Vos T, Barber RM, Bell B, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. *The Lancet* 2015;**386**(9995):743–800.
<http://www.sciencedirect.com/science/article/pii/S0140673615606924> (accessed 17.8.16).
- 2 Hoy D, Bain C, Williams G, et al. A systematic review of the global prevalence of low back pain. *Arthritis Rheum* 2012;**64**(6):2028–2037.
<http://onlinelibrary.wiley.com/doi/10.1002/art.34347/full> (accessed 17.8.16).
- 3 Bromet E, Andrade LH, Hwang I, et al. Cross-national epidemiology of DSM-IV major depressive episode. *BMC medicine* 2011;**9**:90.
<http://bmcmmedicine.biomedcentral.com/articles/10.1186/1741-7015-9-90> (accessed 17.8.16).
- 4 Bair MJ, Robinson RL, Katon W, et al. Depression and pain comorbidity: a literature review. *Arch Intern Med* 2003;**163**(20):2433–2445.
<http://archinte.jamanetwork.com/article.aspx?articleid=216320> (accessed 17.8.16).
- 5 Baumeister H, Knecht A, Hutter N. Direct and indirect costs in persons with chronic back pain and comorbid mental disorders--a systematic review. *J Psychosom Res* 2012;**73**(2):79–85. <http://www.sciencedirect.com/science/article/pii/S0022399912001468> (accessed 17.08.16).
- 6 Baumeister H, Balke K, Härter M. Psychiatric and somatic comorbidities are negatively associated with quality of life in physically ill patients. *J Clin Epidemiol* 2005;**58**(11):1090–1100.
<http://www.sciencedirect.com/science/article/pii/S0895435605001605> (accessed 17.8.16).
- 7 Baumeister H, Hutter N, Bengel J, et al. Quality of life in medically ill persons with comorbid mental disorders: a systematic review and meta-analysis. *Psychother Psychosom* 2011;**80**(5):275–286. <http://www.karger.com/Article/FullText/323404> (accessed 17.08.16).
- 8 Nicholas MK, Coulston CM, Asghari A, et al. Depressive symptoms in patients with chronic pain. *Med J Aust* 2009;**190**(7):S66. <http://europepmc.org/abstract/MED/19351296> (accessed 17.8.16).
- 9 Miles CL, Pincus T, Carnes D, et al. Can we identify how programmes aimed at promoting self-management in musculoskeletal pain work and who benefits? A systematic review of sub-group analysis within RCTs. *Eur J Pain* 2011;**15**(8):775.e1-11.
<http://www.sciencedirect.com/science/article/pii/S1090380111000334> (accessed 17.8.16).
- 10 Williams AC, Eccleston C, Morley S. Psychological therapies for the management of chronic pain (excluding headache) in adults. *Cochrane Database Syst Rev* 2012;**11**:CD007407.
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007407.pub3/full> (accessed 17.08.16).
- 11 Hoffman BM, Papas RK, Chatkoff DK, et al. Meta-analysis of psychological interventions for chronic low back pain. *Health Psychol* 2007;**26**(1):1–9.
<http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0024119/> (accessed 17.08.16).
- 12 Baumeister H, Härter M. Psychische Komorbidität bei muskuloskelettalen Erkrankungen. *Bundesgesundheitsbl.* 2011;**54**(1):52–58. <http://link.springer.com/article/10.1007/s00103-010-1185-x/fulltext.html?view=classic> (accessed 17.08.17).
- 13 Parker JC, Smarr KL, Slaughter JR, et al. Management of depression in rheumatoid arthritis: a combined pharmacologic and cognitive-behavioral approach. *Arthritis Rheum.* 2003;**49**(6):766–777. doi:10.1002/art.11459.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 14 Lin, Elizabeth H B, Katon W, Korff M von, et al. Effect of improving depression care on pain and functional outcomes among older adults with arthritis: a randomized controlled trial. *JAMA* 2003;**290**(18):2428–2429. doi:10.1001/jama.290.18.2428.
 - 15 Kroenke K, Bair MJ, Damush TM, et al. Optimized antidepressant therapy and pain self-management in primary care patients with depression and musculoskeletal pain: a randomized controlled trial. *JAMA* 2009;**301**(20):2099–2110. doi:10.1001/jama.2009.723.
 - 16 Eccleston C, Fisher E, Craig L, et al. Psychological therapies (Internet-delivered) for the management of chronic pain in adults. *Cochrane Database Syst Rev* 2014(2):CD010152. doi:10.1002/14651858.CD010152.pub2.
 - 17 Buhrman M, Gordh T, Andersson G. Internet interventions for chronic pain including headache: A systematic review. *Internet Interv* 2016;**4**:17–34. <http://www.sciencedirect.com/science/article/pii/S2214782915000421>.
 - 18 Ebert DD, Zarski A, Christensen H, et al. Internet and computer-based cognitive behavioral therapy for anxiety and depression in youth: a meta-analysis of randomized controlled outcome trials. *PloS one* 2015;**10**(3):e0119895. <http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0119895> (accessed 17.08.16).
 - 19 Sander L, Rausch L, Baumeister H. Effectiveness of Internet-Based Interventions for the Prevention of Mental Disorders: A Systematic Review and Meta-Analysis. *JMIR Ment Health* 2016;**3**(3):e38. <http://mental.jmir.org/2016/3/e38/> (accessed August 24, 2016).
 - 20 Richards D, Richardson T. Computer-based psychological treatments for depression: a systematic review and meta-analysis. *Clin Psychol Rev* 2012;**32**(4):329–342. <http://www.sciencedirect.com/science/article/pii/S027273581200027X> (accessed 17.08.16).
 - 21 Andrews G, Cuijpers P, Craske MG, et al. Computer therapy for the anxiety and depressive disorders is effective, acceptable and practical health care: a meta-analysis. *PloS one* 2010;**5**(10):e13196. <http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0013196> (accessed 17.08.16).
 - 22 Andersson G. Internet-Delivered Psychological Treatments. *Annu Rev Clin Psychol* 2016;**12**:157–179. <http://www.annualreviews.org/doi/full/10.1146/annurev-clinpsy-021815-093006> (accessed September 15, 2016).
 - 23 Andersson G, Carlbring P, Cuijpers P. Internet interventions: Moving from efficacy to effectiveness. *EJAP* 2010;**5**(2). <http://sensoria.swinburne.edu.au/index.php/sensoria/article/view/169/194> (accessed 17.08.16).
 - 24 Snow V, Beck D, Budnitz T, et al. Transitions of Care Consensus Policy Statement American College of Physicians-Society of General Internal Medicine-Society of Hospital Medicine-American Geriatrics Society-American College of Emergency Physicians-Society of Academic Emergency Medicine. *J Gen Intern Med* 2009;**24**(8):971–976. doi:10.1007/s11606-009-0969-x.
 - 25 Ebert D, Tarnowski T, Gollwitzer M, et al. A Transdiagnostic Internet-Based Maintenance Treatment Enhances the Stability of Outcome after Inpatient Cognitive Behavioral Therapy: A Randomized Controlled Trial. *Psychother Psychosom* 2013;**82**(4):246–256. <http://www.karger.com/Article/FullText/345967> (accessed 17.08.16).
 - 26 Kim CS, Flanders SA. In the Clinic. Transitions of care. *Ann Intern Med* 2013;**158**(5 Pt 1):ITC3-1. <http://annals.org/article.aspx?articleid=1657883> (accessed 17.08.16).
 - 27 Löwe B, Kroenke K, Herzog W, et al. Measuring depression outcome with a brief self-report instrument: sensitivity to change of the Patient Health Questionnaire (PHQ-9). *J Affect Disord* 2004;**81**(1):61–66.

- 1
2
3 <http://www.sciencedirect.com/science/article/pii/S0165032703001988> (accessed
4 17.08.16).
- 5 28 DGPPN BÄ, KBV A, AkdÄ B, et al. S3-Leitlinie/Nationale VersorgungsLeitlinie
6 Unipolare Depression-Langfassung. DGPPN, ÄZQ, AWMF, Berlin, Düsseldorf 2009.
- 7 29 Sander L, Paganini S, Lin J, et al. Effectiveness and cost-effectiveness of a guided Inter-
8 net- and mobile-based intervention for the indicated prevention of major depression in pa-
9 tients with chronic back pain-study protocol of the PROD-BP multicenter pragmatic RCT.
10 BMC Psychiatry 2017;**17**(1):36. doi:10.1186/s12888-017-1193-6.
- 11 30 Ebert D, Lehr D, Baumeister H, et al. GET.ON Mood Enhancer: efficacy of Internet-based
12 guided self-help compared to psychoeducation for depression: an investigator-blinded
13 randomised controlled trial. *Trials* 2014;**15**(1):39.
14 <http://trialsjournal.biomedcentral.com/articles/10.1186/1745-6215-15-39> (accessed
15 17.08.16).
- 16 31 Buntrock C, Ebert DD, Lehr D, et al. Evaluating the efficacy and cost-effectiveness of
17 web-based indicated prevention of major depression: design of a randomised controlled
18 trial. *BMC Psychiatry* 2014;**14**(1):25.
19 <http://bmcp psychiatry.biomedcentral.com/articles/10.1186/1471-244X-14-25> (accessed
20 17.08.16).
- 21 32 Nobis S, Lehr D, Ebert DD, et al. Efficacy and cost-effectiveness of a web-based interven-
22 tion with mobile phone support to treat depressive symptoms in adults with diabetes melli-
23 tus type 1 and type 2: design of a randomised controlled trial. *BMC Psychiatry*
24 2013;**13**:306. [http://bmcp psychiatry.biomedcentral.com/articles/10.1186/1471-244X-13-](http://bmcp psychiatry.biomedcentral.com/articles/10.1186/1471-244X-13-306)
25 306 (accessed 17.08.16).
- 26 33 Cuijpers P, van Straten A, Warmerdam L. Behavioral activation treatments of depression:
27 a meta-analysis. *Clin Psychol Rev* 2007;**27**(3):318–326.
28 <http://www.sciencedirect.com/science/article/pii/S027273580600136X> (accessed
29 17.08.16).
- 30 34 Hopko DR, Lejuez CW, Ruggiero KJ, et al. Contemporary behavioral activation treat-
31 ments for depression: Procedures, principles, and progress. *Clin Psychol Rev*
32 2003;**23**(5):699–717.
33 <http://www.sciencedirect.com/science/article/pii/S0272735803000709> (accessed
34 17.08.16).
- 35 35 Prochaska JO, Velicer WF. The transtheoretical model of health behavior change. *Am J*
36 *Health Promot* 1997;**12**(1):38–48. <http://ahp.sagepub.com/content/12/1/38.long> (accessed
37 17.08.16).
- 38 36 Cuijpers P, van Straten A, Warmerdam L. Problem solving therapies for depression: a
39 meta-analysis. *Eur Psychiatry* 2007;**22**(1):9–15.
40 <http://www.ncbi.nlm.nih.gov/pubmed/17194572> (accessed 17.08.16).
- 41 37 Buntrock C, Ebert D, Lehr D, et al. Effectiveness of a web-based cognitive behavioural
42 intervention for subthreshold depression: pragmatic randomised controlled trial.
43 *Psychother Psychosom* 2015;**84**(6):348–358. <https://www.karger.com/Article/Pdf/438673>
44 (accessed 17.08.16).
- 45 38 Nobis S, Lehr D, Ebert DD, et al. Efficacy of a web-based intervention with mobile phone
46 support in treating depressive symptoms in adults with type 1 and type 2 diabetes: a ran-
47 domized controlled trial. *Diabetes Care* 2015;**38**(5):776–783.
48 <http://care.diabetesjournals.org/content/38/5/776> (accessed 18.08.16).
- 49 39 Ebert DD, Nobis S, Lehr D, et al. 6-months effectiveness of internet-based guided self-
50 help for diabetes and comorbid depression. Results of a randomized controlled trial. *Dia-*
51 *bet Med* (accepted).
- 52 40 Martin A, Härter M, Henningsen P, et al. Evidenzbasierte Leitlinie zur Psychotherapie
53 somatoformer Störungen und assoziierter Syndrome: Hogrefe Verlag 2013.

- 1
2
3 41 Kröner-Herwig B. Rückenschmerz: Hogrefe Verlag 2000.
- 4 42 Lin J, Paganini S, Sander L, et al. Effectiveness of a guided and unguided internet-based
5 Acceptance and Commitment Therapy for chronic pain: study protocol for a three-armed
6 randomised controlled trial. *Deutsches Arzteblatt international*; **in press**.
- 7 43 Lin J, Lüking M, Ebert DD, et al. Effectiveness and cost-effectiveness of a guided and
8 unguided internet-based Acceptance and Commitment Therapy for chronic pain: Study
9 protocol for a three-armed randomised controlled trial. *Internet Interv* 2015;**2**(1):7–16.
10 <http://www.sciencedirect.com/science/article/pii/S2214782914000359> (accessed
11 17.08.16).
- 12 44 Krämer LV, Helmes AW, Bengel J. Understanding activity limitations in depression: Inte-
13 grating the concepts of motivation and volition from health psychology into clinical psy-
14 chology. *Eur Psychol* 2014;**19**(4):278. <http://psycnet.apa.org/journals/epp/19/4/278/> (ac-
15 cessed 17.08.16).
- 16 45 Krämer LV, Helmes AW, Seelig H, et al. Correlates of reduced exercise behaviour in de-
17 pression: The role of motivational and volitional deficits. *Psychol Health*
18 2014;**29**(10):1206–1225.
19 <http://www.tandfonline.com/doi/abs/10.1080/08870446.2014.918978?journalCode=gps2>
20 0 (accessed 17.08.16).
- 21 46 Warmerdam L, van Straten A, Twisk J, et al. Internet-based treatment for adults with de-
22 pressive symptoms: randomized controlled trial. *J Med Internet Res* 2008;**10**(4):e44.
23 <http://www.jmir.org/2008/4/e44/> (accessed 17.08.16).
- 24 47 van Straten A, Cuijpers P, Smits N. Effectiveness of a web-based self-help intervention for
25 symptoms of depression, anxiety, and stress: randomized controlled trial. *J Med Internet*
26 *Res* 2008;**10**(1):e7. <http://www.jmir.org/2008/1/e7/> (accessed 17.08.16).
- 27 48 Ebert D, Lehr D, Boß L, et al. Efficacy of an internet-based problem-solving training for
28 teachers: results of a randomized controlled trial. *Scand J Work Environ Health*
29 2014;**40**(6):582–596. http://www.sjweh.fi/download.php?abstract_id=3449&file_nro=1
30 (accessed 17.08.16).
- 31 49 Thiart H, Lehr D, Ebert DD, et al. Log in and breathe out: internet-based recovery training
32 for sleepless employees with work-related strain - results of a randomized controlled trial.
33 *Scand J Work Environ Health* 2015;**41**(2):164–174.
34 http://www.sjweh.fi/show_abstract.php?abstract_id=3478&fullText=1#box-fullText (ac-
35 cessed 17.08.16).
- 36 50 Ebert DD, Berking M, Thiart H, et al. Restoring depleted resources: Efficacy and mecha-
37 nisms of change of an internet-based unguided recovery training for better sleep and psy-
38 chological detachment from work. *Health Psychol* 2015;**34** **Suppl**:1240–1251.
39 <https://www.apa.org/pubs/journals/releases/hea-hea0000277.pdf> (accessed 17.08.16).
- 40 51 Baglioni C, Battagliese G, Feige B, et al. Insomnia as a predictor of depression: a meta-
41 analytic evaluation of longitudinal epidemiological studies. *J Affect Disord*
42 2011;**135**(1):10–19. <http://www.sciencedirect.com/science/article/pii/S0165032711000292>
43 (accessed 17.08.16).
- 44 52 Morin CM, Bootzin RR, Buysse DJ, et al. Psychological and behavioral treatment of in-
45 somnia: update of the recent evidence (1998-2004). *Sleep* 2006;**29**(11):1398.
46 <http://www.journalsleep.org/ViewAbstract.aspx?pid=26676> (accessed 17.08.16).
- 47 53 Webb T, Joseph J, Yardley L, et al. Using the internet to promote health behavior change:
48 a systematic review and meta-analysis of the impact of theoretical basis, use of behavior
49 change techniques, and mode of delivery on efficacy. *J Med Internet Res* 2010;**12**(1).
50 <http://www.jmir.org/2010/1/e4/> (accessed 17.08.16).
- 51 54 Ritterband L, Gonder-Frederick L, Cox D, et al. Internet interventions: In review, In use,
52 and Into the future. *Prof Psychol Res Pr* 2003;**34**(5):527.
53 <http://psycnet.apa.org/psycinfo/2003-08155-014> (accessed 17.08.16).
- 54
55
56
57
58
59
60

- 1
2
3 55 Fry JP, Neff RA. Periodic prompts and reminders in health promotion and health behavior
4 interventions: systematic review. *J Med Internet Res* 2009;**11**(2):e16.
5 <http://www.jmir.org/2009/2/e16/> (accessed 17.08.16).
- 6 56 Almlöv J, Carlbring P, Berger T, et al. Therapist factors in internet-delivered cognitive
7 behavioural therapy for major depressive disorder. *Cogn Behav Ther* 2009;**38**(4):247–254.
8 <http://www.tandfonline.com/doi/abs/10.1080/16506070903116935?journalCode=sbeh20>
9 (accessed 17.08.16).
- 10 57 Kleiboer A, Donker T, Seekles W, et al. A randomized controlled trial on the role of sup-
11 port in Internet-based problem solving therapy for depression and anxiety. *Behav Res*
12 *Ther* 2015;**72**:63–71.
13 <http://www.sciencedirect.com/science/article/pii/S000579671530005X> (accessed
14 17.08.16).
- 15 58 Baumeister H, Reichler L, Munzinger M, et al. The impact of guidance on Internet-based
16 mental health interventions — A systematic review. *Internet Interv* 2014;**1**(4):205–215.
17 <http://www.sciencedirect.com/science/article/pii/S2214782914000244> (accessed
18 17.08.16).
- 19 59 Hakkaart-Van Roijen L, van Straten A, Donker M, et al. Trimbos/iMTA questionnaire for
20 costs associated with psychiatric illness (TIC-P). Institute for Medical Technology As-
21 sessment, Erasmus University Rotterdam. Trimbos 2002.
- 22 60 Erbe D, Eichert H, Rietz C, et al. Interformat reliability of the patient health questionnaire:
23 Validation of the computerized version of the PHQ-9. *Internet Interv* 2016;**5**:1–4.
24 <http://www.sciencedirect.com/science/article/pii/S2214782916300033> (accessed
25 17.08.16).
- 26 61 Kroenke K, Spitzer RL, Williams JBW. The PHQ-9. *J Gen Intern Med* 2001;**16**(9):606–
27 613. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1495268/> (accessed 17.08.16).
- 28 62 Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive
29 Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psy-
30 chometric evaluation in patients with chronic major depression. *Biol Psychiatry*
31 2003;**54**(5):573–583.
32 <http://www.sciencedirect.com/science/article/pii/S0006322302018668> (accessed
33 17.08.16).
- 34 63 First MB, Spitzer RL, Gibbon M, et al. User's guide for the Structured clinical interview
35 for DSM-IV axis I disorders SCID-I: clinician version: American Psychiatric Pub 1997.
- 36 64 Wittchen HU, Zaudig M, Fydrich T. *Strukturiertes Klinisches Interview für DSM-IV*. Göt-
37 tingen: Hogrefe 1997.
- 38 65 American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders:*
39 *DSM-5*: ManMag 2003.
- 40 66 Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. *Fam*
41 *Med* 2005;**37**(5):360–363. <http://www.stfm.org/fmhub/fm2005/May/Anthony360.pdf> (ac-
42 cessed 17.08.16).
- 43 67 Fleiss JL, ed. *The Design and Analysis of Clinical Experiments*. Hoboken, NJ, USA: John
44 Wiley & Sons, Inc 1999.
- 45 68 Baumeister H, Hutter N. Collaborative care for depression in medically ill patients. *Curr*
46 *Opin Psychiatry* 2012;**25**(5):405–414. [http://meta.wkhealth.com/pt/pt-core/template-
47 journal/lwgateway/media/landingpage.htm?issn=0951-
48 7367&volume=25&issue=5&spage=405](http://meta.wkhealth.com/pt/pt-core/template-journal/lwgateway/media/landingpage.htm?issn=0951-7367&volume=25&issue=5&spage=405) (accessed 17.08.16).
- 49 69 Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for
50 depression in patients with coronary artery disease. *Cochrane Database Syst Rev*
51 2011(9):CD008012.
52 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008012.pub3/full> (accessed
53 17.08.16).

- 1
2
3 70 Hamilton M. A rating scale for depression. *J Neurol Neurosurg Psychiatry* 1960;**23**(1):56–
4 62. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC495331/> (accessed 17.08.16).
- 5 71 Crippa, José Alexandre S, de Lima Osório, Flávia, Del-Ben CM, et al. Comparability be-
6 tween telephone and face-to-face structured clinical interview for DSM-IV in assessing
7 social anxiety disorder. *Perspectives in psychiatric care* 2008;**44**(4):241–247.
8 doi:10.1111/j.1744-6163.2008.00183.x.
- 9 72 Jacobson NS, Truax P. Clinical significance: A statistical approach to defining meaningful
10 change in psychotherapy research. *Journal of Consulting and Clinical Psychology*
11 1991;**59**(1):12–19. doi:10.1037/0022-006X.59.1.12.
- 12 73 Richardson, Jeffrey R J, Peacock SJ, Hawthorne G, et al. Construction of the descriptive
13 system for the assessment of quality of life AQL-6D utility instrument. *Health Qual Life*
14 *Outcomes* 2012;**10**:38. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3349491/> (ac-
15 cessed 11.5.16).
- 16 74 Allen M, Iezzoni LI, Huang A, et al. Improving patient-clinician communication about
17 chronic conditions: description of an internet-based nurse E-coach intervention. *Nurs Res*
18 2008;**57**(2):107–112. <http://www.ncbi.nlm.nih.gov/pubmed/18347482> (accessed
19 17.08.16).
- 20 75 Rabin R, Charro Fd. EQ-SD: a measure of health status from the EuroQol Group. *Ann.*
21 *Med.* 2001;**33**(5):337–343. <http://www.ncbi.nlm.nih.gov/pubmed/11491192> (accessed
22 17.08.16).
- 23 76 Mannion AF, Junge A, Grob D, et al. Development of a German version of the Oswestry
24 Disability Index. Part 2: sensitivity to change after spinal surgery. *Eur Spine J*
25 2006;**15**(1):66–73. <http://link.springer.com/article/10.1007%2Fs00586-004-0816-z> (ac-
26 cessed 17.08.16).
- 27 77 Wittink H, Turk DC, Carr DB, et al. Comparison of the redundancy, reliability, and re-
28 sponsiveness to change among SF-36, Oswestry Disability Index, and Multidimensional
29 Pain Inventory. *Clin J Pain* 2004;**20**(3):133–142.
30 <http://www.ncbi.nlm.nih.gov/pubmed/15100588> (accessed 17.08.16).
- 31 78 Nicholas MK. The pain self-efficacy questionnaire: Taking pain into account. *Eur J Pain*
32 2007;**11**(2):153–163. <http://onlinelibrary.wiley.com/doi/10.1016/j.ejpain.2005.12.008/full>
33 (accessed 17.08.16).
- 34 79 Mittag O, Raspe H. A brief scale for measuring subjective prognosis of gainful employ-
35 ment: findings of a study of 4279 statutory pension insurees concerning reliability
36 (Guttman scaling) and validity of the scale. *Die Rehabilitation* 2003;**42**(3):169–174.
37 <https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2003-40095> (ac-
38 cessed 17.08.16).
- 39 80 Boß L, Lehr D, Vis C, et al. Assessing Client Satisfaction in web-based interventions. *The*
40 *CSWQ-8*. *JMIR in prep*.
- 41 81 Larsen DL, Attkisson CC, Hargreaves WA, et al. Assessment of client/patient satisfaction:
42 development of a general scale. *Eval Program Plann* 1979;**2**(3):197–207.
43 <http://www.sciencedirect.com/science/article/pii/0149718979900946> (accessed 17.08.16).
- 44 82 Thiart H, Lehr D, Ebert DD, et al. Log in and breathe out: efficacy and cost-effectiveness
45 of an online sleep training for teachers affected by work-related strain--study protocol for
46 a randomized controlled trial. *Trials* 2013;**14**:169.
47 <http://trialsjournal.biomedcentral.com/articles/10.1186/1745-6215-14-169> (accessed
48 17.08.16).
- 49 83 Ebert DD, Heber E, Berking M, et al. Self-guided internet-based and mobile-based stress
50 management for employees: results of a randomised controlled trial. *Occup. Environ.*
51 *Med.* 2016;**73**(5):315–323. [http://oem.bmj.com/content/early/2016/02/16/oemed-2015-
52 103269.full.pdf](http://oem.bmj.com/content/early/2016/02/16/oemed-2015-103269.full.pdf) (accessed 17.08.16).
- 53
54
55
56
57
58
59
60

- 1
2
3 84 Duggan C, Parry G, McMurrin M, et al. The recording of adverse events from psycholog-
4 ical treatments in clinical trials: Evidence from a review of NIHR-funded trials. *Trials*
5 2014;**15**(1):335. <http://trialsjournal.biomedcentral.com/articles/10.1186/1745-6215-15-335>
6 (accessed 17.08.16).
- 7 85 Horigian VE, Robbins MS, Dominguez R, et al. Principles for defining adverse events in
8 behavioral intervention research: lessons from a family-focused adolescent drug abuse tri-
9 al. *Clinical Trials* 2010;**7**(1):58–68.
10 <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3163837/> (accessed 17.08.16).
- 11 86 Ladwig I, Rief W, Nestoriuc Y. Welche Risiken und Nebenwirkungen hat
12 Psychotherapie?-Entwicklung des Inventars zur Erfassung Negativer Effekte von
13 Psychotherapie (INEP). *Verhaltenstherapie* 2014;**24**(4):252–263.
14 <http://www.karger.com/Article/PDF/367928> (accessed 17.08.16).
- 15 87 Haase R, Schultheiss T, Kempcke R, et al. Use and acceptance of electronic communica-
16 tion by patients with multiple sclerosis: a multicenter questionnaire study. *J Med Internet*
17 *Res* 2012;**14**(5):e135. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3510727/> (accessed
18 17.08.16).
- 19 88 Schafer JL, Graham JW. Missing data: our view of the state of the art. *Psychological*
20 *methods* 2002;**7**(2):147. <http://psycnet.apa.org/journals/met/7/2/147/> (accessed 17.07.16).
- 21 89 Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: Updated Guidelines for
22 Reporting Parallel Group Randomised Trials. *PLoS Med* 2010;**7**(3):e1000251.
23 doi:10.1371/journal.pmed.1000251 [published Online First:
24 <http://www.bmj.com/content/340/bmj.c332>].
- 25 90 Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of pragmatic trials:
26 an extension of the CONSORT statement. *BMJ* 2008;**337**:a2390.
27 <http://www.bmj.com/content/337/bmj.a2390.long> (accessed 17.08.16).
- 28 91 Proudfoot J, Klein B, Barak A, et al. Establishing guidelines for executing and reporting
29 internet intervention research. *Cogn Behav Ther* 2011;**40**(2):82–97.
30 <http://www.tandfonline.com/doi/abs/10.1080/16506073.2011.573807> (accessed 17.08.16).
- 31 92 Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence,
32 impact on daily life, and treatment. *Eur J Pain* 2006;**10**(4):287–333.
33 <http://www.sciencedirect.com/science/article/pii/S1090380105000868> (accessed
34 17.08.16).
- 35 93 Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for
36 depression in patients with diabetes mellitus and depression. *Cochrane Database Syst Rev*
37 2012;**12**:CD008381.
38 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008381.pub2/full> (accessed
39 17.08.16).
- 40 94 Cuijpers P, van Straten A, Warmerdam L, et al. Recruiting participants for interventions to
41 prevent the onset of depressive disorders: Possible ways to increase participation rates.
42 *BMC Health Serv Res* 2010;**10**(1):181–7.
43 <https://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-10-181> (accessed
44 17.08.16).
- 45 95 Baumeister H. Kein signifikanter Zusatznutzen als Add-on in der allgemeinärztlichen
46 Routineversorgung: (Review und Kommentar). *InFo Neurologie* 2016;**18**(1):14–15.
47 <http://link.springer.com/article/10.1007/s15005-016-1601-3/fulltext.html?view=classic>
48 (accessed 17.08.16).
- 49 96 Gilbody S, Littlewood E, Hewitt C, et al. Computerised cognitive behaviour therapy
50 (cCBT) as treatment for depression in primary care (REEACT trial): large scale pragmatic
51 randomised controlled trial. *BMJ* 2015;**351**:h5627.
52 <http://www.bmj.com/content/351/bmj.h5627> (accessed 17.08.16).
- 53
54
55
56
57
58
59
60

- 1
2
3 97 Baumeister H, Nowoczin L, Lin J, et al. Impact of an acceptance facilitating intervention
4 on diabetes patients' acceptance of Internet-based interventions for depression: A random-
5 ized controlled trial. *Diabetes Res Clin Pract* 2014.
6 <http://www.sciencedirect.com/science/article/pii/S0168822714002149> (accessed
7 17.08.16).
- 8 98 Ebert DD, Berking M, Cuijpers P, et al. Increasing the acceptance of internet-based mental
9 health interventions in primary care patients with depressive symptoms. A randomized
10 controlled trial. *J Affect Disord* 2015(176):9–17.
11 [http://linkinghub.elsevier.com/retrieve/pii/S0165-0327\(15\)00069-5](http://linkinghub.elsevier.com/retrieve/pii/S0165-0327(15)00069-5) (accessed 17.08.16).
- 12 99 Baumeister H, Seiffert H, Lin J, et al. Impact of an Acceptance Facilitating Intervention
13 on Patients' Acceptance of Internet-based Pain Interventions - A Randomised Controlled
14 Trial. *Clin J Pain* 2015(6):528–535. <http://www.ncbi.nlm.nih.gov/pubmed/24866854> (ac-
15 cessed 17.08.16).
- 16 100 Batterham PJ, Sunderland M, Calear AL, et al. Developing a roadmap for the transla-
17 tion of e-mental health services for depression. *Aust N Z J Psychiatry* 2015;49(9):776–
18 784. <http://anp.sagepub.com/content/49/9/776.long> (accessed September 15, 2016).
- 19 101 Coleman EA, Berenson RA. Lost in transition: challenges and opportunities for im-
20 proving the quality of transitional care. *Ann Intern Med* 2004;141(7):533–536.
21 <http://annals.org/article.aspx?articleid=717858> (accessed August 17, 2016).
- 22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. study flow

Flow Chart

297x420mm (300 x 300 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Page NO in manuscript
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
	2b	All items from the World Health Organization Trial Registration Data Set	3
Protocol version	3	Date and version identifier	2
Funding	4	Sources and types of financial, material, and other support	15
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1
	5b	Name and contact information for the trial sponsor	15
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	15
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	15
Introduction			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	4
	6b	Explanation for choice of comparators	(5/10)
Objectives	7	Specific objectives or hypotheses	5

1				
2	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	5-6
3				
4				
5				
6				
7				
8	Methods: Participants, interventions, and outcomes			
9				
10	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	6
11				
12				
13				
14	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	7
15				
16				
17				
18	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	8-9
19				
20				
21				
22		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	7
23				
24				
25				
26		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	9,14
27				
28				
29				
30		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	7
31				
32				
33	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	10-12
34				
35				
36				
37				
38				
39				
40				
41	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	6
42				
43				
44				
45	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	10
46				
47				
48				
49	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	6-7
50				
51				
52				
53	Methods: Assignment of interventions (for controlled trials)			
54				
55	Allocation:			6
56				
57				
58				
59				
60				

1				
2	Sequence	16a	Method of generating the allocation sequence (eg, computer-	6
3	generation		generated random numbers), and list of any factors for	
4			stratification. To reduce predictability of a random sequence,	
5			details of any planned restriction (eg, blocking) should be	
6			provided in a separate document that is unavailable to those	
7			who enrol participants or assign interventions	
8				
9	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central	6
10	concealment		telephone; sequentially numbered, opaque, sealed envelopes),	
11	mechanism		describing any steps to conceal the sequence until interventions	
12			are assigned	
13				
14	Implementation	16c	Who will generate the allocation sequence, who will enrol	6
15			participants, and who will assign participants to interventions	
16				
17	Blinding	17a	Who will be blinded after assignment to interventions (eg, trial	6,10
18	(masking)		participants, care providers, outcome assessors, data analysts),	
19			and how	
20		17b	If blinded, circumstances under which unblinding is permissible,	7
21			and procedure for revealing a participant's allocated intervention	
22			during the trial	
23				
24				
25				
26				
27	Methods: Data collection, management, and analysis			
28	Data collection	18a	Plans for assessment and collection of outcome, baseline, and	5,10-
29	methods		other trial data, including any related processes to promote data	12
30			quality (eg, duplicate measurements, training of assessors) and	
31			a description of study instruments (eg, questionnaires,	
32			laboratory tests) along with their reliability and validity, if known.	
33			Reference to where data collection forms can be found, if not in	
34			the protocol	
35		18b	Plans to promote participant retention and complete follow-up,	5
36			including list of any outcome data to be collected for participants	
37			who discontinue or deviate from intervention protocols	
38				
39	Data	19	Plans for data entry, coding, security, and storage, including any	13
40	management		related processes to promote data quality (eg, double data entry;	
41			range checks for data values). Reference to where details of	
42			data management procedures can be found, if not in the	
43			protocol	
44				
45	Statistical	20a	Statistical methods for analysing primary and secondary	12-13
46	methods		outcomes. Reference to where other details of the statistical	
47			analysis plan can be found, if not in the protocol	
48		20b	Methods for any additional analyses (eg, subgroup and adjusted	13
49			analyses)	
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

1				
2		20c	Definition of analysis population relating to protocol non-	13
3			adherence (eg, as randomised analysis), and any statistical	
4			methods to handle missing data (eg, multiple imputation)	
5				
6				
7				
8				
9				
10				
11				
12				
13				
14				
15				
16				
17				
18				
19				
20				
21				
22				
23				
24				
25				
26				
27				
28				
29				
30				
31				
32				
33				
34				
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

1				
2	Ancillary and	30	Provisions, if any, for ancillary and post-trial care, and for	n.a.
3	post-trial care		compensation to those who suffer harm from trial participation	
4				
5	Dissemination	31a	Plans for investigators and sponsor to communicate trial results	14
6	policy		to participants, healthcare professionals, the public, and other	
7			relevant groups (eg, via publication, reporting in results	
8			databases, or other data sharing arrangements), including any	
9			publication restrictions	
10				
11		31b	Authorship eligibility guidelines and any intended use of	15 /
12			professional writers	n.a.
13				
14		31c	Plans, if any, for granting public access to the full protocol,	n.a.
15			participant-level dataset, and statistical code	
16				
17				
18	Appendices			
19				
20	Informed consent	32	Model consent form and other related documentation given to	6
21	materials		participants and authorised surrogates	
22				
23	Biological	33	Plans for collection, laboratory evaluation, and storage of	n.a.
24	specimens		biological specimens for genetic or molecular analysis in the	
25			current trial and for future use in ancillary studies, if applicable	
26				

27 *It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013
 28 Explanation & Elaboration for important clarification on the items. Amendments to the
 29 protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT
 30 Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by/3.0/)"
 31 license.
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60

BMJ Open

Effectiveness and cost-effectiveness of a guided internet- and mobile-based depression intervention for individuals with chronic back pain: protocol of a multi-centre randomised controlled trial



Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-015226.R2
Article Type:	Protocol
Date Submitted by the Author:	27-Jul-2017
Complete List of Authors:	Lin, Jiayi; Albert-Ludwigs-Universitat Freiburg, Department of Rehabilitation Psychology and Psychotherapy, Institute of Psychology Sander, Lasse; Albert-Ludwigs-Universitat Freiburg, Department of Rehabilitation Psychology and Psychotherapy, Institute of Psychology Paganini, Sarah; Albert-Ludwigs-Universitat Freiburg, Department of Rehabilitation Psychology and Psychotherapy, Institute of Psychology Schlicker, Sandra; Universitatsklinikum Erlangen, Department of Clinical Psychology and Psychotherapy, Institute of Psychology Ebert, David; Friedrich-Alexander University Erlangen Nuremberg, Clinical Psychology and Psychotherapy Berking, Matthias; Universitatsklinikum Erlangen, Department of Clinical Psychology and Psychotherapy, Institute of Psychology Bengel, Jürgen; Albert-Ludwigs-Universitat Freiburg, Department of Rehabilitation Psychology and Psychotherapy, Institute of Psychology Nobis, Stephanie; Hochschule Vechta, Department of Gerontology Lehr, Dirk; University of Lüneburg, Department of Psychology Mittag, Oskar; Universitatsklinikum Freiburg, Center for Medical Biometry and Medical Informatics, Section of Health Care Research and Rehabilitation Riper, Heleen; VU University Amsterdam, Dept. of Clinical Psychology Baumeister, Harald; Universitat Ulm, Department of Clinical Psychology and Psychotherapy, Institute of Psychology
Primary Subject Heading:	Mental health
Secondary Subject Heading:	Evidence based practice, Health economics, Health services research, Public health, Rehabilitation medicine
Keywords:	depression, chronic back pain, e-mental-health, health care services research, randomized controlled trial, study protocol

SCHOLARONE™
Manuscripts

1
2
3 **Effectiveness and cost-effectiveness of a guided internet- and mobile-based depression**
4 **intervention for individuals with chronic back pain: protocol of a multi-centre random-**
5 **ised controlled trial**
6
7
8
9

10
11 Jiaxi Lin¹ (jiaxi.lin@psychologie.uni-freiburg.de)

12 Lasse Sander¹ (lasse.sander@psychologie.uni-freiburg.de)

13 Sarah Paganini¹ (sarah.paganini@psychologie.uni-freiburg.de)

14
15 Sandra Schlicker² (sandra.schlicker@fau.de)

16
17 David Ebert² (david.ebert@fau.de)

18
19 Matthias Berking² (matthias.berking@fau.de)

20
21 Jürgen Bengel¹ (bengel@psychologie.uni-freiburg.de)

22
23 Stephanie Nobis³ (stephanie.nobis@uni-vechta.de)

24
25 Dirk Lehr⁴ (dirk.lehr@inkubator.leuphana.de)

26
27 Oskar Mittag⁵ (oskar.mittag@uniklinik-freiburg.de)

28
29 Heleen Riper⁶ (h.riper@vu.nl)

30
31 Harald Baumeister⁷ (harald.baumeister@uni-ulm.de)

32
33
34
35 1) Department of Rehabilitation Psychology and Psychotherapy, Institute of Psychology,
36 University of Freiburg, Germany

37
38 2) Department of Clinical Psychology and Psychotherapy, Institute of Psychology, University
39 of Erlangen-Nürnberg, Germany

40
41 3) Department of Gerontology, University of Vechta, Germany

42
43 4) Department of Psychology, Leuphana University Lüneburg, Germany

44
45 5) Center for Medical Biometry and Medical Informatics, Section of Health Care Research
46 and Rehabilitation, Medical Center, University of Freiburg, Germany

47
48 6) Department of Clinical, Neuro and Developmental Psychology, VU University Amster-
49 dam, Netherlands

50
51 7) Department of Clinical Psychology and Psychotherapy, Institute of Psychology, University
52 of Ulm, Germany

53
54
55
56 Issue Date: 22 November 2016

57
58 Revision Date: 28 May 2017

1
2
3 2nd Revision Date: 21 July 2017
4
5

6 Correspondence:

7 Address corresponding author:

8 Prof. Dr. Harald Baumeister

9 Department of Clinical Psychology and Psychotherapy,

10 Institute of Psychology and Education, University of Ulm,

11 Albert-Einstein-Allee 47, D-89069 Ulm, Germany

12 Phone: +49-(0)731-50-31180

13 Email: harald.baumeister@uni-ulm.de
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction: Depression often co-occurs with chronic back pain (CBP). Internet- and mobile-based interventions (IMIs) might be a promising approach for effectively treating depression in this patient group. In the present study, we will evaluate the effectiveness and cost-effectiveness of a guided depression IMI for individuals with CBP (eSano BackCare-D) integrated into orthopaedic health care.

Methods and analysis: In this multicentre randomised controlled trial (RCT) of parallel design, the groups eSano BackCare-D vs. treatment as usual will be compared. 210 participants with CBP and diagnosed depression will be recruited subsequent to orthopedic rehabilitation care. Assessments will be conducted prior to randomisation and 9 weeks (posttreatment) and 6 months after randomisation. The primary outcome is depression severity (HAM-D-17). Secondary outcomes are depression remission and response, health related quality of life, pain intensity, pain related disability, self-efficacy and work capacity. Demographic and medical variables as well as internet affinity, intervention adherence, intervention satisfaction and negative effects will also be assessed. Data will be analysed on an intention-to-treat basis and an additional per-protocol analysis. Moreover, a cost-effectiveness and cost-utility analysis will be conducted from a societal perspective after 6 months.

Ethics and dissemination: All procedures are approved by the ethics committee of the Albert-Ludwigs-University of Freiburg and the data security committee of the German Pension Insurance (Deutsche Rentenversicherung). The results will be published in peer-reviewed journals and presented on international conferences.

Registration details: The trial is registered at the WHO International Clinical Trials Registry Platform via the German Clinical Studies Trial Register (DRKS): (DRKS00009272).

Keywords: Guided self-help; Internet-based; Chronic back pain; Depression; after care; Randomised controlled trial, effectiveness, cost-effectiveness

Strengths and limitations of this study

- This is a protocol for the first large scale, multi-centre RCT examining the effectiveness of a depression IMI for individuals with CBP and depression.
- This is the first trial examining the cost-effectiveness of a depression IMI for individuals with CBP and depression.
- The IMI will be implemented as integrated part of routine orthopaedic health care, thus overcoming the self-referral bias of most prior IMI trials, examining the possibility to improve patients' medical sector transitions by means of an e-mental-health offer.
- We use standardised interviews for the diagnosis and clinical rating scales for the assessment of the severity level of depression (SKID and HAMD/QIDS).
- Findings will be limited to patients with back pain and depression receiving a depression IMI as aftercare intervention of a bio-psycho-social focused orthopaedic inpatient treatment, which might limit the (incremental) effectiveness of the intervention.

Introduction

The two widespread conditions chronic back pain (CBP) and depression belong to the top ten causes of years lived with disability (YLDs) worldwide [1]. The global one-month adult prevalence for low back pain is estimated to be 23.2% and a substantial increase during the next decades can be expected [2]. Depression has been shown to be the leading cause of burden of diseases in middle- to high-income countries with a lifetime prevalence of about 14.6% [3]. A strong association between depression and CBP has been frequently reported with prevalence rates for depression ranging from 21% to 50% in back pain and chronic low back pain individuals [4]. Several systematic reviews highlight a significant prognostic association between comorbid depression and increased morbidity of different somatic conditions and health care costs as well as diminished quality of life [5–7]. Moreover, depression is one of the core predictors of persistent pain symptoms, increased pain-related disability, and poor treatment outcomes in pain patients [4, 8, 9].

There is strong evidence for the efficacy of psychological interventions for chronic pain [10] and especially for chronic low back pain [11] aiming at pain intensity or disability/interference as primary outcomes. To the best of our knowledge however, there is no study that has examined the effects of psychological depression interventions in the population of CBP focussing on depression as the primary outcome [12]. Indeed, the evidence on depres-

1
2
3 sion treatments for patients with chronic pain and clinical depression is very limited, mostly
4 relying on a few collaborative/stepped care trials conducted in the last two decades [13–15].
5
6 In order to improve health care for CBP individuals, internet- and mobile-based interventions
7 (IMIs) are considered to be a promising approach [16, 17]. Among numerous meta-analyses
8 highlighting the efficacy of IMIs with regard to the reduction of depressive symptoms [18–
9 21], one meta-analysis quantified the superiority of online depression interventions over wait-
10 ing-list and treatment as usual (TAU) with standardised mean differences of $d = -.68$ (CI: $-.85$;
11 $-.52$; $n = 8$) and $d = -.39$ (CI: $-.66$; $-.12$; $n = 8$) [20], albeit effect moderating factors of IMIs remain
12 unclear [22]. As most trials used highly selective recruitment strategies, the evidence for the
13 effectiveness of IMIs for depression (i.e., performance of an intervention when implemented
14 within typical clinical practice, investigated by means of pragmatic trials) is far less conclu-
15 sive [23] and many health systems have not included IMIs as an integrated treatment compo-
16 nent. As an implemented part of a comprehensive care system, IMIs could reduce the defi-
17 ciencies of most current health care systems in coordinating transitions of care, such as the
18 transition from the inpatient to outpatient setting, where recommendations are regularly lost in
19 transition [24–26].

20
21 The present WARD-BP study (web-based aftercare depression intervention following reha-
22 bilitation for individuals with depression and chronic back pain) aims to investigate the effec-
23 tiveness and cost-effectiveness of the depression IMI “eSano BackCare-D” in a study popula-
24 tion of CBP with a diagnosed depression in the aftermath of orthopaedic rehabilitation care.
25 The primary research question is:

26
27 1) Is eSano BackCare-D effective in reducing depression in individuals with CBP and diag-
28 nosed depression compared to treatment as usual (TAU)?

29
30 Secondary research questions are:

31
32 2) Is eSano BackCare-D effective with regard to depression remission and response, health
33 related quality of life, pain intensity, pain related disability, self-efficacy and work capacity in
34 individuals with CBP and diagnosed depression compared to TAU?

35
36 3) Is eSano BackCare-D cost-effective in individuals with CBP and diagnosed depression
37 compared to TAU from a societal perspective?

38
39 4) Which factors moderate and mediate the effects of eSano BackCare-D?
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Methods and analysis

Study design

WARD-BP is a multi-centre pragmatic randomised controlled clinical trial (RCT) of parallel design. All participants receive TAU. We conduct assessments in both groups before randomisation (T0), nine weeks (T1= post treatment in case of regular IMI use) and six months (T2) after randomisation. Trial participants receive 15€ per completed post- and follow-up telephone assessment, see figure 1 for study flow.

- Figure 1 about here -

Randomisation

Randomisation and allocation of participants to the two groups (intervention or TAU) was prepared in advance by an independent researcher (SaS) by means of a web-based program (<https://www.sealedenvelope.com/>) using permuted block randomisation with variable block sizes of 4,6,8 (randomly arranged), ratio of 1:1. Participants are stratified by center. Centers are all eight orthopedic clinics where recruitment is conducted personally and a ninth (meta-)clinic, which includes all participants recruited by letter (see recruitment). The independent researcher (SaS) is responsible for the allocation of participants to trial arms as well as the administration of the trial and is blinded to the treatment process and assessments of the participants.

Recruitment

Recruitment has started in October 2015 and is planned to end in July 2017. While this study protocol has been submitted for publication after start of recruitment (due to usual writing-up, commenting and approving procedures by all co-authors), clinical trial registry took place prior to recruitment start.

Using the Patient Health Questionnaire (PHQ-9; [27]), we conduct two consecutive depression screenings within 2-3 weeks. In case of only one positive screening (PHQ \geq 5), a third PHQ will be administered two months later via telephone interview. We recruit potential participants in orthopaedic rehabilitation units in Germany with two different recruitment strategies.

In the first recruitment setting (personal recruitment), patients with two positive screenings receive information on the intervention by clinic staff during their orthopedic care. Patients

1
2
3 providing their informed consent to the clinical trial study team (exemplary informed consent
4 form see supplementary material) are contacted by the study team in order to clarify further
5 eligibility criteria by means of an online- and telephone assessment including a telephone
6 administered clinical interview. The participating clinics are compensated for their recruit-
7 ment efforts (i.e. selection of back pain patients, screening procedure, informed consent, doc-
8 umentation according to CONSORT, providing access to medical records) with 320€ per
9 randomised participant. The second recruitment strategy (recruitment by letter) involves a
10 letter with information flyers and study process for back pain patients after discharge from
11 orthopaedic rehabilitation units across Germany with a link to fill out an online PHQ-
12 screening. Individuals screened positive, providing informed consent are contacted for the
13 second PHQ-screening and a clinical interview via telephone equivalent to the first recruit-
14 ment strategy.

Inclusion/exclusion criteria

We include patients if they fulfil the following inclusion criteria:

- 1) age 18 years or older
- 2) CBP assessed by physician for at least six months assessed during telephone interview
- 3) mild to moderate depression or dysthymia according to SCID assessment, assessed during telephone interview
- 4) sufficient knowledge of German language
- 5) Internet and PC access.

Patients are excluded in case of :

- 6) receiving ongoing psychotherapy or beginning psychotherapy within the next three months,
- 7) being currently suicidal or reporting suicidal attempts in the past five years assessed during telephone interview or
- 8) a current diagnosis of severe depression (ICD-10 F32.2/F32.3/F33.2/F33.3 diagnosis) assessed during telephone interview, see table 1.

The exclusion of individuals with severe depression is due to ethical concerns and based on ICD-10 criteria for severe depression according to the German treatment guidelines for depression [28]. A trained psychotherapist (HB, LS, EM or SaS) contacts the participant to initiate further actions when severe depression is classified. We invite participants with a depression severity of PHQ \geq 5, who do not fulfil the criteria to participate, in a parallel conducted trial for CBP and subclinical depressive symptoms: eSano BackCare-DP [29].

Procedure on suicidal ideation

Participants who are currently suffering from suicidal ideation are identified by suicide screenings within the telephone interviews (SCID, HAM-D, QIDS) and questionnaires (PHQ-9) and potentially through communication with the eCoach or the study administration. Following a suicide protocol adapted from prior trials [30–32] we send an email with detailed information on available health services and the advice to seek professional help if participants report low suicidal ideation (HAM-D, QIDS or PHQ-9 item score = 1). In case of moderate to high suicidal ideation during the assessments or any suicidal thoughts or intentions reported to an eCoach or the study administration, a trained psychotherapist from the study team (HB, LS, EM or SaS) contacts the participant and initiate further actions. In the case of suicidal ideation communicated to the eCoach, unblinding is regarded as permissible.

Table 1: Key variables and measurements

Variables	Measurement	Depression screenings			T0	T1	T2
		1	2	3			
Inclusion/exclusion criteria							
Chronic back pain	MR + TI	x			x		
Mild to moderate depression or dysthymia	PHQ-9/HAM-D/QIDS/SCID				x	x	x
Severe depression (ICD-10 F32.2/F32.3/F33.2/F33.3 diagnosis)	SCID				x	x	x
Suicidality	HAM-D/QIDS/SCID				x	x	x
	PHQ-9	x	x	x	x	x	x
Further inclusion and exclusion criteria 1, 4, 5 and 6	SRQ +TI	x			x		
Primary outcome							
Depression severity	HAM-D				x	x	x
Secondary outcomes							
Depression remission and response	HAM-D /SCID/QIDS				x	x	x
Quality of life	AQoL-6D/ EQ-5D-5L				x	x	x
Pain intensity	Numerical Rating scale				x	x	x
Pain related disability	ODI				x	x	x
Pain self-efficacy	PSEQ				x	x	x
Work capacity	SPE				x	x	x
Measurements for the economic evaluation							
Costs	TiC-P				x		x
Quality of life	AQoL-6D/ EQ-5D-5L				x	x	x
Covariates							
Demographic variables	SRQ/MR	x			x		
Depression type and chronicity	SCID				x	x	x
Prior depression treatment	TI				x	x	
Back Pain type and chronicity	MR	x			x		

Internet affinity	IAS	x	x
Patient adherence *	attrition rate	x	x
Patient satisfaction *	CSQ-8		x
Negative effects of the intervention	INEP/SRQ/TI/SReC		x

AQoL-6D = Assessment of Quality of Life; CSQ-8 = Client Satisfaction Questionnaire; EQ-5D-5L = European Quality of Life scale; HAM-D = Hamilton Rating Scale for Depression ; IAS=Internet Affinity Scale; INEP = Inventory for the Assessment of Negative Effects of Psychotherapy; MR = Medical record; ODI= Oswestry Disability Index, PHQ-9= Patient Health Questionnaire-9; PSEQ= Pain Self-Efficacy Questionnaire; SCID = Structured Clinical Interview; SPE = Subjective Prognostic Employment scale; SReC = self-report during treatment to the eCoach; SRQ = self-report assessment questionnaire, TI = telephone interview; TiC-P=Trimbos/iMTA questionnaire for costs associated with psychiatric illness. * intervention group only

Intervention development

eSano BackCare-D is based on cognitive behaviour therapy (CBT), systematic behavioural activation [33–35] and problem solving [36]. The depression-specific components are based upon a prior IMI “GET.ON Mood Enhancer”, that has been evaluated in numerous RCTs in different samples [30, 37, 38] and shown to be effective in lowering depressive symptoms in individuals with diabetes mellitus type 1 and 2 with an intention to treat (ITT) effect size of $d=0.89$ at two-months post treatment [38] and $d=0.83$ at 6 months follow up [39]. We added CBP-relevant information, videos and audio clips, based on existing literature on psychological back pain treatment [40, 41], our clinical experience, and an existing IMI for chronic pain individuals based on acceptance and commitment therapy [42, 43]. Think-aloud interviews with five persons with CBP helped us to pilot validate the intervention and further improve its feasibility and acceptability before recruitment start. Access to the platform proceeds through a unique username password combination and is available on a 24/7 basis from all devices with internet access, however, optimized for PCs, notebooks and (large-screen) tablets. It is not possible to assess which device will be used by individual participants. Additionally, a text message coach is provided in eSano BackCare-D that is described below. All transferred data are secured via www.minddistrict.com based on ISO27001 and guidelines NEN7510.

Intervention content

eSano BackCare-D provides six minimally guided sessions with an estimated proceeding duration of 45-60 minutes each, developed to be processed weekly. Three optional sessions with back pain specific topics (sleep, partnership and sexuality, returning to work) are available at the end of sessions 3 through 5. Two booster sessions following the intervention are offered to

improve sustainability of intervention effects. Session-specific contents and homework assignments are shown in table 2.

Session 1 provides psychoeducational information on depression, the interaction between CBP and depression as well as pain acceptance. Participants define their depression- and CBP-related goals and get to know the mood diary as the homework assignment for the next week. In session 2, the concept of behavioural activation and the connection between pleasant activities and mood is introduced. Based on the principles of action planning and coping planning [44, 45], participants create an individual list and schedule for completion of pleasant activities in the next few days. The main focus in sessions 3 and 4 is on the six-step plan to handle solvable problems and to better manage emerging issues, comparable to other studies [38, 46–48]. In addition, techniques to reduce rumination on unsolvable problems and the concept of mindfulness are introduced. Session 5 includes information and exercises on physical activity [35], a mindfulness exercise and techniques to strengthen self-esteem. The sixth session serves to assess intervention-related changes in mood and provides a list of additional treatment options. Participants are encouraged to create a plan for the future. At the end, they write a letter to themselves about specific goals for the next four weeks and choose the date of the next booster session (after two, four or six weeks) that are developed to review what the participants have learned in previous sessions and to provide motivation to maintain and expand learned skills in the future.

The sleep session builds on an evidence based IMI for insomnia, i.e: GET.ON Recovery [49, 50]. As insomnia is a predictor and symptom of depression [51], participants learn about the principles of sleep hygiene, sleep restriction and stimulus control [52]. The partnership and sexuality session provides communication skills and exercises for improving physical closeness and sexuality. In the returning to work session, participants receive information on self-management and interpersonal competences as well as exercises in problem-solving and physical relaxation.

Table 2 Overview of the sessions

Session	Depression-specific topics	Back pain-specific topics	Assignments
1	Psychoeducational information about depression	Connection between back pain and depression Pain acceptance	To write down medical history and set goals Homework assignment: mood diary
2	Behavioural activation Information on connection between behaviour and mood	Worrying about back pain-related complications	To create an activity plan Homework assignment: to complete the activation plan.

3	Problem solving I Introduction in problem solving. Information on solvable and unsolvable problems		To work with the 6 problem solving steps based on own problems Homework assignment: to implement the problem solving steps during the week
4	Problem solving II Information about techniques to reduce rumination. Introduction to mindfulness	Rumination about back pain	To review the problem solving steps and implement a technique to stop rumination Homework assignment: to practise and track mindfulness exercises
5	Behavioural activation, focus on physical activity and self- esteem. Connection between mood and movement	Physical activity and back pain. Connection between back pain and physical rest	To raise awareness of successes and strengths. To learn to value oneself Homework assignment: to implement physical activity in daily life
6	Plan for the future Collection of pleasant activities	Conversation with a General Practitioner	To improve patient-physician relationship Homework assignment: to implement positive activities and create a future plan
Additional (optional) sessions			
a	Healthy sleep Information on sleep hygiene, sleep restriction and stimu- lus control		To implement the 10 rules for healthy sleep into daily life
b	Partnership and sexuality Information on communication skills, physical closeness and sexuality		To implement communication skills and massage exercises in daily life
c	Returning to the workplace Information on self-management and interpersonal competencies	Fitness exercises at the workplace	To set priorities, to implement the 6 steps for problem-solving at the workplace, and to review communication skills
Booster sessions (within 3 months after the regular sessions)			
7	Summary: behavioural activa- tion; review; pleasant activities; problem solving		To reflect on positive changes and update the activity plan; to practice the 6 steps for problem -solving
8	Summary of the key elements, behavioural activation		Choice of the intervention topics (1-6 above)

Text message coach

The text message coach in eSano BackCare-D automatically sends one supportive text message per day for the duration of six weeks as text message prompts have been shown to increase efficacy and adherence of IMIs [53–55]. The contents include a) reminders to complete the weekly assignments, b) repetition of the content, and c) motivation enhancement components.

Guidance

Based on previous studies showing that guidance and reminders and strict deadlines seem to be important with regard to the respective primary outcomes and adherence in IMIs [20, 56–58] the feedback manual of eSano BackCare-D provides instructions to remind, set deadlines and formulate standardised feedback for each session. Trained and supervised eCoaches (psychologists) serve as contact person and provide feedback within two work days after each completed session. Feedbacks are adapted to the participants' assignments and include posi-

1
2
3 tive reinforcement for completion of assignments and encouragement to proceed with the time
4 spent on guidance will be approximately 60-100 minutes per participant.
5
6

7 ***Control condition***

8 Participants have unrestricted access to TAU. All types of medical/psychological help re-
9 ceived during the last three month are tracked at T0 and T2 with the Trimbos/iMTA question-
10 naire for costs associated with psychiatric illness [59].
11
12

13 ***Proposed sample size/power calculations***

14 The sample size calculation is based on the primary endpoint, the HAM-D score at post
15 treatment. According to the results of trials on online interventions for depression [20], a
16 treatment effect (pooled effect size) of $d=0.39$ would be of clinical interest and is considered
17 feasible for the type of treatment. On the basis of a two-sample t-test at two-sided significance
18 level of 0.05, the study is planned to detect this effect with 80% power. This requires a sample
19 of 105 individuals in each arm.
20
21
22
23
24
25
26

27 ***Assessments***

28 **Depression screening.** Depressive symptoms are assessed by the Patient Health Question-
29 naire (PHQ-9) which is a well validated depression screening instrument that has also been
30 evaluated to be delivered as online-version [60], with a Cronbach's alpha of .89 and 88% sen-
31 sitivity and 88% specificity for major depression [61].
32
33
34

35 **Depression diagnosis.** The 17-item HAM-D is the most widely used clinician-rated measure
36 of depression severity and as such viewed as the gold standard for the assessment of depres-
37 sion severity. Additionally, we use the Quick Inventory of Depressive Symptomatology
38 (QIDS [62]) which assesses the severity of depressive symptoms, covering all criterion symp-
39 tom domains of the DSM-IV to diagnose a major depressive episode [62]. Moreover we use
40 Section A (Affective Syndromes) of the Structured Clinical Interview (SCID; [63]) as a com-
41 prehensive, structured interview designed to be used by trained interviewers for the assess-
42 ment of mental disorders according to the definitions and criteria of DSM. It enables a relia-
43 ble, valid and efficient assessment of depressive disorders [64]. As an add-on to the SCID for
44 DSM-IV, we use a German translation of the SCID-V-RV to allow for DSM-V [65] diagnoses
45 as well.
46
47
48
49
50
51
52

53 Interviewers are trained and weekly supervised by a psychologist (LS, EM) and are blinded to
54 randomisation condition. At the beginning of each interview, participants and interviewers
55 will be reminded to keep blinding throughout the assessment. After an initial training session,
56 a supervisor and the interviewers assess the same participant together, with comparison of
57
58
59
60

1
2
3 results as follows: The Inter-Rater Reliability (IRR) for the SCID, measured by *Cohen's kappa*
4 *pa* and the *Intra-Class Correlation* for the HAM-D and QIDS. An almost perfect Cohen's
5 $\kappa \geq .81$ [66] and an excellent ICC coefficient $\geq .75$ [67] is considered as sufficient. Each
6 interviewer is compared to trainers' rating (LS, EM) until the sufficient IRR values are met.
7 Afterwards, the interviewers are compared to each other on a random basis to assess the IRR.
8
9

10 11 **Primary outcome**

12 **Depression severity.** Depression severity is the core patient-relevant outcome in trials among
13 depressed individuals [68, 69] and is assessed by means of the clinician-rated Hamilton Rat-
14 ing Scale for Depression (HAM-D-17; [70]) (see table 1) at post-treatment (T1) as part of the
15 telephone interview. Inter-rater reliability of the SCID was reported to be high for inter-rater
16 reliability comparing telephone and face-to-face interviews [71].
17
18
19

20 21 **Secondary outcomes**

22 **Depression response and remission.** HAM-D scores are used to determine depression re-
23 sponse in accordance to the recommendations of Jacobson and Truax [72]. Depression remis-
24 sion is assessed by means of the SCID as part of the telephone interviews.
25
26
27

28 **Health related quality of life (QoL).** The AQoL-6D includes 20 items and six dimensions
29 and is suitable for quality of life assessments and economic evaluations of health programs
30 with good psychometric properties [73] and a Cronbach's alpha of .89 [74]. We additionally
31 obtain the most widely used quality of life assessment EuroQol (EQ-5D-5L) as a basis for
32 cost-utility analyses with five health domains of importance to quality of life [75].
33
34
35

36 **Pain intensity.** We use an 11-point numerical rating (0-10) of the worst, least and average
37 pain during the last week and calculate the mean of the three scales. Additionally, we use a
38 categorical rating of pain intensity (none, mild, moderate, severe).
39
40
41

42 **Pain related disability.** We obtain the Oswestry Disability Index (ODI) [76] as a reliable
43 ($\alpha = .86$; [77]) and valid 10 item self-report questionnaire, sensitive to change in difficulties in
44 completing activities of daily living [76].
45
46

47 **Pain self-efficacy.** The Pain Self-Efficacy Questionnaire (PSEQ) is a validated and reliable
48 (internal consistency: $\alpha = 0.93$) 10 item instrument that assesses self-efficacy expectations
49 related to pain [78].
50
51

52 **Work capacity.** The subjective prognostic employment scale (SPE) is a validated 3-item self-
53 report questionnaire (sum score 0-3) with high internal consistency (rep (Guttman scaling) =
54 .99; [79]).
55
56
57
58
59
60

1
2
3 **Intervention adherence.** The attrition rate (calculated using the percentage of individuals
4 who no longer use the intervention, as assessed by their log in data) gives an estimate of the
5 individuals' intervention adherence.
6
7

8 **Patient satisfaction.**

9
10 The Client Satisfaction Questionnaire (CSQ-8, German: ZUF-8), optimised for the assessment
11 of client satisfaction in IMIs (CSIQ-8) [80] is a validated 8 item instrument with high internal
12 consistency ($\alpha = 0.92$) [81]. The adapted version for the assessment of client satisfaction in
13 IMIs has shown to have high internal consistency in a range of studies ($\alpha = 0.92-0.94$) [50, 82,
14 83] and to be associated with treatment adherence and outcome.
15
16
17

18
19 **Negative effects of psychotherapy.** We include different ways of monitoring serious adverse
20 events (SAE) adapted from the National Institute for Health Research recommendations [84]
21 and Horigian et al. [85] who give general principles and examples to help illustrate their defi-
22 nition of SAEs: participants' responses in interviews, reported SAEs to the eCoach and SAEs
23 assessed by means of the Inventory for the Assessment of Negative Effects of Psychotherapy
24 (INEP) during the online assessments [86]. The INEP consists of 15 items assessing a range
25 of common changes participants experienced in line with the intervention. Cronbach's alpha
26 is $\alpha = 0.86$ [86]. At the beginning of every session, participants are asked about adverse events
27 and are also encouraged to report the events to their eCoach who monitors the SAEs and initi-
28 ates further actions if needed.
29
30
31
32
33
34
35
36

37 **Costs.**

38 We use the German version of the Cost Questionnaire "Trimbos Institute and Institute of
39 Medical Technology Questionnaire for Costs Associated with Psychiatric Illness" (TiC-P;
40 59), adapted for the German health care system by Nobis and colleagues [32] and for CBP
41 individuals by the present authors. The TiC-P allows assessment of all direct healthcare ser-
42 vices received during the last three months. Moreover, direct non-medical costs (e.g. travel
43 costs) and indirect costs are assessed, including the number of 'work loss' days (absenteeism),
44 the number of 'work cut-back' days (presentism) and costs associated with domestic tasks.
45
46
47
48

49 **Covariates.** Demographic variables, prior depression treatments, and internet affinity level
50 are assessed by patient self-report, see table 1. We use the German version of the Internet Af-
51 finity Scale (IAS) by Haase and colleagues [87] to assess familiarity with the Internet. De-
52 pression type (Major Depression yes/no), baseline severity and depression chronicity are as-
53 sessed by the SCID, back pain type, severity and chronicity are extracted from medical rec-
54 ords.
55
56
57
58
59
60

Statistical Analysis

Clinical analyses. The primary endpoint will be analysed with the HAM-D score at T1 as dependent variable and baseline value as covariates, adjusting for sex and age. Continuous secondary outcomes will be analysed accordingly. Standardised mean differences and 95% confidence intervals will be calculated to measure the between-group effect size at post-treatment and follow-up. Additionally, clinical significance analyses, such as number needed to treat (NNT) will be conducted. All analyses will be performed on an intention-to-treat (ITT) principle with multiple imputations to replace missing data [88]. Completer analyses (per-protocol) will be conducted to investigate the influence of study attrition on study results. Rates of patient-reported adverse events will be compared.

Economic evaluation. We will conduct a cost-effectiveness analysis (CEA) and a cost-utility analysis (CUA). Outcome estimates will be the incremental cost-effectiveness ratio (ICER) and the incremental cost-utility ratio (ICUR) after six months. A cost-effectiveness analysis with depression response as clinical outcome will be conducted. The generic outcome for the cost-utility analysis will be quality-adjusted life-years (QALYs), that will be based on the AQL-6D [73] and in a sensitivity analysis based on the EQ-5D-5L [75]. Both analyses will be conducted from a societal perspective including all direct and indirect costs. Nonparametric bootstrapping will be used to take into account stochastic uncertainty of the ICER. Further, we will calculate a cost-acceptability curve to test the likelihood that the intervention is cost-effective relative to TAU, given varying threshold for the willingness to pay for one depression response or QALY gained, respectively.

Ethics and dissemination

All procedures are approved by the ethics committee of the Albert-Ludwigs-University of Freiburg and the data security committee of the German Pension Insurance (Deutsche Rentenversicherung). The trial has been registered prior to recruitment start at the WHO International Clinical Trials Registry Platform via the German Clinical Studies Trial Register (DRKS): (DRKS00009272).

We conduct and report the RCT in accordance with the CONSORT 2010 Statement [89], the supplement of the CONSORT statement for pragmatic effectiveness trials [89, 90] and current guidelines for executing and reporting Internet intervention research [91]. The results will be published in peer-reviewed journals and presented on international conferences.

Quality assurance and safety

The Clinical Trials Unit Freiburg performs monitoring visits to the participating clinic centres before, during and after completion of the study to ensure that the study is conducted, recorded and reported according to the study protocol, relevant standard operating procedures (SOPs), and requirements of the sponsor and/or the Ethic Committees in accordance with ICH-GCP. Rigorous operating procedures for data management and safety have been implemented. The principal investigator and the research assistants have access to the source data that will be kept for as long as the study takes until 10 years after completion.

Furthermore, an independent Data Safety and Monitoring Board (DSMB) consisting of two experienced scientists and psychotherapists (MHä, MHa) and one statistician (LK) with long-standing experience in clinical trials has been established. The function of the DSMB is to monitor the course of the study and, if necessary, to give recommendations to the steering committee for discontinuation, modification or continuation of the study.

Discussion

The present effectiveness and cost-effectiveness trial focusses on individuals with CBP and comorbid depression as two of the most frequent, most disabling health conditions with high associated economic burden [5, 92].

The WARD-BP trial is innovative in several ways: a) Studies examining the effectiveness of psychological depression interventions are regularly methodologically limited as they lack diagnostic clarification of depression status [20, 69, 93]. By carrying out the SCID and HAM-D prior to randomization and at follow-up assessments, the present trial will be the first trial on a psychological depression intervention for people with chronic pain with verified DSM diagnosis of depression. b) With a target sample of 210 participants, the study will be optimally powered, overcoming limitations of small scale trials on psychological depression interventions in the medically ill [12, 69, 93]. c) The eSano BackCare-D intervention is tailored to the special needs of the target group of chronic back pain patients. This has been discussed to have an uptake and adherence facilitating effect [94], likely to improve the effectiveness of online interventions. d) The implementation of the intervention into the health-care system overcomes one of the main criticisms regarding IMI trial being only representative for a selective online population [95, 96]. e) The current trial design will allow examination of the reach of this IMI and will provide valuable information about which CBP individuals are willing to utilise such interventions. With the use of two different recruitment strategies, we will be able to compare two different ways of implementing IMIs into clinical routine. This will allow for conclusions on feasible ways of improving the adherence and uptake of IMIs in respective

1
2
3 target populations [97–99]. f) Finally, as one of still few clinical trials on psychological de-
4 pression interventions the present trial comprises a cost-effectiveness analysis.

5
6 If the results of WARD-BP indicate that eSano BackCare-D is effective and cost-effective, its
7 clinical impact on depression health care services could be substantial. When implemented as
8 part of the standard health care, IMIs have the potential to reduce the “lost in transition phe-
9 nomenon” caused by fragmented health care systems [26, 100, 101]. Engaging individuals in
10 treatment at the interface of different health care sectors, as in the present (cost-)effectiveness
11 trial, will contribute important information on potential approaches to improve the delivery of
12 mental health care and at the same time provide insights on possible ways of implementing
13 depression IMIs into chronic back pain care in order to exploit their full potential. The first
14 results of WARD-BP are expected in 2018.
15
16
17
18
19
20
21
22
23

24 *Authors' contributions*

25 HB, DE, MB, OM and HR initiated this study. All authors contributed to the design of this
26 study. HB, LS, SP, DE, SaS, DL, SN, JB, HR, MB and JL developed the intervention content
27 or intervention content eSano BackCare-D is based on as well as the assessment. HB, LS, SP,
28 SaS, DE, and JL are responsible for recruitment. SaS is responsible for randomisation and
29 allocation as well as the administration of participants. JL wrote the draft of the manuscript.
30 HB provided expertise on depression, CBP and psychological pain interventions. All authors
31 contributed to the further writing of the manuscript and approved the final version of the
32 manuscript.
33
34
35
36
37
38
39

40 *Conflict of interest*

41 JL, LS, SP, SS, JB, SN, OM, HR and HB report no conflict of interest. DE, MB, and DL are
42 stakeholders of the “Institute for Online Health Trainings”, a company aiming to transfer sci-
43 entific knowledge related to the present research into routine health care. A committee of in-
44 dependent scientists has been formed (Data Safety and Monitoring Board (DSMB)) to super-
45 vise study-related decisions and prevent any influence of a potential conflict of interest.
46
47
48
49
50
51
52

53 *Funding*

54 This study is funded by the Federal Ministry of Education and Research of Germany (project:
55 Effectiveness of a guided web-based intervention for depression in back pain rehabilitation
56 aftercare, Grant number: 01GY1330A). This funding source has no influence on the design of
57
58
59
60

1
2
3 this study and will not influence its execution, analyses, interpretation of the data, or decision
4 to submit results.
5
6
7

8 *Acknowledgements*

9 We thank Dr. Kristin Kieselbach and Prof. Dr. Anja Göritz for their support with providing
10 their expertise in the content of the intervention. We thank colleagues who were part of the
11 development of prior interventions [32, 43] that partly build the basis of eSano© BackCare-D.
12 Moreover we like to thank our study assistants and interns and students for their support in the
13 development of the intervention and in conducting the study. We thank Ellen Meierotto for
14 supervising the SCID-interviewers. Many thanks go to the Data Safety and Monitoring Board,
15 consisting of Prof. Dr. Martin Hautzinger, Prof. Dr. Martin Härter and Dr Levente Kriston as
16 well as the Clinical Trials Unit Freiburg for their support in carrying out the study project.
17 Special thanks go to the eight orthopedic clinics Schoen Klinik, Bad Staffelstein; Rehaklinik
18 Sonnhalde, Donaueschingen; RehaKlinikum Bad Säckingen; Städt. Rehakliniken Bad Wald-
19 see; Schwarzwaldklinik Orthopädie - Abteilung Medizinische Rehabilitation, Bad Krozingen;
20 Rheintalklinik Bad Krozingen; REGIO-Reha Tagesklinik, Freiburg and Universitäts- und
21 Rehabilitationskliniken, Ulm as well as the further orthopaedic rehabilitation units of the se-
22 cond recruitment strategy. We are very grateful to Mary Wyman for proofreading and lan-
23 guage editing of this manuscript.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

- 1 Vos T, Barber RM, Bell B, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. *The Lancet* 2015;**386**(9995):743–800.
<http://www.sciencedirect.com/science/article/pii/S0140673615606924> (accessed 17.8.16).
- 2 Hoy D, Bain C, Williams G, et al. A systematic review of the global prevalence of low back pain. *Arthritis Rheum* 2012;**64**(6):2028–2037.
<http://onlinelibrary.wiley.com/doi/10.1002/art.34347/full> (accessed 17.8.16).
- 3 Bromet E, Andrade LH, Hwang I, et al. Cross-national epidemiology of DSM-IV major depressive episode. *BMC medicine* 2011;**9**:90.
<http://bmcmmedicine.biomedcentral.com/articles/10.1186/1741-7015-9-90> (accessed 17.8.16).
- 4 Bair MJ, Robinson RL, Katon W, et al. Depression and pain comorbidity: a literature review. *Arch Intern Med* 2003;**163**(20):2433–2445.
<http://archinte.jamanetwork.com/article.aspx?articleid=216320> (accessed 17.8.16).
- 5 Baumeister H, Knecht A, Hutter N. Direct and indirect costs in persons with chronic back pain and comorbid mental disorders--a systematic review. *J Psychosom Res* 2012;**73**(2):79–85. <http://www.sciencedirect.com/science/article/pii/S0022399912001468> (accessed 17.08.16).
- 6 Baumeister H, Balke K, Härter M. Psychiatric and somatic comorbidities are negatively associated with quality of life in physically ill patients. *J Clin Epidemiol* 2005;**58**(11):1090–1100.
<http://www.sciencedirect.com/science/article/pii/S0895435605001605> (accessed 17.8.16).
- 7 Baumeister H, Hutter N, Bengel J, et al. Quality of life in medically ill persons with comorbid mental disorders: a systematic review and meta-analysis. *Psychother Psychosom* 2011;**80**(5):275–286. <http://www.karger.com/Article/FullText/323404> (accessed 17.08.16).
- 8 Nicholas MK, Coulston CM, Asghari A, et al. Depressive symptoms in patients with chronic pain. *Med J Aust* 2009;**190**(7):S66. <http://europepmc.org/abstract/MED/19351296> (accessed 17.8.16).
- 9 Miles CL, Pincus T, Carnes D, et al. Can we identify how programmes aimed at promoting self-management in musculoskeletal pain work and who benefits? A systematic review of sub-group analysis within RCTs. *Eur J Pain* 2011;**15**(8):775.e1-11.
<http://www.sciencedirect.com/science/article/pii/S1090380111000334> (accessed 17.8.16).
- 10 Williams AC, Eccleston C, Morley S. Psychological therapies for the management of chronic pain (excluding headache) in adults. *Cochrane Database Syst Rev* 2012;**11**:CD007407.
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007407.pub3/full> (accessed 17.08.16).
- 11 Hoffman BM, Papas RK, Chatkoff DK, et al. Meta-analysis of psychological interventions for chronic low back pain. *Health Psychol* 2007;**26**(1):1–9.
<http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0024119/> (accessed 17.08.16).
- 12 Baumeister H, Härter M. Psychische Komorbidität bei muskuloskelettalen Erkrankungen. *Bundesgesundheitsbl.* 2011;**54**(1):52–58. <http://link.springer.com/article/10.1007/s00103-010-1185-x/fulltext.html?view=classic> (accessed 17.08.17).
- 13 Parker JC, Smarr KL, Slaughter JR, et al. Management of depression in rheumatoid arthritis: a combined pharmacologic and cognitive-behavioral approach. *Arthritis Rheum.* 2003;**49**(6):766–777. doi:10.1002/art.11459.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 14 Lin, Elizabeth H B, Katon W, Korff M von, et al. Effect of improving depression care on pain and functional outcomes among older adults with arthritis: a randomized controlled trial. *JAMA* 2003;**290**(18):2428–2429. doi:10.1001/jama.290.18.2428.
 - 15 Kroenke K, Bair MJ, Damush TM, et al. Optimized antidepressant therapy and pain self-management in primary care patients with depression and musculoskeletal pain: a randomized controlled trial. *JAMA* 2009;**301**(20):2099–2110. doi:10.1001/jama.2009.723.
 - 16 Eccleston C, Fisher E, Craig L, et al. Psychological therapies (Internet-delivered) for the management of chronic pain in adults. *Cochrane Database Syst Rev* 2014(2):CD010152. doi:10.1002/14651858.CD010152.pub2.
 - 17 Buhrman M, Gordh T, Andersson G. Internet interventions for chronic pain including headache: A systematic review. *Internet Interv* 2016;**4**:17–34. <http://www.sciencedirect.com/science/article/pii/S2214782915000421>.
 - 18 Ebert DD, Zarski A, Christensen H, et al. Internet and computer-based cognitive behavioral therapy for anxiety and depression in youth: a meta-analysis of randomized controlled outcome trials. *PloS one* 2015;**10**(3):e0119895. <http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0119895> (accessed 17.08.16).
 - 19 Sander L, Rausch L, Baumeister H. Effectiveness of Internet-Based Interventions for the Prevention of Mental Disorders: A Systematic Review and Meta-Analysis. *JMIR Ment Health* 2016;**3**(3):e38. <http://mental.jmir.org/2016/3/e38/> (accessed August 24, 2016).
 - 20 Richards D, Richardson T. Computer-based psychological treatments for depression: a systematic review and meta-analysis. *Clin Psychol Rev* 2012;**32**(4):329–342. <http://www.sciencedirect.com/science/article/pii/S027273581200027X> (accessed 17.08.16).
 - 21 Andrews G, Cuijpers P, Craske MG, et al. Computer therapy for the anxiety and depressive disorders is effective, acceptable and practical health care: a meta-analysis. *PloS one* 2010;**5**(10):e13196. <http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0013196> (accessed 17.08.16).
 - 22 Andersson G. Internet-Delivered Psychological Treatments. *Annu Rev Clin Psychol* 2016;**12**:157–179. <http://www.annualreviews.org/doi/full/10.1146/annurev-clinpsy-021815-093006> (accessed September 15, 2016).
 - 23 Andersson G, Carlbring P, Cuijpers P. Internet interventions: Moving from efficacy to effectiveness. *EJAP* 2010;**5**(2). <http://sensoria.swinburne.edu.au/index.php/sensoria/article/view/169/194> (accessed 17.08.16).
 - 24 Snow V, Beck D, Budnitz T, et al. Transitions of Care Consensus Policy Statement American College of Physicians-Society of General Internal Medicine-Society of Hospital Medicine-American Geriatrics Society-American College of Emergency Physicians-Society of Academic Emergency Medicine. *J Gen Intern Med* 2009;**24**(8):971–976. doi:10.1007/s11606-009-0969-x.
 - 25 Ebert D, Tarnowski T, Gollwitzer M, et al. A Transdiagnostic Internet-Based Maintenance Treatment Enhances the Stability of Outcome after Inpatient Cognitive Behavioral Therapy: A Randomized Controlled Trial. *Psychother Psychosom* 2013;**82**(4):246–256. <http://www.karger.com/Article/FullText/345967> (accessed 17.08.16).
 - 26 Kim CS, Flanders SA. In the Clinic. Transitions of care. *Ann Intern Med* 2013;**158**(5 Pt 1):ITC3-1. <http://annals.org/article.aspx?articleid=1657883> (accessed 17.08.16).
 - 27 Löwe B, Kroenke K, Herzog W, et al. Measuring depression outcome with a brief self-report instrument: sensitivity to change of the Patient Health Questionnaire (PHQ-9). *J Affect Disord* 2004;**81**(1):61–66.

- 1
2
3 <http://www.sciencedirect.com/science/article/pii/S0165032703001988> (accessed
4 17.08.16).
- 5 28 DGPPN BÄ, KBV A, AkdÄ B, et al. S3-Leitlinie/Nationale VersorgungsLeitlinie
6 Unipolare Depression-Langfassung. DGPPN, ÄZQ, AWMF, Berlin, Düsseldorf 2009.
- 7 29 Sander L, Paganini S, Lin J, et al. Effectiveness and cost-effectiveness of a guided Inter-
8 net- and mobile-based intervention for the indicated prevention of major depression in pa-
9 tients with chronic back pain-study protocol of the PROD-BP multicenter pragmatic RCT.
10 BMC Psychiatry 2017;**17**(1):36. doi:10.1186/s12888-017-1193-6.
- 11 30 Ebert D, Lehr D, Baumeister H, et al. GET.ON Mood Enhancer: efficacy of Internet-based
12 guided self-help compared to psychoeducation for depression: an investigator-blinded
13 randomised controlled trial. *Trials* 2014;**15**(1):39.
14 <http://trialsjournal.biomedcentral.com/articles/10.1186/1745-6215-15-39> (accessed
15 17.08.16).
- 16 31 Buntrock C, Ebert DD, Lehr D, et al. Evaluating the efficacy and cost-effectiveness of
17 web-based indicated prevention of major depression: design of a randomised controlled
18 trial. *BMC Psychiatry* 2014;**14**(1):25.
19 <http://bmcp psychiatry.biomedcentral.com/articles/10.1186/1471-244X-14-25> (accessed
20 17.08.16).
- 21 32 Nobis S, Lehr D, Ebert DD, et al. Efficacy and cost-effectiveness of a web-based interven-
22 tion with mobile phone support to treat depressive symptoms in adults with diabetes melli-
23 tus type 1 and type 2: design of a randomised controlled trial. *BMC Psychiatry*
24 2013;**13**:306. [http://bmcp psychiatry.biomedcentral.com/articles/10.1186/1471-244X-13-](http://bmcp psychiatry.biomedcentral.com/articles/10.1186/1471-244X-13-306)
25 306 (accessed 17.08.16).
- 26 33 Cuijpers P, van Straten A, Warmerdam L. Behavioral activation treatments of depression:
27 a meta-analysis. *Clin Psychol Rev* 2007;**27**(3):318–326.
28 <http://www.sciencedirect.com/science/article/pii/S027273580600136X> (accessed
29 17.08.16).
- 30 34 Hopko DR, Lejuez CW, Ruggiero KJ, et al. Contemporary behavioral activation treat-
31 ments for depression: Procedures, principles, and progress. *Clin Psychol Rev*
32 2003;**23**(5):699–717.
33 <http://www.sciencedirect.com/science/article/pii/S0272735803000709> (accessed
34 17.08.16).
- 35 35 Prochaska JO, Velicer WF. The transtheoretical model of health behavior change. *Am J*
36 *Health Promot* 1997;**12**(1):38–48. <http://ahp.sagepub.com/content/12/1/38.long> (accessed
37 17.08.16).
- 38 36 Cuijpers P, van Straten A, Warmerdam L. Problem solving therapies for depression: a
39 meta-analysis. *Eur Psychiatry* 2007;**22**(1):9–15.
40 <http://www.ncbi.nlm.nih.gov/pubmed/17194572> (accessed 17.08.16).
- 41 37 Buntrock C, Ebert D, Lehr D, et al. Effectiveness of a web-based cognitive behavioural
42 intervention for subthreshold depression: pragmatic randomised controlled trial.
43 *Psychother Psychosom* 2015;**84**(6):348–358. <https://www.karger.com/Article/Pdf/438673>
44 (accessed 17.08.16).
- 45 38 Nobis S, Lehr D, Ebert DD, et al. Efficacy of a web-based intervention with mobile phone
46 support in treating depressive symptoms in adults with type 1 and type 2 diabetes: a ran-
47 domized controlled trial. *Diabetes Care* 2015;**38**(5):776–783.
48 <http://care.diabetesjournals.org/content/38/5/776> (accessed 18.08.16).
- 49 39 Ebert DD, Nobis S, Lehr D, et al. 6-months effectiveness of internet-based guided self-
50 help for diabetes and comorbid depression. Results of a randomized controlled trial. *Dia-*
51 *bet Med* (accepted).
- 52 40 Martin A, Härter M, Henningsen P, et al. Evidenzbasierte Leitlinie zur Psychotherapie
53 somatoformer Störungen und assoziierter Syndrome: Hogrefe Verlag 2013.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 41 Kröner-Herwig B. Rückenschmerz: Hogrefe Verlag 2000.
- 42 Lin J, Paganini S, Sander L, et al. Effectiveness of a guided and unguided internet-based Acceptance and Commitment Therapy for chronic pain: study protocol for a three-armed randomised controlled trial. *Deutsches Arzteblatt international*; **in press**.
- 43 Lin J, Lüking M, Ebert DD, et al. Effectiveness and cost-effectiveness of a guided and unguided internet-based Acceptance and Commitment Therapy for chronic pain: Study protocol for a three-armed randomised controlled trial. *Internet Interv* 2015;**2**(1):7–16. <http://www.sciencedirect.com/science/article/pii/S2214782914000359> (accessed 17.08.16).
- 44 Krämer LV, Helmes AW, Bengel J. Understanding activity limitations in depression: Integrating the concepts of motivation and volition from health psychology into clinical psychology. *Eur Psychol* 2014;**19**(4):278. <http://psycnet.apa.org/journals/epp/19/4/278/> (accessed 17.08.16).
- 45 Krämer LV, Helmes AW, Seelig H, et al. Correlates of reduced exercise behaviour in depression: The role of motivational and volitional deficits. *Psychol Health* 2014;**29**(10):1206–1225. <http://www.tandfonline.com/doi/abs/10.1080/08870446.2014.918978?journalCode=gps200> (accessed 17.08.16).
- 46 Warmerdam L, van Straten A, Twisk J, et al. Internet-based treatment for adults with depressive symptoms: randomized controlled trial. *J Med Internet Res* 2008;**10**(4):e44. <http://www.jmir.org/2008/4/e44/> (accessed 17.08.16).
- 47 van Straten A, Cuijpers P, Smits N. Effectiveness of a web-based self-help intervention for symptoms of depression, anxiety, and stress: randomized controlled trial. *J Med Internet Res* 2008;**10**(1):e7. <http://www.jmir.org/2008/1/e7/> (accessed 17.08.16).
- 48 Ebert D, Lehr D, Boß L, et al. Efficacy of an internet-based problem-solving training for teachers: results of a randomized controlled trial. *Scand J Work Environ Health* 2014;**40**(6):582–596. http://www.sjweh.fi/download.php?abstract_id=3449&file_nro=1 (accessed 17.08.16).
- 49 Thiart H, Lehr D, Ebert DD, et al. Log in and breathe out: internet-based recovery training for sleepless employees with work-related strain - results of a randomized controlled trial. *Scand J Work Environ Health* 2015;**41**(2):164–174. http://www.sjweh.fi/show_abstract.php?abstract_id=3478&fullText=1#box-fullText (accessed 17.08.16).
- 50 Ebert DD, Berking M, Thiart H, et al. Restoring depleted resources: Efficacy and mechanisms of change of an internet-based unguided recovery training for better sleep and psychological detachment from work. *Health Psychol* 2015;**34** **Suppl**:1240–1251. <https://www.apa.org/pubs/journals/releases/hea-hea0000277.pdf> (accessed 17.08.16).
- 51 Baglioni C, Battagliese G, Feige B, et al. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. *J Affect Disord* 2011;**135**(1):10–19. <http://www.sciencedirect.com/science/article/pii/S0165032711000292> (accessed 17.08.16).
- 52 Morin CM, Bootzin RR, Buysse DJ, et al. Psychological and behavioral treatment of insomnia: update of the recent evidence (1998-2004). *Sleep* 2006;**29**(11):1398. <http://www.journalsleep.org/ViewAbstract.aspx?pid=26676> (accessed 17.08.16).
- 53 Webb T, Joseph J, Yardley L, et al. Using the internet to promote health behavior change: a systematic review and meta-analysis of the impact of theoretical basis, use of behavior change techniques, and mode of delivery on efficacy. *J Med Internet Res* 2010;**12**(1). <http://www.jmir.org/2010/1/e4/> (accessed 17.08.16).
- 54 Ritterband L, Gonder-Frederick L, Cox D, et al. Internet interventions: In review, In use, and Into the future. *Prof Psychol Res Pr* 2003;**34**(5):527. <http://psycnet.apa.org/psycinfo/2003-08155-014> (accessed 17.08.16).

- 1
2
3 55 Fry JP, Neff RA. Periodic prompts and reminders in health promotion and health behavior
4 interventions: systematic review. *J Med Internet Res* 2009;**11**(2):e16.
5 <http://www.jmir.org/2009/2/e16/> (accessed 17.08.16).
- 6 56 Almlöv J, Carlbring P, Berger T, et al. Therapist factors in internet-delivered cognitive
7 behavioural therapy for major depressive disorder. *Cogn Behav Ther* 2009;**38**(4):247–254.
8 <http://www.tandfonline.com/doi/abs/10.1080/16506070903116935?journalCode=sbeh20>
9 (accessed 17.08.16).
- 10 57 Kleiboer A, Donker T, Seekles W, et al. A randomized controlled trial on the role of sup-
11 port in Internet-based problem solving therapy for depression and anxiety. *Behav Res*
12 *Ther* 2015;**72**:63–71.
13 <http://www.sciencedirect.com/science/article/pii/S000579671530005X> (accessed
14 17.08.16).
- 15 58 Baumeister H, Reichler L, Munzinger M, et al. The impact of guidance on Internet-based
16 mental health interventions — A systematic review. *Internet Interv* 2014;**1**(4):205–215.
17 <http://www.sciencedirect.com/science/article/pii/S2214782914000244> (accessed
18 17.08.16).
- 19 59 Hakkaart-Van Roijen L, van Straten A, Donker M, et al. Trimbos/iMTA questionnaire for
20 costs associated with psychiatric illness (TIC-P). Institute for Medical Technology As-
21 sessment, Erasmus University Rotterdam. Trimbos 2002.
- 22 60 Erbe D, Eichert H, Rietz C, et al. Interformat reliability of the patient health questionnaire:
23 Validation of the computerized version of the PHQ-9. *Internet Interv* 2016;**5**:1–4.
24 <http://www.sciencedirect.com/science/article/pii/S2214782916300033> (accessed
25 17.08.16).
- 26 61 Kroenke K, Spitzer RL, Williams JBW. The PHQ-9. *J Gen Intern Med* 2001;**16**(9):606–
27 613. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1495268/> (accessed 17.08.16).
- 28 62 Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive
29 Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psy-
30 chometric evaluation in patients with chronic major depression. *Biol Psychiatry*
31 2003;**54**(5):573–583.
32 <http://www.sciencedirect.com/science/article/pii/S0006322302018668> (accessed
33 17.08.16).
- 34 63 First MB, Spitzer RL, Gibbon M, et al. User's guide for the Structured clinical interview
35 for DSM-IV axis I disorders SCID-I: clinician version: American Psychiatric Pub 1997.
- 36 64 Wittchen HU, Zaudig M, Fydrich T. *Strukturiertes Klinisches Interview für DSM-IV*. Göt-
37 tingen: Hogrefe 1997.
- 38 65 American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders:*
39 *DSM-5*: ManMag 2003.
- 40 66 Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. *Fam*
41 *Med* 2005;**37**(5):360–363. <http://www.stfm.org/fmhub/fm2005/May/Anthony360.pdf> (ac-
42 cessed 17.08.16).
- 43 67 Fleiss JL, ed. *The Design and Analysis of Clinical Experiments*. Hoboken, NJ, USA: John
44 Wiley & Sons, Inc 1999.
- 45 68 Baumeister H, Hutter N. Collaborative care for depression in medically ill patients. *Curr*
46 *Opin Psychiatry* 2012;**25**(5):405–414. [http://meta.wkhealth.com/pt/pt-core/template-
47 journal/lwwgateway/media/landingpage.htm?issn=0951-
48 7367&volume=25&issue=5&spage=405](http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0951-7367&volume=25&issue=5&spage=405) (accessed 17.08.16).
- 49 69 Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for
50 depression in patients with coronary artery disease. *Cochrane Database Syst Rev*
51 2011(9):CD008012.
52 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008012.pub3/full> (accessed
53 17.08.16).

- 1
2
3 70 Hamilton M. A rating scale for depression. *J Neurol Neurosurg Psychiatry* 1960;**23**(1):56–
4 62. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC495331/> (accessed 17.08.16).
- 5 71 Crippa, José Alexandre S, de Lima Osório, Flávia, Del-Ben CM, et al. Comparability be-
6 tween telephone and face-to-face structured clinical interview for DSM-IV in assessing
7 social anxiety disorder. *Perspectives in psychiatric care* 2008;**44**(4):241–247.
8 doi:10.1111/j.1744-6163.2008.00183.x.
- 9 72 Jacobson NS, Truax P. Clinical significance: A statistical approach to defining meaningful
10 change in psychotherapy research. *Journal of Consulting and Clinical Psychology*
11 1991;**59**(1):12–19. doi:10.1037/0022-006X.59.1.12.
- 12 73 Richardson, Jeffrey R J, Peacock SJ, Hawthorne G, et al. Construction of the descriptive
13 system for the assessment of quality of life AQL-6D utility instrument. *Health Qual Life*
14 *Outcomes* 2012;**10**:38. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3349491/> (ac-
15 cessed 11.5.16).
- 16 74 Allen M, Iezzoni LI, Huang A, et al. Improving patient-clinician communication about
17 chronic conditions: description of an internet-based nurse E-coach intervention. *Nurs Res*
18 2008;**57**(2):107–112. <http://www.ncbi.nlm.nih.gov/pubmed/18347482> (accessed
19 17.08.16).
- 20 75 Rabin R, Charro Fd. EQ-SD: a measure of health status from the EuroQol Group. *Ann.*
21 *Med.* 2001;**33**(5):337–343. <http://www.ncbi.nlm.nih.gov/pubmed/11491192> (accessed
22 17.08.16).
- 23 76 Mannion AF, Junge A, Grob D, et al. Development of a German version of the Oswestry
24 Disability Index. Part 2: sensitivity to change after spinal surgery. *Eur Spine J*
25 2006;**15**(1):66–73. <http://link.springer.com/article/10.1007%2Fs00586-004-0816-z> (ac-
26 cessed 17.08.16).
- 27 77 Wittink H, Turk DC, Carr DB, et al. Comparison of the redundancy, reliability, and re-
28 sponsiveness to change among SF-36, Oswestry Disability Index, and Multidimensional
29 Pain Inventory. *Clin J Pain* 2004;**20**(3):133–142.
30 <http://www.ncbi.nlm.nih.gov/pubmed/15100588> (accessed 17.08.16).
- 31 78 Nicholas MK. The pain self-efficacy questionnaire: Taking pain into account. *Eur J Pain*
32 2007;**11**(2):153–163. <http://onlinelibrary.wiley.com/doi/10.1016/j.ejpain.2005.12.008/full>
33 (accessed 17.08.16).
- 34 79 Mittag O, Raspe H. A brief scale for measuring subjective prognosis of gainful employ-
35 ment: findings of a study of 4279 statutory pension insurees concerning reliability
36 (Guttman scaling) and validity of the scale. *Die Rehabilitation* 2003;**42**(3):169–174.
37 <https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2003-40095> (ac-
38 cessed 17.08.16).
- 39 80 Boß L, Lehr D, Vis C, et al. Assessing Client Satisfaction in web-based interventions. *The*
40 *CSWQ-8*. *JMIR in prep*.
- 41 81 Larsen DL, Attkisson CC, Hargreaves WA, et al. Assessment of client/patient satisfaction:
42 development of a general scale. *Eval Program Plann* 1979;**2**(3):197–207.
43 <http://www.sciencedirect.com/science/article/pii/0149718979900946> (accessed 17.08.16).
- 44 82 Thiart H, Lehr D, Ebert DD, et al. Log in and breathe out: efficacy and cost-effectiveness
45 of an online sleep training for teachers affected by work-related strain--study protocol for
46 a randomized controlled trial. *Trials* 2013;**14**:169.
47 <http://trialsjournal.biomedcentral.com/articles/10.1186/1745-6215-14-169> (accessed
48 17.08.16).
- 49 83 Ebert DD, Heber E, Berking M, et al. Self-guided internet-based and mobile-based stress
50 management for employees: results of a randomised controlled trial. *Occup. Environ.*
51 *Med.* 2016;**73**(5):315–323. [http://oem.bmj.com/content/early/2016/02/16/oemed-2015-
52 103269.full.pdf](http://oem.bmj.com/content/early/2016/02/16/oemed-2015-103269.full.pdf) (accessed 17.08.16).
- 53
54
55
56
57
58
59
60

- 1
2
3 84 Duggan C, Parry G, McMurrin M, et al. The recording of adverse events from psychological treatments in clinical trials: Evidence from a review of NIHR-funded trials. *Trials* 2014;**15**(1):335. <http://trialsjournal.biomedcentral.com/articles/10.1186/1745-6215-15-335> (accessed 17.08.16).
- 4
5
6
7 85 Horigian VE, Robbins MS, Dominguez R, et al. Principles for defining adverse events in behavioral intervention research: lessons from a family-focused adolescent drug abuse trial. *Clinical Trials* 2010;**7**(1):58–68. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3163837/> (accessed 17.08.16).
- 8
9
10
11 86 Ladwig I, Rief W, Nestoriuc Y. Welche Risiken und Nebenwirkungen hat Psychotherapie?-Entwicklung des Inventars zur Erfassung Negativer Effekte von Psychotherapie (INEP). *Verhaltenstherapie* 2014;**24**(4):252–263. <http://www.karger.com/Article/PDF/367928> (accessed 17.08.16).
- 12
13
14
15 87 Haase R, Schultheiss T, Kempcke R, et al. Use and acceptance of electronic communication by patients with multiple sclerosis: a multicenter questionnaire study. *J Med Internet Res* 2012;**14**(5):e135. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3510727/> (accessed 17.08.16).
- 16
17
18
19 88 Schafer JL, Graham JW. Missing data: our view of the state of the art. *Psychological methods* 2002;**7**(2):147. <http://psycnet.apa.org/journals/met/7/2/147/> (accessed 17.07.16).
- 20
21
22
23 89 Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials. *PLoS Med* 2010;**7**(3):e1000251. doi:10.1371/journal.pmed.1000251 [published Online First: <http://www.bmj.com/content/340/bmj.c332>].
- 24
25
26
27 90 Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. *BMJ* 2008;**337**:a2390. <http://www.bmj.com/content/337/bmj.a2390.long> (accessed 17.08.16).
- 28
29
30
31 91 Proudfoot J, Klein B, Barak A, et al. Establishing guidelines for executing and reporting internet intervention research. *Cogn Behav Ther* 2011;**40**(2):82–97. <http://www.tandfonline.com/doi/abs/10.1080/16506073.2011.573807> (accessed 17.08.16).
- 32
33
34
35 92 Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. *Eur J Pain* 2006;**10**(4):287–333. <http://www.sciencedirect.com/science/article/pii/S1090380105000868> (accessed 17.08.16).
- 36
37
38
39 93 Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for depression in patients with diabetes mellitus and depression. *Cochrane Database Syst Rev* 2012;**12**:CD008381. <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008381.pub2/full> (accessed 17.08.16).
- 40
41
42
43 94 Cuijpers P, van Straten A, Warmerdam L, et al. Recruiting participants for interventions to prevent the onset of depressive disorders: Possible ways to increase participation rates. *BMC Health Serv Res* 2010;**10**(1):181–7. <https://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-10-181> (accessed 17.08.16).
- 44
45
46
47 95 Baumeister H. Kein signifikanter Zusatznutzen als Add-on in der allgemeinärztlichen Routineversorgung: (Review und Kommentar). *InFo Neurologie* 2016;**18**(1):14–15. <http://link.springer.com/article/10.1007/s15005-016-1601-3/fulltext.html?view=classic> (accessed 17.08.16).
- 48
49
50
51 96 Gilbody S, Littlewood E, Hewitt C, et al. Computerised cognitive behaviour therapy (cCBT) as treatment for depression in primary care (REEACT trial): large scale pragmatic randomised controlled trial. *BMJ* 2015;**351**:h5627. <http://www.bmj.com/content/351/bmj.h5627> (accessed 17.08.16).
- 52
53
54
55
56
57
58
59
60

- 1
2
3 97 Baumeister H, Nowoczin L, Lin J, et al. Impact of an acceptance facilitating intervention
4 on diabetes patients' acceptance of Internet-based interventions for depression: A random-
5 ized controlled trial. *Diabetes Res Clin Pract* 2014.
6 <http://www.sciencedirect.com/science/article/pii/S0168822714002149> (accessed
7 17.08.16).
- 8 98 Ebert DD, Berking M, Cuijpers P, et al. Increasing the acceptance of internet-based mental
9 health interventions in primary care patients with depressive symptoms. A randomized
10 controlled trial. *J Affect Disord* 2015(176):9–17.
11 [http://linkinghub.elsevier.com/retrieve/pii/S0165-0327\(15\)00069-5](http://linkinghub.elsevier.com/retrieve/pii/S0165-0327(15)00069-5) (accessed 17.08.16).
- 12 99 Baumeister H, Seiffert H, Lin J, et al. Impact of an Acceptance Facilitating Intervention
13 on Patients' Acceptance of Internet-based Pain Interventions - A Randomised Controlled
14 Trial. *Clin J Pain* 2015(6):528–535. <http://www.ncbi.nlm.nih.gov/pubmed/24866854> (ac-
15 cessed 17.08.16).
- 16 100 Batterham PJ, Sunderland M, Calear AL, et al. Developing a roadmap for the transla-
17 tion of e-mental health services for depression. *Aust N Z J Psychiatry* 2015;49(9):776–
18 784. <http://anp.sagepub.com/content/49/9/776.long> (accessed September 15, 2016).
- 19 101 Coleman EA, Berenson RA. Lost in transition: challenges and opportunities for im-
20 proving the quality of transitional care. *Ann Intern Med* 2004;141(7):533–536.
21 <http://annals.org/article.aspx?articleid=717858> (accessed August 17, 2016).
- 22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. study flow

Flow Chart

297x420mm (300 x 300 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Page NO in manuscript
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
	2b	All items from the World Health Organization Trial Registration Data Set	3
Protocol version	3	Date and version identifier	2
Funding	4	Sources and types of financial, material, and other support	17
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1
	5b	Name and contact information for the trial sponsor	15
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	15
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	15
Introduction			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	4-5
	6b	Explanation for choice of comparators	(5/11)
Objectives	7	Specific objectives or hypotheses	5

1				
2				
3				
4				
5				
6				
7				
8				
9				
10				
11				
12				
13				
14				
15				
16				
17				
18				
19				
20				
21				
22				
23				
24				
25				
26				
27				
28				
29				
30				
31				
32				
33				
34				
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	6
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	7
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	9-10
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	7
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	9-11,16
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	7
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	8, 10-14
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	6, Figure 1
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	11-12
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	6-7

Methods: Assignment of interventions (for controlled trials)

Allocation:			6
-------------	--	--	---

1				
2	Sequence	16a	Method of generating the allocation sequence (eg, computer-	6
3	generation		generated random numbers), and list of any factors for	
4			stratification. To reduce predictability of a random sequence,	
5			details of any planned restriction (eg, blocking) should be	
6			provided in a separate document that is unavailable to those	
7			who enrol participants or assign interventions	
8				
9	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central	6
10	concealment		telephone; sequentially numbered, opaque, sealed envelopes),	
11	mechanism		describing any steps to conceal the sequence until interventions	
12			are assigned	
13				
14	Implementation	16c	Who will generate the allocation sequence, who will enrol	6
15			participants, and who will assign participants to interventions	
16				
17	Blinding	17a	Who will be blinded after assignment to interventions (eg, trial	6,12
18	(masking)		participants, care providers, outcome assessors, data analysts),	
19			and how	
20		17b	If blinded, circumstances under which unblinding is permissible,	7-8
21			and procedure for revealing a participant's allocated intervention	
22			during the trial	
23				
24				
25				
26				

Methods: Data collection, management, and analysis

27				
28	Data collection	18a	Plans for assessment and collection of outcome, baseline, and	5, Figure 1, 7-
29	methods		other trial data, including any related processes to promote data	8. 12-
30			quality (eg, duplicate measurements, training of assessors) and	14
31			a description of study instruments (eg, questionnaires,	
32			laboratory tests) along with their reliability and validity, if known.	
33			Reference to where data collection forms can be found, if not in	
34			the protocol	
35		18b	Plans to promote participant retention and complete follow-up,	5-6
36			including list of any outcome data to be collected for participants	
37			who discontinue or deviate from intervention protocols	
38	Data	19	Plans for data entry, coding, security, and storage, including any	15-16
39	management		related processes to promote data quality (eg, double data entry;	
40			range checks for data values). Reference to where details of	
41			data management procedures can be found, if not in the	
42			protocol	
43	Statistical	20a	Statistical methods for analysing primary and secondary	14-15
44	methods		outcomes. Reference to where other details of the statistical	
45			analysis plan can be found, if not in the protocol	
46		20b	Methods for any additional analyses (eg, subgroup and adjusted	15
47			analyses)	
48				
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

1		20c	Definition of analysis population relating to protocol non-	15
2			adherence (eg, as randomised analysis), and any statistical	
3			methods to handle missing data (eg, multiple imputation)	
4				
5				
6				
7				
8				
9				
10				
11				
12				
13				
14				
15				
16				
17				
18				
19				
20				
21				
22				
23				
24				
25				
26				
27				
28				
29				
30				
31				
32				
33				
34				
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

1	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	15-16
2				
3				
4				
5				
6	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	n.a.
7				
8				
9	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	15
10				
11				
12				
13				
14				
15				
16		31b	Authorship eligibility guidelines and any intended use of professional writers	17 / n.a.
17				
18				
19		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	n.a.
20				
21				
22	Appendices			
23				
24	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	attached
25				
26				
27	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	n.a.
28				
29				
30				

31 *It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013
 32 Explanation & Elaboration for important clarification on the items. Amendments to the
 33 protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT
 34 Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](http://creativecommons.org/licenses/by-nc-nd/3.0/)"
 35 license.
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60